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In this thesis, nanosuspensions of two hydrophobic active pharmaceutical ingredient 
compounds, mefenamic acid (MEF) and dalcetrapib (DCP) have been prepared using 
an antisolvent precipitation method (Chapter III and V, respectively). Variation of 
process parameters such as concentration, temperature, stirring rate or antisolvent to 
solvent ratio allowed for particle size reduction into the low micron (MEF, 0.25 µm – 
3.05 µm) or nano (DCP, ~430 nm) size range. However, the suspensions of the 
prepared particles of both compounds were highly unstable and formed larger 
micron-sized agglomerates over time. 
A method of introducing different additives at different times during the process, i.e. 
stepwise addition of additives has been developed to improve the formation and 
stability of MEF nanocrystals (Chapter III). From the eight surfactant and polymeric 
additives evaluated to produce nanoparticles in suspension, the most effective 
additive was sodium docusate (DOSS). When DOSS was present initially in the 
system, nanoparticles, ~312 nm in size, were generated. However, the particle size 
was not stable but increased to ~788 nm after 80 minutes in suspension associated 
with a polymorphic transformation. Combining the initial use of DOSS with the 
subsequent addition of hydroxypropyl methylcellulose allowed for the production of 
a suspension of MEF nanocrystals (~317 nm) with improved stability. The size of the 
crystals did not change in the first two hours and only increased to ~365 nm after 18 
hours. The interaction of hydroxypropyl methylcellulose with MEF particles delayed 
polymorphic transformation by inhibiting nucleation and/or growth of the stable 
MEF polymorph.  
The hypothesis that the reduction of the size of MEF nanocrystals in the presence of 
DOSS is due to nucleation promotion by the additive, a phenomenon rarely captured 
experimentally, was studied by performing a series of induction time experiments 
under moderate supersaturations, varying the solvent composition and the 
concentration of DOSS (Chapter IV). In 40 % dimethylacetamide – 60 % water and 
in the presence of DOSS (at concentrations of 0.1 mg/mL and 0.2 mg/mL), classical 
nucleation theory reveals that the pre-exponential factor (A) increases by 
approximately 50 % while the interfacial energy is essentially uninfluenced. It is also 
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found that the crystal growth rate becomes higher in the presence of DOSS. It is thus 
hypothesized that transport and desolvation of MEF molecules is facilitated in the 
presence of DOSS. With increasing amount of dimethylacetamide in the binary 
solvent mixture, the influence of DOSS appears to decrease.  
As an alternative to using soluble additives, DCP nanoparticles have been stabilized 
and formulated as solid nanocomposites on larger montmorillonite (MMT) carrier 
particles. This method combines the very high dissolution rate of the DCP 
nanoparticles with the simple solid-liquid separation and drying of the MMT 
composite microparticles (Chapter V). The solid state nanocomposite microparticles 
demonstrated fast dissolution up to a drug loading of 20.9 % and the formulation was 
stable for a minimum of 10 weeks in the solid state. No surface functionalisation of 
the MMT particles was needed and the presence of soluble surfactant and polymeric 
additives even hindered the preparation of the composite particles, decreasing 
nanoparticle attachment to the carrier particles and thus limiting the maximum 
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Modern drug discovery strategies utilize high throughput screening technologies in 
combination with advances in molecular genetics and combinatorial chemistry that 
enable the screening of hundreds of thousands of compounds [1]. Due to the nature 
of the screen, new substances entering the development process tend to have high 
molecular weight and lipophilicity and consequently, poor water solubility [1][2]. It 
has been estimated that 40 % of marketed compounds exhibit poor aqueous solubility 
whereas this number is as high as 65 % in the early development stage [3].  
Poorly soluble drugs present higher developmental risk due to poor and erratic 
bioavailability and often sub-optimal therapeutic effects in patients, especially when 
the drug is orally administered [4]. The bioavailability of a compound measures the 
rate and extent to which a substance is available at its site of action [5]. Following 
oral administration of a solid dosage form such as tablet or capsule, the drug must 
dissolve from the formulation in the gastrointestinal tract, migrate through the 
lipophilic intestinal membrane and enter the systemic circulation unchanged to 
ultimately reach its site of action [6]. Thus, the bioavailability of orally administered 
drugs, besides various first pass metabolisms, may be limited by the rate (dissolution 
rate) and extent (solubility) at which drug molecules transfer into solution or by the 
rate of intestinal permeation.  
The Biopharmaceutical Classification System (BCS), introduced in 1995 to aid as a 
guide for bioequivalence standards for immediate release oral dosage forms, 
categorizes drug substances based on their aqueous solubility and intestinal 
membrane permeability into four classes [7][8][9], Figure 1.1. Further modifications 
with greater focus on drug developability (Developability Classification System, 
DCS) [10] and in vivo predictive dissolution methodologies [11] have been proposed 
to more precisely anticipate bioavailability limitations (dissolution rate/solubility, 
permeability) in the early development process. This in turn can be linked to viable 
formulation strategies or based on the severity of the barrier, serve as a warning sign 
to redesign the molecule or terminate the development [3][10][12]. While Class I 
compounds are easy to formulate, Class IV compounds are the most challenging due 
to their low solubility and permeability and thus, are the least likely to reach the 
market. Permeability limitations associated with Class III and Class IV compounds 
are difficult to address, as permeability is mainly determined by the intrinsic 
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lipophilicity of the drug. Class II compounds, exhibiting dissolution limited 
bioavailability, may be formulated in a crystalline form using traditional formulation 
techniques (micronisation, adequate excipients), IIa, or by employing advanced 
crystal engineering and formulation strategies, often aiming to increase the 
dissolution rate through increasing the apparent solubility of the drug, IIb [10].  
 
Figure 1.1.  Biopharmaceutical Classification System [7], highlighting 
subcategories of Class II proposed in the drug Developability Classification System 
[10]. Class determination principles within the two systems are somewhat different.  
Strategies to overcome the dissolution limited bioavailability of Class II drugs are 
various, but many of them are still under research to reach or widen industrial 
applicability. Examples include crystal modification (metastable polymorph, salt 
[13], cocrystal [14]), nanocrystal formation [15][16], amorphous solid formulations 
[17][18], cyclodextrin complexation [19] or lipid based formulations [20]. While all 
these methods have their advantages along with different efficiency, cost and 
complexity, there is no general strategy that fits all drugs. When selecting the most 
appropriate approach for a given drug, formulators need to consider both drug 
specific properties (chemical structure, physicochemical properties, pharmacokinetic 
profile and required dose) and technology availability (safety, equipment availability, 
internal expertise, cost and patent situations) [21].  
Among the above mentioned strategies, improving the dissolution rate of a 
compound through crystal size reduction into the nanometer size range offers the 
advantages of relatively wide applicability, high dose and reduced excipient related 
Class I 
 
Good solubility  
Good permeability  
Class II 
 
Poor solubility  
Good permeability  
Class III 
 
Good solubility  
Poor permeability  
Class IV 
 
Poor solubility  





side effects, as well as tuneable crystal properties [4]. Proven by several pre-clinical 
and clinical trials [15][22], administration of nanocrystal formulations translates to 
enhanced bioavailability due to a substantial increase in the dissolution rate and 
prolonged drug retention time in the gastrointestinal tract, both associated with the 
reduced particle size. Consequently, patients can benefit from improved dose 
proportionality, reduced variability, reduced dose or dosing frequency and 
elimination of food effects, all improving safety and patient compliance [22][23][24]. 
Industrial suitability of nanocrystal formulations is also proven by the increasing 
number of nanocrystalline drug applications received by the U.S. Food and Drug 
Administration (FDA) until 2015 [22].  
Existing nanoparticle formulations on the market are generally produced by 
mechanical size reduction technologies; however, limitations in current industrially 
applied processing technologies exist. Antisolvent precipitation as a crystallisation-
based alternative method offers the benefit of low-energy consumption, simplicity 
and possibility of tuning the product properties such as size, habit and polymorphic 
form. Suitable additives that facilitate the formation of small particles and improve 
the stability of the formed nanosuspension are generally required in the process. 
However, identification of additives for a particular drug is challenging due to the 
lack of knowledge about the specific action of the additive in the process. After the 
formation of nanoparticles in suspension, isolation of them is required if the 
development of a solid dosage formulation is the goal. However, industrial scale 
isolation processes used for larger micron sized pharmaceuticals are not suitable for 
nanoparticles thus alternative methods are needed.  
The aim of this project is to advance the state of the art of nanoparticle production by 
antisolvent precipitation process. Throughout the preparation of nanoparticles of two 
active pharmaceutical ingredients, mefenamic acid and dalcetrapib, the project 
focuses on how the control over nanoparticle formation and stabilization in 
suspension can be improved using molecular additives and how nanoparticle 
isolation to solid state can be facilitated by a filtration based process using insoluble 
carrier particles.  
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The thesis is continued with a review of the relevant literature, Chapter II, including 
the state of the art preparation of nanocrystals using antisolvent precipitation as a 
controlled crystallisation approach, the role of stabilisers in the process and strategies 
to convert nanosuspensions to solid dosage forms. Chapter III introduces the concept 
of stepwise additive addition method for improved control over the preparation and 
stabilisation of a mefenamic acid nanosuspension. Chapter IV studies how a 
surfactant additive promotes the nucleation of an organic compound, mefenamic 
acid, a phenomenon that is rarely captured experimentally. Chapter V presents a 
carrier-mediated isolation method for the stabilisation and solid state conversion of 
dalcetrapib nanoparticles in suspension, with special focus on the factors controlling 
the achievable drug loading in the formulation. Finally in Chapter VI, a conclusion is 
made along with future recommendations to progress the industrial feasibility of the 
antisolvent precipitation technique for the preparation of nanoparticles with 




REFERENCES TO CHAPTER I  
[1] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational 
approaches to estimate solubility and permeability in drug discovery and development settings, 
Adv. Drug Deliv. Rev. 46 (2001) 3–26.  
[2] P.D. Leeson, B. Springthorpe, The influence of drug-like concepts on decision-making in 
medicinal chemistry, Nat. Rev. Drug Discov. 6 (2007) 881–890.  
[3] M.S. Ku, W. Dulin, A biopharmaceutical classification-based Right-First-Time formulation 
approach to reduce human pharmacokinetic variability and project cycle time from First-In-
Human to clinical Proof-Of-Concept., Pharm. Dev. Technol. 17 (2012) 285–302.  
[4] R.O. Williams III, D.A. Miller, A.B. Watts (Eds.), Formulating poorly water soluble drugs, 1st 
ed., Springer, 2012.  
[5] R. Löbenberg, G.L. Amidon, Modern bioavailability, bioequivalence and biopharmaceutics 
classification system. New scientific approaches to international regulatory standards, Eur. J. 
Pharm. Biopharm. 50 (2000) 3–12.  
[6] I. Buxton, L. Benet, Pharmacokinetics: The dynamics of drug absorption, distribution, 
metabolism, and elimination, in: J.F. Shanahan, C. Naglieri (Eds.), Goodman Gilman’s 
Pharmacol. Basis Ther., 12th ed., The McGraw-Hill Companies, 2011: 17–39. 
[7] G.L. Amidon, H. Lennernäs, V.P. Shah, J.R. Crison, A theoretical basis for a biopharmaceutic 
drug classification: the correlation of in vitro drug product dissolution and in vivo 
bioavailability, Pharm. Res. 12 (1995) 413–420.  
[8] Food and Drug Administration (FDA), Guidance for industry: Dissolution testing of immediate 
release solid oral dosage forms, (1997). 
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064964
.htm. 
[9] CDER/FDA, Guidance for Industry, Waiver of in vivo bioavailability and bioequivalence 
studies for immediate release solid oral dosage forms based on a biopharmaceutics 
classification system, Cent. Drug Eval. Res. (2015) 1–2. 
[10] J.B. Butler, J.B. Dressman, The Developability Classification System: application of 
biopharmaceutics concepts to formulation development, J. Pharm. Sci. 99 (2010) 4940–4954. 
[11] Y. Tsume, D.M. Mudie, P. Langguth, G.E. Amidon, G.L. Amidon, The Biopharmaceutics 
Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and 
IVIVC, Eur. J. Pharm. Sci. 57 (2014) 152–163.  
[12] Y. Kawabata, K. Wada, M. Nakatani, S. Yamada, S. Onoue, Formulation design for poorly 
water-soluble drugs based on biopharmaceutics classification system: basic approaches and 
  CHAPTER I 
7 
practical applications, Int. J. Pharm. 420 (2011) 1–10.  
[13] A.T.M. Serajuddin, Salt formation to improve drug solubility, Adv. Drug Deliv. Rev. 59 (2007) 
603–616.  
[14] N. Blagden, M. de Matas, P.T. Gavan, P. York, Crystal engineering of active pharmaceutical 
ingredients to improve solubility and dissolution rates, Adv. Drug Deliv. Rev. 59 (2007) 617–
630.  
[15] F. Kesisoglou, S. Panmai, Y. Wu, Nanosizing - oral formulation development and 
biopharmaceutical evaluation, Adv. Drug Deliv. Rev. 59 (2007) 631–644.  
[16] J.P. Möschwitzer, Drug nanocrystals in the commercial pharmaceutical development process, 
Int. J. Pharm. 453 (2013) 142–156.  
[17] G. Van den Mooter, The use of amorphous solid dispersions: A formulation strategy to 
overcome poor solubility and dissolution rate, Drug Discov. Today. Technol. 9 (2012) 71–85.  
[18] L.S. Taylor, G.G.Z. Zhang, Physical chemistry of supersaturated solutions and implications for 
oral absorption, Adv. Drug Deliv. Rev. 101 (2016) 122–142.  
[19] T. Loftsson, M.E. Brewster, Pharmaceutical applications of cyclodextrins: Basic science and 
product development, J. Pharm. Pharmacol. 62 (2010) 1607–1621.  
[20] C.W. Pouton, Lipid formulations for oral administration of drugs: Non-emulsifying, self-
emulsifying and “self-microemulsifying” drug delivery systems, Eur. J. Pharm. Sci. 11 (2000) 
93–98.  
[21] A. Siew, Industry perspectives: Achieving solutions for the challange of poorly water-soluble 
drugs, Pharm. Technol. 37 (2013). 
[22] M.-L. Chen, M. John, S.L. Lee, K.M. Tyner, Development considerations for nanocrystal drug 
products, AAPS J. 19 (2017) 642–651.  
[23] R. Shegokar, R.H. Müller, Nanocrystals: industrially feasible multifunctional formulation 
technology for poorly soluble actives, Int. J. Pharm. 399 (2010) 129–139.  
[24] Y. Wang, Y. Zheng, L. Zhang, Q. Wang, D. Zhang, Stability of nanosuspensions in drug 





























CHAPTER II  




2.1.  PROPERTIES OF PHARMACEUTICAL NANOCRYSTALS  
In pharmaceutical science, drug nanocrystals are defined as crystals composed of 
100 % drug having a mean size less than 1000 nm [1], whereas the term drug 
nanoparticles can be used when the drug is in an amorphous form or when the form 
is not specified or known. The suspension of these particles, both nanocrystals and 
amorphous nanoparticles, is called a nanosuspension. Nanocrystal formulations have 
advantages over the conventional larger micron-sized drug formulations such as 
higher dissolution rate and saturation solubility, and prolonged residence time in the 
gastrointestinal tract, all promoting the rate and extent of dissolution and thus, 
bioavailability of a drug substance [2][3][4].  
The rate at which a crystal dissolves (dc/dt), described by the Noyes – Whitney 
equation [5][6], is governed by the surface area of the crystal (A), the diffusivity of 
the compound (D), the volume of the dissolution media (V) and the concentration 
gradient for the diffusion from the vicinity of the crystal into the bulk solution  





  (2.1) 
The reduction of the crystal size from micrometer to nanometer range increases the 
specific surface area of the crystals by orders of magnitude, leading to a 
proportionally increased dissolution rate for the same mass of crystals. In addition, 
the thickness of the diffusion layer is also reduced due to a reduced hydrodynamic 
boundary layer around the particles, predicted by the Prandtl equation [7]. As an 
example, by reducing the size of the particles from 30 µm to 5 µm, a two fold 
increase in the solubility-corrected, surface specific dissolution rate was observed by 
Bistrat and Nyström [7], with a tendency for an even more pronounced increase at 
lower sizes. It is expected though that the surface specific dissolution rate has a 
maximum corresponding either to an infinitesimally small diffusion layer thickness 
or to a change in the rate limiting step, i.e. from a diffusion controlled to an 
interfacial reaction controlled dissolution process. 
The solubility of small crystals is larger than the solubility of larger ones due to the 
higher ratio of surface molecules that have a higher free energy than the bulk 
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molecules. The size dependent solubility, c(r), is described by the Ostwald – 












where c(∞) is the solubility of a crystal with infinitely large surface curvature, γ is 
the interfacial energy, υm is the volume occupied by a molecule in the crystal, k is the 
Boltzmann constant and T is absolute temperature. However, significant increase 
only appears well below the micron range as theoretically one can expect 10-15 % 
solubility increase for a typical drug at a particle size of 100 nm [9]. Thus, the 
influence of increased solubility on the dissolution rate is less pronounced than the 
influence of increased surface area, unless the crystals are very small (< 100 nm).  
Besides the improved dissolution rate and solubility, it has been proposed [4], similar 
to polymeric nanoparticles, that an increased gastrointestinal residence time arising 
from the increased adhesiveness of the nanoparticles to surfaces and cell membranes 
could also contribute to a higher extent of drug absorption, especially when the 
nanoparticle surface is functionalized with mucoadhesive polymers.  
In many cases, it is difficult to evaluate the effect of crystal size reduction on the 
dissolution rate and solubility as not just the size but other properties of the particles 
also might change during the size reduction procedure. Crystallisation methods using 
high supersaturation often produce amorphous particles [10][11][12][13] and 
mechanical size reduction methods can also create high energy surfaces [14]. Muller 
and Peters [14] reported that the solubility of RMKP 22 crystals increased by a factor 
of 1.75 when the size was decreased by high pressure homogenisation from 2.4 µm 
to 800 nm or 300 nm. However, this rather substantial increase might have been the 
effect of disruption of the crystal surface due to the employed high energy. Xia et al. 
[15] also reported an increase in the solubility of nitrendipine nanocrystals prepared 
by a crystallisation technique compared to that of the larger raw crystals, arising 
from the partial amorphous nature of the prepared nanoparticles. Together with the 
particle size decrease, this allowed for a significantly improved in vivo dissolution 
rate. While uncontrolled amorphisation of the nanoparticles is avoidable, there is a 
great potential in controlled and deliberate preparation of amorphous nanoparticles 
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coupled with adequate stabilisation of them for bioavailability improvement, 
especially when not just the rate, but also the extent of solubilisation are limiting 
factors. 
Several pre-clinical and clinical studies demonstrate that formulation of a drug as 
nanocrystals is an effective approach to improve the bioavailability of the drug [9]. 
As an example, in one of the earliest studies, Liversidge and Cundy [16] tested the 
performance of crystalline danazol nanosuspensions (169 nm) versus conventional 
danazol microparticles in dogs. They found a dramatically increased bioavailability 
from 5.1 % to 82.3 % with the administration of the nanosuspension, where 100 % 
bioavailability corresponded to a reference cyclodextrane formulation. 
Table 2.1. Examples of marketed nanocrystal formulations [2][17]. 
Trade name API Pharma company 
Administration 
route 
Rapamune® Rapamycin, Sirolimus Pfizer Oral 
Emend® Aprepitant Merck & Co. Oral 
Tricor® Fenofibrate Abbott Oral 
Triglide® Fenofibrate SkyePharma Oral 
Megace ES® Magesterol acetate Par Pharmaceutical Oral 
Avinza® Morphin sulphate Pfizer Oral 
Ritalin® LA Methylphenidate HCl Novartis Oral 
Zanaflex CapsulesTM Tizanidine HCl Acorda Oral 
Invega® Sustenna® Paliperidone palmitate Janssen Intramuscular 
The first commercial nanocrystal formulation, Rapamune®, entered the market in 
2000 [18]. During the last eighteen years, several other ‘nano’ products were 
launched onto the market (Table 2.1). A recent review of U.S. Food and Drug 
Administration (FDA) applications including nano and low micron range (a 
minimum of 10 % of the particles below 1000 nm) products counted a total of 82 
submissions by 2015, from which the majority was investigational new drug 
applications (application prior to clinical studies, 55 %), followed by abbreviated 
new drug applications (generic drug applications, 32 %) and new drug applications 
(13 %). This study also revealed that although oral administration is the most 
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preferred way of administration of nanoparticles/low micron sized particles (65 %), 
the benefits of particle size reduction are also present in other administration routes 
such as intravenous (20 %), intramuscular (7 %) and ocular (3 %). 
2.2.  NANOCRYSTAL PREPARATION METHODS  
The different methods of preparing pure drug nanocrystals can be classified into two 
main categories: mechanical size reduction and controlled crystallisation techniques, 
Figure 2.1. While comminution approaches employ mechanical energy for size 
reduction of drug particles to the nanometer range, crystallisation methods start with 
drug molecules in solution which form nanoparticles due to changed conditions. The 
combination of the two approaches also exists where generally a crystallisation 
method is followed by a size reduction technique. Depending on the drug properties, 
product requirements and technology availability, one can select the most suitable 
method for nanocrystal preparation. Examples of the most extensively studied 
methods in industry and also in academia along with advantages and limitations of 
them are summarized in Table 2.2, and will be discussed below.  
 
Figure 2.1. Nanocrystal preparation approaches 
The commonly used mechanical size reduction technologies are wet ball milling [19] 
and high pressure homogenisation [20]. Compared to crystallisation methods, to date, 
size reduction techniques have been industrially more feasible, as one can see from 
the considerably higher number of related patents and marketed drug nanocrystal 
products produced in this manner [21]. The success of these techniques, and 
especially the milling method, is due to the robust preparation method – the main 
factors influencing the size of the crystals are the time and energy input [14][19][22]. 
However, these methods have their limitations as well. Particle size reduction to the 
comminution crystallisation 
molecules in solution micron-sized crystals nanosuspension
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nanometer range requires high energy, expensive equipment and often, long 
processing time, especially when the aim is to obtain crystals below the size of 
100 nm [23]. Change in the drug’s crystalline state during the process due to the 
applied high energy [24] and product contamination from the equipment have also 
been reported [25].  
Table 2.2. Advantages and limitations of commonly used nanocrystal preparation 
techniques.  
Method Advantages Limitations/Disadvantages 
Mechanical size reduction 
 
Wet ball milling Simple process, applicability 
to a wide variety of drugs 
Contamination from grinding 
media, long processing time, 
broad particle size distribution, 
change in crystallinity  
 
HPH Can be used for 
thermosensitive drugs, water 
free option available 
Preprocessing required to avoid 
clogging, expensive equipment, 
change in crystallinity, use of 









Simple, fast, inexpensive, 
suitable for thermosensitive 
molecules 
Requires good solubility in a 
water miscible solvent, residual 
solvent content, control of 





Suitable for thermosensitive 
molecules 
Control of crystal nucleation and 






(RESS), suitable for 
thermosensitive molecules, 
no drying required (RESS), 
smaller particles (SAS) 
Solubility in CO2 needed 
(RESS), expensive equipment, 
use of high pressures, control of 
crystal nucleation and growth is 
required 
 
Spray freezing into 
liquid nitrogen 
 
Suitable for thermosensitive 
molecules 
Lyophilisation required, slow 
process, larger particles, control 
of crystal nucleation and growth 
is required 
Combination 
techniques with HPH 
No clogging problems, 
reduced processing time  
Adds more complexity and cost, 
two-step process 
Abbreviations: HPH: high pressure homogenisation, RESS: rapid expansion of supercritical 
solutions, SAS: supercritical antisolvent process. 
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Controlled crystallisation methods include simple antisolvent precipitation [26], 
evaporative antisolvent precipitation [27], sonoprecipitation [28], methods based on 
microemulsions [29][30], reactive precipitation [31], spray freezing into liquid [32] 
or supercritical fluid technologies [33][34]. In contrast to size reduction methods, 
crystallisation methods typically require low energy, are potentially cheaper and are 
suitable for thermosensitive drugs [23]. Using these techniques, there is also a 
possibility of preparing small nanocrystals (<100 nm) with uniform size distribution, 
as energy input does not limit the size [35]. Another advantage is that not just the 
size, but also other properties of the nanocrystals can be tuned in a controlled way 
such as polymorphic form and habit. While these crystallisation methods have good 
potential, all face the challenge of controlling nucleation and particle growth during 
the process [36].  
2.3.  THERMODYNAMICS AND KINETICS OF SOLUTION CRYSTALLISATION 
Crystal formation from solution can be seen as a two-step process [37]. During 
nucleation, initial phase separation occurs and a nucleus of a new crystal forms. This 
may happen in the absence (primary nucleation) or the presence of crystals of the 
compound (secondary nucleation). Primary nucleation can be further classified into 
homogeneous and heterogeneous nucleation depending on whether nucleation occurs 
in bulk or on a foreign particle/surface in the system. Nucleation is followed by 
crystal growth during which further building units attach to the nucleus and a 
macroscopic crystal form. In addition, in case of fine particles, particle 
agglomeration and Ostwald ripening generally occur as secondary particle growth 
mechanisms, increasing the size of the particles and thus reducing the energy 
associated to the large total surface area. 
2.3.1.  Supersaturation and driving force for crystallisation 
Crystallisation from solution requires a driving force [38]. A solution can be 
undersaturated, saturated or supersaturated depending on the concentration of the 
solute. When a solution is saturated at a specific temperature, it is said to be in 
thermodynamic equilibrium with the solid phase of the solute. When the solution is 
supersaturated, crystal nucleation and growth is thermodynamically favorable. 
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Supersaturated solutions can be generated by cooling a solution to under its 
saturation temperature [39], evaporating the solvent [40], mixing the solution with an 
antisolvent [41] or by mixing the solution with a reagent solution to form a less 
soluble compound [31]. 
In thermodynamic terms, the driving force for crystallisation at a given temperature 
is the difference in chemical potential of the solute molecule in the supersaturated 
solution, µ, and that of the solute molecule in the crystal, the latter being equal to the 
chemical potential of the solute in the saturated solution, µeq [42]. The chemical 
potential difference can be expressed using the ratio of solute activities, a, which, in 
case of dilute solutions, can be approximated by the ratio of molar concentrations, c, 
as shown [42]: 
 ln ln lneq
eq eq
a c
kT kT kT S
a c
  
   
        
      
 (2.3) 
where k is the Boltzmann constant, T is the absolute temperature and S is the 
supersaturation ratio.  
2.3.2.  Crystal nucleation  
In a supersaturated solution, according to the classical nucleation theory (CNT), 
energy fluctuations lead to the formation of clusters of molecules [43]. While the 
formation of a cluster containing n building units is accompanied by a gain in bulk 
free energy (ΔGV = -nΔµ), the energy gain is counterbalanced by the energy required 
to create a thermodynamically unfavorable interface between the cluster and the 
solution (ΔGS = c(υmn)
2/3γ) with a surface area of c(υmn)
2/3 and interfacial energy of γ 
[43]: 
        2/3V S mG n G n G n n c n          (2.4) 
in which c is a shape factor, being c = (36π)1/3 for spherical clusters and υm is the 
volume occupied by a molecule in the cluster. At small cluster sizes, the positive 
surface energy term dominates and the attachment of an additional molecule causes 
unfavorable positive free energy change (Figure 2.2). In contrast, when the number 
of building units exceeds a critical value, n*, the bulk energy term becomes dominant 
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and the attachment of a further solute molecule is favorable. Thus, n* is the size of a 
nucleus corresponding to the balance point [44]. Clusters containing less molecules 
than n* tend to dissolve, whereas larger clusters tend to grow to macroscopic 
crystals. The free energy of cluster formation has a maximum value at n* which 
value is the energy barrier (ΔG*) that must be surpassed for nucleation to occur.  
 
Figure 2.2. Free energy excess, ΔG(n), of a nucleus as a function of nucleus size 
(n) [44][45]. 
Assuming a spherical nucleus, the critical free energy (ΔG*) can be expressed as a 
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The stationary rate of primary crystal nucleation, J, is defined as the number of 
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 (2.6) 
where C* is the equilibrium concentration of critical nuclei, f* is the frequency of 
attachment of building units to the critical nucleus and z is the Zeldovich factor 
accounting for the use of equilibrium rather than actual critical nuclei concentration, 
and for the fraction of clusters that are larger than the critical nucleus but eventually 
dissolve rather than grow to a macroscopic crystal. The term C* includes the 
thermodynamic information about the nucleation process, being the product of the 
Surface free 









concentration of nucleation sites in the system, C0, and an exponential term 
containing the free energy barrier, ΔG*. 









  (2.7) 
Attachment of monomers occurs by diffusion of the solute from the bulk solution to 
the nucleus and by transferring the solute from the vicinity of the nucleus to a 
position incorporated in the nucleus. Assuming interface transfer control, the 
attachment frequency can be expressed as [44]: 
 
 
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 
 (2.8) 
where λ is the sticking coefficient accounting for the molecules in the vicinity of the 
nucleus that actually do adsorb to the nucleus, A* is the surface area of the nucleus, c 
is the concentration of the monomers in the solution, d is the distance of the jump 
that could be approximated by the molecular diameter and D is the diffusion 
coefficient. D can be expressed with an Arrhenius type equation (D = D0exp(-
ΔE/kT)) [43] where E describes an energy barrier that needs to be surpassed 
associated with a desolvation process and/or conformational change of the molecule 
during incorporation into the nucleus. Expressing c using S and elaborating the term 
A* for a spherical nuclei provides the form of the attachment frequency on the right 
hand side of the formula. 
By combining equation 2.5 – 2.8, the nucleation rate can be expressed by A = zf*C0/S, 





   
 
 (2.9) 
The nucleation rate is influenced by supersaturation in a highly non-linear manner. 
Higher supersaturation decreases the free energy barrier of nucleation and increases 
the nucleation rate. Although theoretically nucleation can occur at every given 
supersaturation (S > 1), primary nucleation is only probable above a critical level of 
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supersaturation. The supersaturation region below the critical value of 
supersaturation is called the metastable zone, where homogeneous primary 
nucleation is improbable within a certain time period, but secondary nucleation and 
crystal growth can occur when seeded with crystals of the compound. 
At moderate supersaturations, the aforementioned homogeneous nucleation is less 
common. It is more likely that heterogeneous nucleation occurs at an interface of the 
solution and a foreign body, lowering the free energy barrier for nucleation [44]. The 
decrease in the energy barrier depends on the affinity of the crystal to the foreign 
surface and can be characterized by a reduced interfacial energy γeff < γ, accounting 
for the influence of the heterogeneous surface. Besides the size and geometry of the 
heterogeneous surface [47], the most important surface attributes directing 
heterogeneous nucleation of organic crystals were found to be complementary 
surface functionality, surface hydrophobicity and topography [48][49][50][51].  
The classical nucleation theory discussed above is based on several assumptions 
[52]. One assumption is that the nucleus is described as a spherical particle with a 
sharp interface and an interfacial energy independent of the nucleus size and surface 
curvature. The nucleation mechanism assumes a cluster growth through step-by-step 
addition of individual molecules leading to a cluster that has the same structure as the 
macroscopic crystal. This means that the alterations in density and structure between 
the supersaturated solution and the cluster happen simultaneously. In the last few 
decades, several researchers suggested more complex routes to nucleation. Vekilov 
[45] described a two-step nucleation mechanism, observed predominantly in the field 
of protein crystallisation, in which nucleation of a crystalline phase takes place in 
pre-existing metastable, disordered, liquid-like solute clusters. As such, fluctuations 
in density and order are not occurring simultaneously but successively. Gebauer and 
Cölfen [53] reviewed evidence for stable pre-nucleation clusters (with respect to free 
species in solution), predominantly detected in inorganic systems, that may assist in a 
multi-step nucleation pathway as a precursor for liquid like nanodroplets. 
Baumgartner et al. [54] proposed a modified CNT model that includes cluster free 
energy, regulating the nucleation mechanism in the system. Zhan [55] also 
rationalized the complex nucleation pathways based on the classical concept of 
competing interface and bulk energy terms. However, these approaches treat the 
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clusters as an alternative second phase with an existing interface and size 
independent interfacial energy, whereas Gebauer and Cölfen [53] defines pre-
nucleation clusters as solutes that do not have an interface with the solution. 
Nevertheless, it seems that there is no single pathway generic to all systems, and the 
thermodynamically favored way depends on many factors [56]. In the case of small 
organic molecules, although nonclassical nucleation routes have been suggested for 
some systems [57][58][59], CNT is still considered to be the best model for the 
nucleation mechanism.  
2.3.3.  Crystal growth  
Nucleation is followed by growth to form a macroscopic crystal. The development of 
a macroscopic crystal by attachment of growth units from a supersaturated solution is 
overall a thermodynamically favorable process, reducing the free energy of the 
system. The process involves the bulk diffusion of growth units through a diffusion 
layer around the crystal, followed by stepwise desolvation, surface diffusion and 
integration into the crystal lattice. Since the free energy gain due to formation of 
bonds between a growth unit and the crystal surface increases from a terrace to a 
ledge and to a kink position, Figure 2.3a, incorporation is more probable at kink 
positions [60].  
On a flat, smooth surface, the presence of dislocations (imperfect crystal) or two 
dimensional nucleation sites (perfect crystal) may supply kinks for the attachment of 
growth units, while rough surfaces have a large number of inherent kink sites. Thus, 
depending on the type of surface and molecular arrangement, supersaturation, 
temperature etc. crystal growth follows different mechanisms. The three types of 
generally accepted mechanisms for crystal growth [61]: screw dislocation 
mechanism (Burton – Cabrera – Frank, BCF), two-dimensional nucleation and 
growth (birth and spread, B+S) and rough interfacial growth, differ in activation 
energy and thus dominate at different supersaturation ranges for flat surfaces, Figure 
2.3b. At high supersaturations and thus high driving forces for crystal growth, growth 
units may deposit and be incorporated even on terrace sites, roughening the surface 





Figure 2.3. (a) Different positions for the attachment of growth units on a flat 
crystal-medium interface, (b) schematic diagram illustrating the dependence of 
growth rate on the supersaturation at different crystal growth mechanisms, (c) 
supersaturation-dependent transition between flat and rough crystal-solution 
interface. Graph modified after ref. [61]. 
The final crystal size distribution depends on the relative kinetics of nucleation and 
growth [62] that govern the number of particles formed in the system. Equation 2.9 
describes the highly non-linear dependence of primary nucleation on supersaturation, 
meaning that the nucleation rate decreases rapidly with decreasing supersaturation 
and may be considered negligible reaching a threshold of supersaturation. In contrast, 
growth is less sensitive to supersaturation. The dependence of growth rate (G) on 
supersaturation can be generally expressed by an empirical power law function with 
a kinetic constant kg and an order of g = 1-2 [42]: 
 ggG k S  (2.10) 
Starting from high supersaturations, the nucleation rate is high and a large number of 
nuclei form in a short time [68]. The formation of nuclei consumes supersaturation, 
quickly reducing the rate of nucleation with less influence on the growth rate. Due to 
the large number of nuclei, only a small amount of solute is available per nuclei for 
further growth leading to the formation of small crystals. In contrast, at low 




















which drives nucleation and crystal growth is a local value and changes over time, 
effective mixing is necessary to avoid mass transfer limitations which can lead to 
significantly different local supersaturations than the average one. Non-uniform 
supersaturation, differences in growth time and growth rate dispersion can all 
contribute to a broad crystal size distribution [63]. 
2.3.4. Secondary particle growth processes: Ostwald ripening and 
agglomeration  
When the supersaturation and thus the driving force for crystallisation is very high, 
large numbers of small crystals form within a very short time, i.e. a high nucleation 
rate exists. In such a system of fine crystals, the surface area to volume ratio is 
significant, creating thermodynamically unfavorable, high total surface energy. Thus, 
to reduce the surface energy of the system, crystals tend to grow over time or 
agglomerate, altering the final particle size distribution. 
Ostwald ripening is the phenomenon where larger crystals continue to grow over 
time at the expense of smaller ones [24]. As discussed earlier in section 2.1, small 
crystals have a higher saturation solubility than larger ones due to the higher ratio of 
surface molecules. As a consequence of size dependent solubility, a drug 
concentration gradient exists between larger and smaller crystals leading to the 
diffusion of molecules to the less concentrated areas around the larger crystals. This 
diffusion process generates undersaturated solutions for small crystals leading to 
their dissolution and supersaturated solutions for larger crystals leading to their 
further growth. According to the diffusion controlled ripening model derived 
originally for emulsions, the rate of the ripening process depends on the crystal size 
distribution, the solubility and diffusion properties of the compound in the solution, 
the interfacial energy between the solid and liquid phase and on the temperature [64]. 
Agglomeration is the process when colliding crystals stick together forming a bigger 
particle, and so reducing the crystal surface area in contact with the solution. The 
process is governed by the sum of attraction and repulsion forces between the 
particles and the rate of particle collision [8][23]. Therefore, besides the 
physicochemical properties of the particles, the rate of agglomeration is highly 
influenced by the population density of the particles, the temperature and the 
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viscosity of the medium. If the transport mechanism which brings the particles 
together is other than Brownian motion, additional parameters such as mixing energy 
should be considered as well [65].  
2.4. ANTISOLVENT PRECIPITATION FOR THE PREPARATION OF NANOPARTICLES 
Antisolvent precipitation is a potential low-energy crystallisation method which can 
overcome the limitations of mechanical size reduction technologies, with a potential 
for scale-up to a continuous process [66][67]. To use this method, the drug needs to 
be sufficiently soluble in a solvent which is miscible with an antisolvent that is 
generally water. However, sometimes both the antisolvent and the solvent can be 
organic solvents with suitable properties [13]. Although the relative high solubility of 
the drug is essential when considering the solvent, solvent toxicity, boiling point and 
the interaction between the solvent and additives also need to be taken into account 
[23].  
In the process, the drug solution is quickly mixed with the antisolvent and 
precipitation occurs immediately due to the decreased solubility of the compound in 
the antisolvent – solvent mixture [68]. The process creates a high supersaturation 
level resulting in a high number of low micron- or nano-sized crystals. To highlight 
the fast rate of crystallisation and the possibility of formation of amorphous 
nanoparticles, the term precipitation is often used instead of crystallisation in this 
area.  
The properties of the product crystals can be controlled by varying different process 
parameters which influence the extent and uniformity of supersaturation, such as 
drug concentration, stirring rate, temperature, solution infusion rate into the 
antisolvent and ratio of the antisolvent to the solvent. As these parameters are 
interdependent, the application of a suitable experimental design such as central 
composite design [69], Box – Behnken design [70] or factorial design [36] is useful 
to find the optimum preparation conditions, whereas a single factor design can be 
useful to understand the effect of the change of a single parameter [12][15]. 
Table 2.3 shows some examples of drug nanocrystals and nanoparticles prepared by 
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antisolvent precipitation, including the process conditions reported to produce the 
smallest particle size. 
Table 2.3. Examples of drug nanocrystals and nanoparticles prepared by 
antisolvent precipitation showing process conditions reported to produce the smallest 
size. AS/S is the antisolvent to solvent ratio, c is the concentration of the drug in the 
solvent, s is the stirring rate, TAS is the temperature of the antisolvent, and t is the 
aging time. US means ultrasonic treatment and if it is not stated otherwise, additives 



































Amphotericin B [13] 135 13 20 2000 12 30 - 
Artemisinin [36] 373 9 15 1200 15 n/a - 
Ascorbyl palmitate [71] 780 10 10 n/a 1 n/a US, T-mixer 
Atorvastation calcium [12] 240 10 60 1000 20 0.5 - 
Beclomethasone 
dipropionate [72] 
850 20 30 2000 4 4 No additive 
Cefuroxime axetil [11] 300 20 80 1200 10 n/a No additive 
Cefuroxime axetil [73] 80 n/a n/a n/a 5 1 
US, no 
additive 
Ellagic acid [26] 429 5 30 2500 3 2 No additive 
Fenofibrate [66] 318 10 50 1000 roomT <1 - 
Fenofibrate [71] 882 10 10 n/a 1 n/a US, T-mixer 
Glyburide [36] 261 9 5 1200 15 n/a - 
Ibuprofen [36] 85 9 30 1200 15 n/a - 
Itraconazole [27] 216 10 6.4 13000 80 n/a 
Evaporative 
precipitation 
Itraconazole [71] 347 10 10 n/a 1 n/a US, T-mixer 
Magestrol acetate [35] 208 10 20 2500 3 n/a - 
Nitrendipine [15] 209 10 30 400 <3 15 
US after 
precipitation 




4 5 n/a roomT n/a - 
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Higher antisolvent to solvent ratio decreases the particle size and narrows the particle 
size distribution [27][35][75]. When the antisolvent to solvent ratio increases, the 
solubility of the drug in the final antisolvent – solvent mixture decreases [35][68]. 
Keeping the same drug concentration in the final mixture, reduced drug solubility 
increases the level of supersaturation. A higher degree of supersaturation increases 
nucleation rates and results in smaller particle sizes [75]. However, after reaching a 
critical antisolvent to solvent ratio, further particle size reduction is generally not 
observed [35].  
Drug concentration in the solvent as well as in the final antisolvent – solvent mixture 
has an optimum value [12][15][69][75]. In the concentration range below this 
optimum level of concentration, increasing concentration leads to a higher 
supersaturation level and an accelerated nucleation rate, resulting in smaller particle 
sizes [12][75]. However, when the concentration exceeds the optimum, 
agglomeration of the created primary crystals becomes significant due to an 
increased rate of particle collision [23], leading to an increased particle size. It has 
been proposed that increasing drug concentration also has an effect on mixing at the 
molecular level, increasing the size of the nanoparticles [10][11].  
By increasing the efficiency of mixing, more uniform local supersaturation levels are 
achieved prior to precipitation, generating smaller and more uniform particle size 
distributions [9][76]. As an example, Zhang et al. reported that the size of 
cefuroxime axetil nanoparticles decreased from approximately 800 nm to 300 nm 
when the stirring rate was increased from 300 rpm to 1200 rpm [11]. High infusion 
rate of the drug solution into the antisolvent is also necessary for high and uniform 
supersaturation levels [36][76]. Therefore in many applications on a laboratory scale, 
the drug solution is simply poured or quickly injected into the antisolvent under 
stirring. To intensify mixing and the molecular diffusion between the antisolvent and 
solvent phase, special mixing devices such as rotating packed beds for high gravity 
precipitation [67][77], confined impinging jets [78], T-mixers [71] are also used, 
especially when high production rate is required [67]. By using such mixing devices, 
the mixing time can be reduced to milliseconds or microseconds.  
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Based on theoretical considerations, variation in temperature has a complex influence 
on the crystallisation process and the stability of the system. Experimentally, it has 
been generally observed that a lower antisolvent temperature reduces the particle size 
and narrows the particle size distribution [15][35][36][76]. Lower temperature 
reduces the solubility of the drug in the antisolvent – solvent mixture, leading to an 
increased supersaturation and thus higher nucleation rate and smaller particles [15]. 
However, temperature has also an opposing effect on the driving force for nucleation 
(Δµ=kTlnS) but the effect of increased supersaturation on the driving force dominates 
the effect of decreased temperature at high supersaturations and moderately low 
temperatures [36]. In addition, lower temperature decreases the rate of crystal growth 
and Ostwald ripening [35] and reduces particle mobility for agglomeration through 
increased viscosity [23].  
Depending on the stability of the nanosuspension, aging time (the time between 
particle formation and isolation of particles) can also be an important process 
parameter [12][66][74]. Since nanoparticles have high surface area to volume ratio, 
they tend to grow and agglomerate to reduce the surface energy of the system [24]. 
The time scale of particle growth by Ostwald ripening and agglomeration is system 
dependent. Hu et al. reported the successful preparation of fenofibrate nanoparticles 
with the size of 318 nm immediately after precipitation, but the size of the particles 
increased to 2.5 µm within 10 minutes aging time [66]. In contrast, all the three types 
of drug nanosuspensions prepared by Khan et al. remained relatively stable during 30 
days of storage [36].  
Although antisolvent precipitation method is a simple method for preparing 
nanoparticles, often smaller size and narrower size distribution can be achieved by 
using an additional external factor. In the process of heat induced evaporative 
precipitation into aqueous solution [27], the temperature of the antisolvent is above 
the boiling point of the solvent leading to rapid evaporation of the solvent after drug 
solution injection, with less prominent evaporation of the higher boiling point 
antisolvent. This further decreases the solubility of drug in the system and facilitates 
nucleation process. Ultrasonic treatment may be also applied during the antisolvent 
precipitation process [71][73][79][80]. Ultrasound creates cavitational bubbles 
followed by a collapse of the bubbles creating high energy shock waves with extreme 
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local temperature and pressure. This energy intensifies micromixing and increases 
the nucleation rate leading to smaller particle sizes. In addition, enhancement of 
suspension stability has been also reported due to ultrasound assisted conversion of 
particles into a more stable solid form and enhancement of additive adsorption onto 
the particle surface [28].  
2.5. INFLUENCE OF ADDITIVES ON THE FORMATION AND STABILISATION OF 
NANOPARTICLES  
Additives are generally used during the antisolvent precipitation process with an aim 
to prepare small nanoparticles with narrow size distribution and long term suspension 
stability. For the purpose of size reduction, it is desired that additives promote or at 
least do not prevent nucleation, inhibit, or at least slow down, crystal growth and 
stabilize the system against subsequent particle transformation processes including 
Ostwald ripening, polymorphic transformation and particle agglomeration. Additives 
used for these purposes are generally surfactants or polymers that are 
pharmaceutically accepted. A summary about the complex and often interdependent 
effects of additives in an antisolvent precipitation process and their important 
parameters is shown in Table 2.4, and is discussed in more detail below.  
How additives influence the processes of nucleation and crystal growth is difficult to 
study within nanocrystallisation experiments due to the extremely high 
supersaturations leading to fast particle formation kinetics. However, the mode of 
action of additives at moderate supersaturations within conventional nucleation and 
crystal growth experiments may be linked to the mechanisms at higher 








Table 2.4. Summary of the most important effects of additives highlighting the 
important parameters of the additives. 
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2.5.1. Influence of additives on nucleation 
The mechanisms by which additives influence the nucleation of a molecular 
compound is a topic of intensive interest in the crystallisation community [81]. 
According to the classical nucleation theory, the presence of additives may influence 
the kinetics of nucleation by altering (i) the thermodynamic driving force for 
nucleation through affecting solubility of the compound, (ii) the nucleus – solution 
interfacial energy influencing the energy barrier of nucleus formation, (iii) the pre-
exponential factor or (iv) the crystallisation mechanism from homogeneous to 
heterogeneous affecting also the nucleus – solution interfacial energy. These effects 
may be caused by changing the solution structure and properties [82], by inducing 
molecular ordering [83][84], by adsorption or chemisorption onto the nuclei [85], by 
acting as heteronuclei [86][87][88] or by chemical reaction or complex formation 
[89]. 
In 2009, Anwar et al. [90] used molecular dynamic simulations to examine the effect 
of additives on nucleation. They modelled the interaction between solute, solvent and 
additive using a Lennard-Jones system, systematically modulating the size of the 
additive and the affinity of the additive to the solute, solvent and to itself. Promotion 
of nucleation was found to be most effective when the additive had surfactant type 
properties, reducing the nucleus – solution interfacial energy upon adsorption onto 
the interface and thus, reducing the nucleation work. In line with this, Poon, Seritan 
and Peters [91][92] derived a theoretical model for low dosage additives that can 
accelerate nucleation through reducing the interfacial energy. In another study, Poon 
et al. [93] reported that, in addition to reducing the interfacial energy similarly to 
molecular scale surfactants, surface active oligomeric additives may serve as 
nucleation centres offering a heterogeneous surface for nucleation. In contrast, the 
study by Anwar et al. [90] also proposed that additives having solute like properties 
and strong affinity to the solute could retard or completely inhibit nucleation by 
occupying surface places or disrupting the packing of the emerging nucleus.  
There are only a limited number of studies showing direct experimental evidence of 
the facilitation of nucleation of molecular compounds by soluble molecular additives. 
Kim and co-workers [94] conducted induction time experiments using moderate 
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supersaturations and found that amphiphilic additives promoted the nucleation of the 
hexahydro-1,3,5-trinitro-1,3,5-triazine molecule. However, the results showed an 
increasing nucleation rate over time in contrast to the stationary rate assumed by the 
classical nucleation theory and thus, they were unable to estimate interfacial energy 
values for the studied systems. Poornachary et al. [95] found that 
polyvinylpyrrolidone (PVP) promoted the nucleation of naproxen crystals by 
increasing the pre-exponential factor with an insignificant change in the 
thermodynamic parameter and thus, interfacial energy for nucleation. The authors 
concluded that PVP acted as a heterogeneous nucleation centre in the crystallisation 
process.  
In contrast, nucleation retardation by additives is more commonly studied and 
observed experimentally due to the importance in the area of supersaturating 
amorphous formulations [85][96][97][98][99][89][100]. Ilevbare et al. [96] studied 
the effectiveness of a series of polymeric nucleation inhibitors for ritonavir, efivarenz 
and celecoxib molecules by unseeded desupersaturation experiments. The authors 
concluded that an effective nucleation inhibitor has a similar level of hydrophobicity 
to that of the drug molecule and a bulky structure, promoting polymer – solute 
interactions and, by assuming two-step nucleation, disrupting the reorganization of a 
cluster of solute molecules. In another contribution [85], strong polymer – solute 
interactions in solution, retarding solute diffusion to form a critical cluster, was 
proposed to be the key factor for inhibition. Structurally related additives or 
impurities could retard nucleation by incorporation into the nucleus, leading to an 
increased difficulty of the incorporation of a following solute molecule at the same 
site [99]. In addition, nucleation inhibition through solution complexation has been 
also reported [89].  
Depending on the additive concentration and supersaturation range, the influence of 
an additive may vary [95][99], suggesting the dominance of different mechanisms 
under different conditions. For example, Pino-Garcia and Rasmuson found that 
structurally related additives decreased the induction time of vanillin at low additive 
concentrations and low supersaturations compared to that of the pure system, while 
the additives tended to have the opposite effect at higher additive concentrations and 
supersaturations [99]. Analyses based on the classical nucleation theory revealed that 
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both the nucleus – solution interfacial energy and the pre-exponential factor for 
nucleation of vanillin was altered in the presence of the additives.  
2.5.2. Influence of additives on growth 
Compared to the influence on nucleation, the theoretical basis of how additives could 
influence crystal growth, supported by experiments predominantly in the field of 
inorganic crystallisation, is more advanced [42][60][101]. Molecular additives, 
besides influencing solution properties (e.g. equilibrium solubility, diffusivity), can 
alter the characteristics of the adsorption layer at the crystal – solution interface and 
affect the integration of growth units or can incorporate into the crystals, especially 
when there is some lattice similarity [42]. Adsorbed additives, especially large 
molecular polymers, create a mechanical barrier for the diffusion of growth units 
onto the crystal surface. In addition, additive adsorption may retard or inhibit the 
advancing of growth steps through kink-blocking or step-pinning, or can enhance 
crystal growth by decreasing the step free energies or providing kink sites for solute 
attachment [60]. Additive-assisted desolvation or surface diffusion can also promote 
crystal growth if these steps are rate limiting [102][103]. Selective action of the 
additives on the different crystal facets alters the relative growth rates of the facets 
and leads to the modification of crystal habit [104]. 
Several studies found polymers to be effective crystal growth inhibitors and 
identified optimum polymer hydrophobicity [105][106][107], specific drug-polymer 
interactions [108], and open conformation of the adsorbed polymer [109][110] as the 
key properties for the efficiency.  
2.5.3. Influence of additives on Ostwald ripening 
While the rate and extent of Ostwald ripening can be decreased by decreasing the 
temperature of the suspension or the solubility of the drug through evaporation of the 
organic solvent content, additives are often required to slow down particle 
dissolution, solute diffusion and crystal growth. In addition, a powerful, 
thermodynamically driven approach to inhibit the ripening process is the 
incorporation of a second, miscible, less soluble component into the particles [64]. 
However, this approach is rather specific and thus is only used in limited cases. 
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2.5.4. Influence of additives on polymorphic transformation 
Particle formation under high supersaturation often leads to an amorphous form or a 
metastable polymorph that can convert to a more stable crystalline form over time to 
reduce the free energy of the system. In a suspension, this polymorphic 
transformation generally follows a solvent assisted route, in which the stable form, 
having a lower solubility and thus experiencing a supersaturated solution, nucleates 
and grows at the expense of the metastable form [111][112][113]. Thus, depending 
on the rate limiting step of the process, additives are required to inhibit or retard 
nucleation, growth, particle dissolution and solute diffusion, as discussed in the 
above sections.  
2.5.5. Influence of additives on particle agglomeration 
Colloidal stabilisation by surfactant and polymeric additives is a highly studied and 
well established area. Stabiliser adsorption onto the particles, governed by the 
interactions between the additive, the particles and the solvent molecules, can 
decrease the tendency of particle agglomeration through thermodynamic (decreased 
interfacial energy) or kinetic (electrostatic or steric mechanism) effects, from which 
the latter is often required for long term stability. Electrostatic stabilisation in 
aqueous medium is described by the classical Derjaguin – Landau – Verwey –
 Overbeek (DLVO) theory [24] and postulates high suspension stability when the 
surface potential of the particles is high and the ion strength of the medium is low. 
Thus, determination of the zeta potential, i.e. electrical potential at the shear plane, 
helps to predict the stability of the system. It is observed, that if the zeta-potential is 
higher than ± 30 mV, the system has a good stability [8]. In the case of steric 
stabilisation, non-ionic polymers or amphiphilic block co-polymers adsorb at the 
surface of the nanoparticles and generally form a tail-train-loop structure [8]. When 
the colloidal particles approach each other, the polymer layers may interpenetrate, 
which is unfavorable when the medium is a good solvent for the polymer [24]. In 
order to obtain good steric stabilisation, the medium must be a good solvent for the 
stabilising part of the polymer and the thickness and density of the adsorbed polymer 
layer must be sufficient. Thus, apart from the chemical structure and affinity of the 
additive to the drug, the conformation and molecular weight of the additive are also 
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important [8]. In addition, when particles are not fully covered due to insufficient 
amount of polymer, particle-particle interaction or polymer assisted bridging 
interactions can take place [23]. Thus, the concentration of the polymer is also a 
crucial factor. The viscosity of the additive solution also affects the particle size [23]. 
Highly viscous solutions reduce the mobility of the particles resulting in reduced 
collision frequency of particles. Since nucleation is generally an instantaneous 
process during antisolvent precipitation, fast and sufficient additive adsorption is 
required to prevent the growth and early agglomeration of the created high number of 
nuclei. The kinetics of additive adsorption depends on the affinity, diffusion rate and 
concentration of the additive, which are typically interdependent. As an example, 
increasing additive affinity through a longer hydrophobic tail may lead to decreased 
diffusivity.  
2.5.6. General influence of additives during antisolvent precipitation 
From the previous sections, it is evident that additives have a complex influence on 
the different processes during nanocrystal and nanoparticle formation and 
stabilisation. While the identification of the effect of a particular additive is 
challenging, the effectiveness of an additive on size control might be quantified and 
compared by measuring the size of nanoparticles in suspension either quickly after 
precipitation or followed for a prolonged period of time, or after isolation. 
The concentration of the additive has a major effect on the size and stability of the 
nanoparticles, often showing an optimum value. Matteuci et al. [76] reported that 
increased additive concentration increased the nucleation rate of itraconazole 
resulting in smaller particles and narrower size distribution. They also suggested that 
higher additive adsorption onto the surface of the growing particles inhibited crystal 
growth and reduced agglomeration. Both effects were more prominent when the 
additive was added to the solvent phase possibly due to the higher concentration of 
additives in the vicinity of the nuclei and crystals formed immediately after drug 
solution injection in a nonhomogeneous solvent – antisolvent mixture. In contrast, 
Raghavan et al. reported that increasing hydroxypropyl methylcellulose 
concentration increased the size of the prepared triclosan particles [68]. They 
proposed that the increase in the size could be the result of particle agglomeration at 
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high polymer concentration. Xia et al. [15] also reported an optimum 
polyvinylalcohol concentration for the preparation of nitrendipine nanoparticles. 
They explained the results by insufficient surface coverage at low and increased 
medium viscosity at high polymer concentration.  
Combinations of additives are often found to be more effective. The combination of 
a non-ionic and an ionic additive can reduce the self-repulsion between ionic groups, 
resulting in better packing of the adsorbed layer [24][35]. The combination of the 
two stabilisation mechanisms, that is, using a non-ionic polymer and an ionic 
surfactant can be also beneficial. The superior stability achieved by the additive 
combination can be explained also by the kinetics of additive adsorption [114]. Ionic 
surfactants such as sodium dodecyl sulphate are small molecules compared to 
polymers, therefore they can quickly diffuse and adsorb to the surface of the particles 
providing fast early stage stability. However, steric stability provided by polymers is 
better for longer term stability. 
Screening of additives for the production of nanocrystals by size reduction 
technologies has been carried out, highlighting the importance of concentration 
[114][115] and hydrophobicity [115][116] of the additive as well as the milling 
properties of the drug [114] in the process. In contrast, although nanoparticles of 
numerous drugs have been successfully produced by antisolvent precipitation to date 
(Table 2.5), only a limited number of reports focused on the systematic screening of 
a wide selection of additives. Zhang et al. [35] probed eight additives for the 
preparation of megestrol acetate nanocrystals and found that the combination of a 
polymer (polyvinlypyrrolidone) and an anionic surfactant (sodium dodecyl sulphate) 
yielded the smallest crystals. Khan et al. [36] screened nine additives and several 
combinations of them for the production of artemisinin, glyburide and ibuprofen 
nanoparticles by determining the size of the particles over time in suspension. They 
were able to obtain nanoparticles from the three rather different drugs, but the size of 
the nanoparticles were quite varied, 92 nm for ibuprofen and 300 nm and 400 nm for 
glyburide and artemisinin, respectively. The choice of additives greatly affected the 
size of the particles formed, but there was no generic set of additives that yielded 
stable, low-particle-size nanocrystals for all three drugs. In addition, no correlation 
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was found between the molecular structure of the effective additives and the 
predicted dominant drug crystal surface.  
Table 2.5. Examples of optimal nanocrystal and nanoparticle formulations with the 
duration of suspension stability (mean size less than 1 µm) indicated.  
Compound Additives tested 








Tween 80 Poloxamer 188 drug/Tween 80  
ratio 1:0.975 















373 > 30 days 
Atorvastatin 
calcium [12] 
HPMC  drug/HPMC  
ratio 2:1 





 drug/VES/SDS  
ratio 1:0.66:0.79 



































PVP K30  
ratio 1:18:18 













P F127  
ratio 1:3:3 
85 > 30 days 
Itraconazole 
[71] 

























Continued on the next page. 
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Table 2.5. Continued.  
Compound Additives tested 








PVA  drug/PVA 
ratio 1:0.5 
209 > 15 min 
Spironolactone 
[74] 
HPMC  drug/HPMC 
ratio 2:1 
300 < 10 min 
Triclosan 
[68] 




> 45 days 
Abbreviations: hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone K30 (PVP K30), 
polyvinylalcohol (PVA), polyethyleneglycol (PEG), polyethelene glycol methyl eter (MPEG), 
Pluronic F68 (PF68), Pluronic F108 (PF108), Pluronic F127 (PF127), sodium deoxycholate 
(NaDC), sodium dodecyl sulphate (SDS), sodium laureth sulphate (SLS), α-tocopherol succinate 
(VES), microcrystalline cellulose (MCC). 
2.6. ISOLATION OF NANOPARTICLES 
Nanoparticles in suspension are often isolated and dried to form solid products in 
order to remove the toxic organic solvent, obtain long term stability and provide a 
more convenient solid dosage formulation. This step is just as crucial as the 
crystallisation and suspension stabilisation steps, since the small particle size must be 
maintained during isolation and drying to preserve the improved properties of the 
nanoparticles.  
Traditional isolation and drying techniques such as filtration or centrifugation 
followed by drying at elevated temperatures are not suitable for the preparation of 
redispersable nanoparticles. Filtration and centrifugation of suspensions with small 
particle size and higher viscosity requires unfeasibly long processing times and 
simple drying at elevated temperatures causes irreversible agglomeration [35].  
Extensive research has been conducted using freeze drying and spray drying for 
nanoparticle isolation [118][119][120][121]. During a freeze drying process, the 
suspension is frozen and the solvent is removed from the frozen state by sublimation 
under high vacuum [122]. The process generates freezing and capillary stresses that 
often leads to irreversible agglomeration and fusion of the nanoparticles, especially 
when the particle surface is highly hydrophobic, ultimately hindering the dissolution 
rate improvement [123]. Thus, to preserve the small particle size, cryoprotectants and 
lyoprotectants are generally added to the suspension prior to drying [119][120]. 
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Cryoprotectants such as sugars and polymers form physical barriers against 
agglomeration whereas lyoprotectants serve as water substitutes at the end of the 
drying process forming H-bond interactions with the particles [122]. However, freeze 
drying is a relatively slow and expensive process and may not be used in the 
presence of organic solvents [122]. In contrast, spray drying is more cost effective 
and can be employed in continuous processing of nanoparticles [66][119]. During the 
process, the suspension is atomised into fine droplets and dried rapidly with hot gas. 
Redispersable nanoparticles may be formulated using matrix formers such as lactose, 
sucrose and mannitol in the suspension [119]. However, this process is not suitable 
for thermosensitive drugs, can promote phase change when elevated temperatures are 
used and can lead to significant yield loss due to powder accumulation in the drying 
chamber [121]. Another disadvantage of both processes is the increased process 
complexity arising not just from the need of additional, process and system 
dependent stabilisers but also from the evaluation of process parameters that can 
significantly affect product quality [121][124]. 
Alternative nanoparticle isolation strategies have been suggested to overcome the 
limitations of the conventional techniques, including coacervate formation and 
filtration [125], nanoparticle embedment in polymer gels [126], spray granulation 
with carrier particles [127] and preparation of fluidised bed coated nanocomposite 
microparticles [128]. Khan et al. [129] introduced the use of insoluble dibasic 
calcium phosphate as carrier microparticles for the recovery of ibuprofen and 
glibenclamide nanocrystals from suspension. In their process, the carrier particles 
were added to the additive stabilised nanosuspensions, prepared either by milling or 
antisolvent precipitation processes, and the nanocrystals attached onto the surface of 
the carrier particles. Then, the carrier-attached nanocrystals could be simply 
recovered by filtration, offering a low-cost and robust, and thus industrially 
appealing alternative process for nanocrystal isolation. The recovery of nanocrystals 
was 90 % or better with an unchanged crystal size supported by dissolution tests 
showing the same dissolution profile for the redispersed nanosuspensions as for the 
fresh nanosuspensions. Thus, the approach offers the possibility of developing solid 
dosage forms with a dissolution rate similar to nanosuspensions. However, the 
approach had the limitation of low maximum drug loading of 0.35 w/w %, restricting 
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the use to high potency drugs only. In 2016, Tierney et al. [130] further developed 
this approach in our laboratory using surface functionalized montmorillonite (MMT) 
clay as carrier microparticle for the isolation of fenofibrate and mefenamic acid 
nanoparticles. Surface functionalization of the negatively charged MMT particles 
with a positively charged cationic polymer, protamine, enabled a uniform and 
segregated attachment of nanoparticles on MMT particles. Present during or added 
shortly after nanoparticle formation, MMT stabilised the nanoparticles in the 
suspended state without the presence of soluble additive molecules. Fast dissolution 
of the dried nanoparticles was retained up to 9.1 w/w % (fenofibrate) and 4.8 w/w % 
(mefenamic acid) drug loading of the nanocomposite microparticles.  
2.7. CONCLUSIONS  
As a solution to dissolution limited bioavailability, nanoparticle formulation of 
poorly water soluble drugs can be developed using antisolvent precipitation as a 
controlled crystallisation method. How the properties of the nanoparticles may be 
varied by varying different process parameters such as drug concentration, 
temperature or the ratio of the antisolvent to the solvent is generally understood. 
However, system dependent features require the optimization of process parameters 
for each particular drug. 
Further control can be achieved using soluble surfactant and polymeric additives 
with the desired effects of nucleation facilitation, crystal growth inhibition and 
prevention of subsequent particle transformation processes. However, nucleation and 
crystal growth studies at moderate supersaturations indicate that individual additives 
often affect crystal nucleation and growth in a similar manner, i.e. either retarding or 
facilitating both of them, which limits the efficiency of the additive. Adding to the 
complexity, the prevention of subsequent particle growth mechanisms might require 
additional additives not needed or even having an adverse effect during the earlier 
steps.  
Although nanoparticles of several pharmaceutical compounds have been successfully 
produced by antisolvent precipitation to date, the systematic screening of a wide 
selection of additives is rather scarce. In these studies, additive screening is generally 
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done based on particle size and further examination is limited to the additive or 
combination of additives producing the smallest particle size. A more detailed study 
could provide information about the specific effect of the additive on the different 
stages of the nanoparticle formation and stabilisation processes, from which crystal 
nucleation, growth and particle stabilisation could be separately targeted. 
While experimental evidence for nucleation retardation by additives, especially in 
case of polymeric ones, is often encountered, facilitation of nucleation is less 
commonly seen and studied. In addition, although being undoubtedly valuable, 
quantifying the effect of additives during a nanoparticle formation process is 
extremely difficult at high supersaturations, inherent to the process. Recent 
computational and theoretical studies propose that additives may promote nucleation 
through lowering the interfacial energy while the limited number of experimental 
studies at medium supersaturations suggest the possibility of other mechanisms too.  
From an industrial perspective, carrier mediated filtration of nanoparticles is an 
appealing nanoparticle isolation process due to its simplicity and low cost. However, 
more research is needed to validate its general usability for different compounds, to 
specify the effect of soluble additives in the process, and to address the limitation of 
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CHAPTER III  
MEFENAMIC ACID NANOCRYSTALS 






In Chapter II it has been shown that antisolvent precipitation is a potential low-
energy crystallisation method for the production of drug nanoparticles with improved 
therapeutic response. Additives are often used during the precipitation process to 
control particle size and are generally present in the antisolvent or solvent phase prior 
to the mixing of the two solutions for the production of the crystals. Example of 
additives include polymers such as hydroxypropyl methylcellulose [1][2], 
polyvinylalcohol [3][4], polyvinylpyrrolidone [5], Pluronic F127 [6], and surfactants 
like Tween 80 or sodium dodecyl sulphate [7]. 
The role of additives in the process is complex; it is desired that additives promote or 
at least do not prevent nucleation, inhibit, or at least slow down, crystal growth and 
stabilize the system against subsequent particle transformation. However, nucleation 
and crystal growth studies, using moderate supersaturations, indicate that individual 
additives often cannot comply with all of these requirements. Poornachary and co-
workers [8] found that the presence of polyvinylpyrrolidone not just increased the 
nucleation, but also enhanced the growth rate of naproxen crystals in the studied 
supersaturation range. In contrast, the presence of hydroxypropyl methylcellulose 
(HPMC) decreased simultaneously the nucleation rate and the growth rate of 
naproxen at most of the tested supersaturations. Similarly, Alonzo et al. [9] found 
that the presence of HPMC inhibited both nucleation and growth of felodipine 
crystals. After the preparation of the nanosuspension, reasonable long term 
suspension stability is required for further processability. The prevention of 
subsequent particle growth mechanisms, which include particle agglomeration [2], 
Ostwald ripening [3][10] and polymorphic transformation, might require additional 
additives not needed or even having an adverse effect during the earlier steps.  
Although nanoparticles of numerous drugs have been successfully produced by 
antisolvent precipitation to date, only a limited number of reports focused on the 
systematic screening of a wider selection of additives. Khan et al. [6] screened nine 
additives and several combinations of them for the production of artemisinin, 
glyburide and ibuprofen nanoparticles by determining the size of the particles over 
time in suspension. Similarly, Tierney et al. [3] tested seven additives and 
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combinations of them by measuring the particle size of fenofibrate nanoparticles in 
suspension. Zhang et al. [5] probed eight additives for the preparation of megestrol 
acetate nanocrystals by determining the size of the isolated crystals. In all these 
studies, only formulations having the smallest particle size were selected for further 
characterization. The more detailed influence of additives producing larger particle 
sizes was not further examined.  
A more detailed study of the influence of each single additive can shed light on the 
specific action of the additive during the different stages of the crystallisation and 
nanoparticle stabilisation processes. From this knowledge, nucleation, crystal growth 
and other particle transformation processes can be separately targeted. This would 
allow for a rationale selection and a more targeted application of the additives, and a 
wider applicability of antisolvent precipitation for the preparation of stable 
nanosuspensions.  
In the present study, submicron crystals of a poorly water soluble drug, mefenamic 
acid (MEF) are prepared using an antisolvent precipitation process. At first, process 
conditions like antisolvent to solvent ratio, temperature and concentration are 
optimized in the absence of additives using a factorial design approach. In the second 
step, the influence of various single additives on the particle size in suspension, and 
on the size, habit and polymorphic form of the isolated particles is investigated to 
identify the particular action of each additive in the nanocrystal formation and 
stabilisation processes. From these results, for the first time to our knowledge, 
stepwise addition of additive combinations is used to separately target the nucleation 
and particle growth/phase transformation processes, preparing MEF nanocrystals of 
the desired polymorphic form with improved suspension stability. It is demonstrated 
here that additives that have an adverse effect on the nucleation of the nanoparticles 
can be useful for stabilisation if added later in the process. Thus, introducing 
different additives at specific stages of the crystallisation process can provide a wider 
applicability of the additives and can be a powerful approach to control the properties 
of the product crystals.  
MEF is a non-steroidal anti-inflammatory drug categorized as a BCS II class 
compound having dissolution limited bioavailability. It has three known polymorphic 
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forms, all of them having a triclinic crystal structure [11]. Form I is the stable form at 
ambient conditions [12] and is present in the commercial formulations. Form II is 
enantiotropically related to Form I with a transition temperature of 86.6 °C [13], 
whereas Form III is metastable within the studied temperature range [11]. Several 
formulation approaches have been investigated to improve the dissolution rate of 
MEF, such as preparation of nanoparticles by electrospray drying [14] or by dry 
grinding [15] and preparation of microsheperes [16] and solid dispersions [17]. 
However, preparation of MEF nanocrystals by an antisolvent precipitation method 
has not previously been reported. 
3.2. MATERIALS AND METHODS  
3.2.1. Materials 
Mefenamic acid (MEF, > 98 %), N,N-dimethylacetamide (DMA, > 99.9 %), 
polyvinylalcohol (PVA, 9-10 kDa, 80 % hydrolyzed)), hydroxypropyl 
methylcellulose (HPMC, 15 cP), Pluronic® F127 (PF127), Pluronic® F68 (PF68), 
Tween 20, Tween 80, sodium docusate (dioctyl sulfosuccinate sodium salt, DOSS) 
and sodium dodecyl sulfate (SDS), were obtained from Sigma Aldrich. Deionized 
water was used for aqueous solutions (18 MΩ, ELGA, Purelab Ultra). All chemicals 
were used as received.  
The metastable polymorphic form, MEF Form II was prepared by heating the as 
received MEF Form I at 160 °C for 48 hours [12]. The structural purity of the 
product was examined by PXRD and FTIR. 
3.2.2. Solubility of MEF Form I 
The solubility of MEF Form I (as received form) in DMA – water mixtures with 40 
volume/volume % (v/v %) or lower water content was determined by a gravimetric 
method at 25, 30, 35, 40 and 45 °C. Solutions were saturated by adding an excess of 
solid to the solvent mixture and placing into a water bath (Grant GR150, accuracy ± 
0.1 °C) under magnetic stirring at 500 rpm. After 48 h, 3-5 mL samples were filtered 
with polytetrafluoroethylene (PTFE) or nylon syringe filters (0.2 µm pore size, 
VWR) into a pre-weighed vial. The solutions were then weighed and placed in an 
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oven at 60 °C to evaporate the solvent. The solubility was calculated by dividing the 
amount of dried solid by the amount of evaporated solvent (accuracy of balance ± 
0.0001 g). Powder X-ray diffraction experiments verified that the crystalline state of 
the suspended MEF Form I did not change during the equilibration.  
3.2.3. Antisolvent precipitation and isolation of MEF particles 
MEF was dissolved in DMA and the solution was filtered through a PTFE membrane 
(0.2 µm pore size, VWR) to eliminate particulate impurities. The antisolvent phase 
was either pure deionized water or an aqueous additive solution (concentration of 
each additive was 1.053 mg/mL), filtered through a nylon membrane (0.2 µm pore 
size, VWR). To prepare the particles, a volume of MEF solution at 25 °C was 
quickly injected into the antisolvent solution under magnetic stirring. The volume of 
the final suspension was 10 ml and the temperature was controlled with a waterbath 
(accuracy ± 0.1 °C). When indicated, an injection of 1 mL of 10 mg/mL additive 
solution was done 5 seconds after the initial solvent/antisolvent mixing. At specific 
times after mixing of the solvent and antisolvent solutions, called “aging time”, the 
particles were isolated by filtration (0.2 µm pore size nylon membrane, Whatman) 
and washed with deionized water. The filtration time varied from 15 seconds to 10 
minutes, being shorter for larger particle sizes and longer for smaller ones. The 
particles were then transferred into an Eppendorf tube and dried under vacuum (< 27 
Pa) at room temperature for 20 hours.  
Firstly, the effect of four different process parameters were studied in the absence of 
additives, using a full, two-level factorial design with: MEF concentration in the final 
solvent – antisolvent mixture (cf) of 2 or 5 mg/mL, stirring rate (s) of 200 or 
1600 rpm, antisolvent temperature (TAS) of 25 °C or 5 °C and antisolvent to solvent 
ratio (AS/S) of 4 or 19. The product properties after 30 seconds aging time were 
evaluated. Then, using the optimum process conditions (cf = 2 mg/ml, s = 1600 rpm, 
TAS = 5 °C, AS/S = 19), the influence of different additives was investigated. The 
additives included non-ionic polymers (HPMC, PVA), non-ionic block-copolymers 
(PF68, PF127), non-ionic surfactants (Tween 20, Tween 80) and anionic surfactants 
(DOSS, SDS). The molecular structure of MEF and the additives are shown in Figure 
3.1. Precipitation of the additives in the antisolvent – solvent system was tested by 
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injecting pure DMA into the additive solutions under the same process conditions 
(TAS = 5 °C, AS/S = 19). Precipitation of the additives was not observed visually 
during 3 days in the stirred solution. All the samples were prepared for 
characterisation at least in duplicate, unless otherwise stated.  
 
Figure 3.1.  Structure of MEF and additives 
3.2.4. Characterization of the particles in suspension 
Particle size distribution. The particle size distribution of the precipitated MEF 
suspensions was measured by laser diffraction (Mastersizer 3000, Malvern), using 
water as the dispersion medium. The suspension was sampled after specific aging 
times and diluted 5 times in water. Then the sample was added to the dispersion 
chamber to reach a dilution giving approximately 5-7 % obscuration and allowed to 
disperse for forty seconds. Each sample was measured with three consecutive sub-
runs using 10 seconds delay between runs and the average volume-weighted mean 
diameter (D[4,3]) was recorded. The relative standard deviation of the results of sub-
runs was generally less than 3 %, except when HPMC and PVA were used as single 
additives, where it was 2-10 %. Based on the analysis of the difference between the 
real light scattering data and fitted data, an imaginary part of 0.01 was applied with 
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not differentiate between individual particles and agglomerates composed of 
individual particles. 
Zeta potential. The zeta potential of the precipitated suspensions was determined by 
a Malvern Zetasizer Nano ZSP, using a folded capillary cell (cell type: DTS1070). 
The suspension was sampled after 30 seconds aging time and diluted 20 times in 
water and the temperature was equilibrated at 20 °C prior the measurement. Each 
sample was measured with three consecutive sub-runs and the average (relative 
standard deviation less than 2 %) was recorded as the result of the measurement. Zeta 
potentials were calculated in the software using the Henry equation with 
Smoluchowski approximation for aqueous suspensions. 
Precipitation yield. Precipitation yield was determined by characterizing the amount 
of MEF in the filtrate after separating off the particles by filtration. The filtrate was 
diluted with DMA to reach 50 % DMA content, and the concentration of MEF was 
measured by UV-Vis at 290 nm using a Perkin Elmer spectrophotometer. When 
additives were used, the additives were also present in the blank solution.  
3.2.5. Characterization of isolated particles 
Scanning electron microscopy (SEM). The size and shape of the isolated individual 
particles/crystals was characterized by a HITACHI SU-70 scanning electron 
microscope. To facilitate faster filtration and preserve the size of particles in 
suspension at specific aging times, an alternative method, filtration of 2 mL of the 
suspension, was used to isolate the particles in the presence of additives. The 
filtration time in this way was comparable for all the systems, being around a few 
seconds. The particles were then washed and dried under vacuum (< 27 Pa) at room 
temperature for 20 hours. To prepare the SEM samples, a small amount of the 
isolated particles were placed onto an adhesive carbon tape attached to a cylindrical 
aluminum sample holder and samples were gold sputtered at 20 mA for 1 minute 
using an EMITECH K550. The approximate particle/crystal size distribution was 
determined by manually analyzing 100 particles using ImageJ 1.42 software [18]. 
Thus, this method could characterize the size of individual particles, irrespective of 
their agglomeration in suspension. To describe the distribution, the following six 
characteristic lengths were recorded for each sample: the minimum, the average and 
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the maximum lengths, and the lengths at which 10 %, 50 % and 90 % of the particles 
are equal to or smaller than (D10, D50, D90).  
Powder X-ray diffraction (PXRD). The crystalline state of the isolated particles was 
characterized by a Philips PANAlytical X’pert diffractometer using Ni filtered Cu 
Kα radiation (λ=1.54 Å), 40 kV accelerating voltage and 40 mA anode current. The 
sample was placed between amorphous tapes and measured in transmission 
geometry. The diffraction pattern was collected between 5˚ and 40˚ (2θ) and the 
separately measured diffraction pattern of the amorphous tape was subtracted from 
the diffractogram.  
Differential scanning calorimetry (DSC). Thermal analysis of the isolated particles 
was performed using a Perkin-Elmer Pyris 1 differential scanning calorimeter. To 
perform the thermographs, approximately 3 mg powder was placed into a closed 
aluminum pan and 30 mL/min N2 gas flow and 50 °C/min heating rate were used 
during the measurement. Calibration was made using indium and the same heating 
rate. After baseline subtraction, the onsets of thermal events were determined.  
Infrared spectroscopy (FTIR). Fourier transform infrared spectroscopy was 
employed to determine the presence of additives and possible interactions between 
MEF and the additives in the isolated particles. Spectra were recorded between 650-
4000 cm-1 using 2 cm-1 spectral resolution and 16 scan per sample with a Perkin 
Elmer Spectrum 100 ATR FTIR.  
3.3. RESULTS 
3.3.1. Antisolvent precipitation in the absence of additives 
The solubility of MEF Form I in pure DMA at 25 °C was found to be 553.1 ± 
1.4 mg/g solvent and it sharply decreased by increasing the water content of the 
cosolvent system (Table A3.1 in Appendix A). Injection of the yellow MEF solution 
into the antisolvent in the absence of additives resulted in the formation of a yellow 




Figure 3.2a shows selected SEM micrographs of the isolated MEF crystals prepared 
under different process conditions and Figure 3.2b summarizes the D10, D50, D90 
lengths of the crystal size distributions measured from the SEM micrographs. The 
combination of lower concentration, lower stirring rate, higher temperature and 
lower antisolvent to solvent ratio (X) yielded crystals with rod-like habit, in the range 
of 0.7 - 14.4 µm (minimum - maximum lengths) having a D50 of 2.6 ± 0.3 µm. The 
increase of the MEF concentration in the final DMA – water mixture (A), the stirring 
rate (B) or the antisolvent to solvent ratio (D), or the decrease of the temperature of 
the antisolvent (C) reduced the length of the crystals. Changing only one parameter 
at a time, the increase of the antisolvent to solvent ratio from 4 to 19 had the biggest 
influence on the crystal size (D), creating crystals in the range of 0.18-4.3 µm with a 
D50 of 0.79 ± 0.06 µm. Using the antisolvent to solvent ratio of 19, alteration of 
other parameters only slightly changed the lengths of the crystals. The combination 
of the antisolvent to solvent ratio of 19 and final suspension concentration of 
5 mg/mL resulted in the creation of larger spherical agglomerates, irrespective of the 
stirring rate or temperature (Figure A3.1 in Appendix A). Based on the analysis of 
SEM images, MEF concentration in the final DMA – water mixture of 2 mg/mL, 
stirring rate of 1600 rpm, antisolvent temperature of 5 °C and antisolvent to solvent 
ratio of 19 were chosen as the optimum process conditions for further studies. The 
habit of the crystals prepared under these conditions was rod-like and the length of 
the crystals ranged from 0.22 µm to 2.71 µm with a D50 of 0.84 ± 0.05 µm (Figure 
3.2, BCD).  
All samples prepared by altering the process conditions had intense diffraction peaks 
of the metastable polymorph, Form II, along with less intense peaks of the stable 
polymorph, Form I (selected samples shown in Figure 3.3). Form I can be 
characterized by the peaks at 6.4˚, 15.2˚ and 21.5˚, whereas Form II has 









































Figure 3.2. (a) SEM images of isolated MEF crystals prepared in the absence of 
additives using different process conditions. (b) Summary of D10, D50 and D90 
characteristic values of the crystal length distributions (n = 3), determined from SEM 
images. X = MEF concentration in the final mixture of cf = 2 mg/mL, stirring rate of 
s = 200 rpm, antisolvent temperature of TAS = 25 °C, antisolvent to solvent ratio of 
AS/S = 4; A = higher final concentration (cf = 5 mg/mL); B = higher stirring rate 
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antisolvent to solvent ratio (AS/S = 19). Crystals were isolated at 30 seconds aging 
time. 



























Figure 3.3.  PXRD diffractograms of precipitated samples prepared with different 
process conditions and isolated at 30 seconds aging time: (a) cf = 2 mg/mL, s = 200 
rpm, TAS = 25 °C, AS/S = 4; (b) cf = 2 mg/mL, s = 200 rpm, TAS = 25 °C, AS/S = 19; 
(c) cf = 2 mg/ml, s = 1600 rpm, TAS = 5 °C, AS/S = 19; (d) cf = 5 mg/mL, s = 1600 
rpm, TAS = 5 °C, AS/S = 19; and that of MEF polymorphs (e) Form II, (f) Form I. 
3.3.2. Influence of single additives 
Injection of MEF solution into the antisolvent, in the presence of most of the 
additives, showed the same early color change of the formed suspension as without 
additives, from yellow to white. However, the presence of HPMC as a single additive 
in the antisolvent significantly delayed the color change from a few seconds to 1.5 
minutes and the suspension was not filterable after 1 minute aging time. Thus, MEF 
suspensions prepared in the presence of HPMC was characterized at later aging times 
only, after 5 minutes aging. The mass of MEF corresponding to the measured MEF 
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concentration in the filtrate after separating off the particles (Table A3.2 in Appendix 
A) was negligible compared to the total mass of MEF in the starting solution. 
Accordingly, the solid phase retained by the filter contains basically the entire mass 
of MEF. Since MEF content of the filtrate includes both dissolved MEF molecules 
and MEF particles that passed through the filter membrane, the measured negligible 
amount of MEF confirms both the high product yield as well as the validity of the 
filtration method for the isolation of the particles.  
 
Figure 3.4. Volume-weighed mean size, D[4,3], of MEF particles in suspension 
prepared with different additive solutions and characterized at different aging times. 
Bottom diagram magnifies the upper one showing the size below 3 µm. Each data 
point was measured once.  
The presence of most of the selected additives in the antisolvent reduced the initial 
particle size in suspension, except HPMC, as shown in Figure 3.4. In the presence of 
Pluronics and surfactants, the particle size did not change significantly during the 
studied 30 minutes aging. In contrast, in the presence of HPMC and PVA, the 
particle size substantially increased during aging. Using the drug to additive weight 
ratio of 2 to 1, the effectiveness of a single additive in the preparation of MEF 
nanoparticles in suspension can be ranked as follows: DOSS ~ SDS > Tween 20 ~ 






















Figure 3.5 compares the particle size distribution of the MEF suspension prepared in 
the absence of additives and in the presence of the most effective additive, DOSS, 
after 1 minute aging time. The presence of DOSS in the antisolvent significantly 
reduced the volume-weighed mean size of the particles in suspension, from 
12.1 ± 0.6 µm to 312.0 ± 0.5 nm. In parallel to the particle size change, the zeta 
potential of the particles increased from -35.3 ± 1.3 mV (no additives) to -60.3 ± 1.8 
mV measured after 30 seconds aging time when DOSS was present in the 
antisolvent. 
 
Figure 3.5. Particle size distribution of MEF suspension after 1 minute aging time, 
prepared in the absence of additives (red) and in the presence of DOSS (blue) (n =3).  
SEM micrographs of the isolated particles can be seen in Figure 3.6, after 1 minute 
aging time. The presence of various additives in the antisolvent altered both the habit 
and size of the dried particles. The habit of the particles was clearly different 
depending on the additive used. For most of the additives, the surface of the prepared 
particles was smooth, whereas particles prepared in the presence of HPMC or PVA 
had a rough surface, which might indicate the presence of the polymers. In addition 
to the differences in habit, the length of the particles also varied, being the longest for 
PF127 and shortest for DOSS. In the presence of the most effective additive, DOSS, 
a mixture of particles having cubic and rod-like habit in the range of 0.14 – 1.38 µm 
(minimum-maximum lengths) were isolated. This length is shorter than the length of 
the particles when no additive was present in the antisolvent (0.25 – 3.05 µm), while 

















312.0 ± 0.5 nm
D[4,3]=
12.1 ± 0.6 µm
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minutes aging in suspension, the average length of the particles prepared in the 
absence or presence of additives only changed moderately (Figure A3.2 in Appendix 
A). In the case of HPMC and PVA, this is in contrast to the observed significant 
particle size increase in suspension during aging. In addition, although the average 
length of the isolated particles did not change greatly over 30 minutes aging time, the 
habit of the particles did change in the presence of DOSS and SDS (Figure A3.2 in 
Appendix A).  
 
Figure 3.6.   SEM images of MEF crystals prepared in the presence of different 
additives and isolated after 1 minute (no additive, PVA, PF127, PF68, Tween 80, 
Tween 20, DOSS, SDS) or 5 minutes (HPMC) aging time, indicating the average 
length of the individual crystals and the deviation of the average among different 
samples.  
3 µm 3 µm 
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0.98 ± 0.07 µm 1.12 ± 0.02 µm 1.81 ± 0.18 µm 
2.62 ± 0.05 µm 2.06 ± 0.09 µm 1.08 ± 0.04 µm 
1.11 ± 0.01 µm 0.42 ± 0.02 µm 1.05 ± 0.01 µm 
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Figure 3.7. PXRD graphs of MEF crystals prepared in the presence of different 
additives isolated after 1 minute (no additive, PVA, PF127, PF68, Tween 80, Tween 
20, DOSS, SDS) or 5 minutes (HPMC) aging time (solid line, black) and 30 minutes 
aging time (dashed line, red), along with the PXRD graphs of pure MEF polymorphs. 
Similarly to the particles prepared in the absence of additives, MEF particles 
prepared in the presence of PF127, PF68, DOSS and SDS were a mixture of the 
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stable Form I and the metastable Form II polymorphs of MEF, Figure 3.7. In 
contrast, the presence of Tween 80 and Tween 20 resulted in the isolation of pure 
Form I crystals. In the case of particles prepared with HPMC and PVA, the 
diffraction peaks were significantly broader with reduced intensity, which implies 
reduced crystallinity. In the case of PVA, beside the Form II content, the presence of 
Form I was also indicated but only by the peaks at 15.9˚ and 21.5˚ in the 
diffractogram, whereas no Form I content was detected in the presence of HPMC. 
After 30 minutes aging in suspension, the relative intensity of the peaks characteristic 
of Form I increased compared to that after 1 minute aging time in the mixtures (no 
additive, PF68, DOSS, SDS). This indicates polymorphic transformation during 
aging in suspension. The greatest change was observed in the presence of DOSS 
where the peaks corresponding to the metastable Form II content almost disappeared 
after 30 minutes aging time. In contrast, the diffraction pattern of samples prepared 
in the presence of HPMC or PVA remained the same after 30 minutes aging time 
with no indication of change in crystallinity or polymorphic transformation.  
DSC analysis was also performed to verify the polymorphic form and the reduced 
crystallinity in the particles prepared with HPMC and PVA. Figure 3.8 presents the 
obtained DSC thermograms of pure MEF polymorphs, selected isolated MEF 
particles and pure additives, magnifying the area below the melting point of MEF. 
Extended thermograms up to the melting point were recorded only for pure MEF 
polymorphs (Figure A3.3, Appendix A) to avoid contamination of the instrument 
from the decomposition of MEF during melting [19][20]. The melting onset of MEF 
Form II was in good agreement with previous reports [11][19], being here 230.6 ± 
0.4 °C. In the case of pure Form I, the endothermic event of transformation of Form I 
to the enantiotropically related Form II [11] was observed at 170.8 ± 1.0 °C, also in 
agreement with literature values [19][20]. In cases of MEF particles prepared in the 
absence of additives or in the presence of DOSS, the transformation of Form I 
content to Form II occurred at lower temperatures (123.9 °C and 152.2 °C, 
respectively). This can be explained by the presence of Form II crystals already in 
the sample which accelerates the transformation [20].  A reduced size of the particles 
and thus, improved contact with the heated pan also contributes. These observed 
transformation temperature values for the precipitated samples are still above the true 
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transformation temperature of 86.6 °C, determined through solubility measurements 
by Park et al. [13], which supports our findings. In the case of particles prepared with 
HPMC and PVA, endothermic events were also observed, but the interpretation of 
these events is difficult due to the presence of thermal events in the same temperature 
range (~150 °C) for the corresponding pure additives. In addition, in the presence of 
HPMC and PVA, an exothermic event was also observed during heating with an 
onset of 115.4 ± 2.7 °C and 84.9 ± 3.3 °C, respectively, shown by the circles in 
Figure 3.8. This could correspond to the crystallisation of amorphous content [21]. 
No such an event was observed in the case of the particles precipitated in the absence 
of additives and in the presence of DOSS or in the thermograms of the pure additives 
in this temperature range.  
 
Figure 3.8. DSC thermograms of pure MEF polymorphs: (a) Form I, (b) Form II; 
thermograms of particles prepared (c) in the absence of additives, (d) in the presence 
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of pure additives: (g) HPMC, (h) PVA, (i) DOSS. Arrows indicate the onset of 
transformation of Form I to Form II, whereas circles highlight exothermic events that 
may correspond to the crystallisation of amorphous content. 
In order to further study the polymorphic form and explain the loss in crystallinity 
observed in the presence of HPMC and PVA, infrared spectroscopy was used, 
Figure 3.9. Form I and Form II can be clearly distinguished by the band position 
associated with the amine stretch [12][22], being 3308 cm-1 for Form I and 3344 cm-1 
for Form II. Particles prepared in the absence of additives or in the presence of 
DOSS had two peaks at 3345 cm-1 and 3311 cm-1 indicating that they were a mixture 
of Form I and Form II. In contrast, particles prepared in the presence of HPMC had 
just one peak at 3346 cm-1 verifying Form II content, and no Form I content. 
Particles prepared in the presence of PVA had a peak at 3347 cm-1 with a small 
shoulder below this indicating the presence of some Form I with the Form II content. 
These results were in good agreement with the PXRD analysis previously discussed. 
In the spectra of both polymorphs, a carbonyl stretch [22] was observed at 1646 cm-1 
with a shoulder at 1652 cm-1, a result of intermolecular hydrogen bonding in the 
crystal structure. The position and relative intensity of these bands remained the 
same for particles prepared in the absence of additives or presence of DOSS, while 
the relative intensity of the bands inverted and the shoulder band became the more 
intense band in the presence of HPMC and PVA. This shows altered hydrogen 
bonding interactions in the presence of these polymers. In addition, comparison of 
the spectra of the precipitated particles and the spectra of the corresponding pure 
additives showed no indication of the presence of DOSS, whereas the presence of 
HPMC was identified by the broad peak at 1050 cm-1. An IR study was not 
performed on pure PVA due to the large size of the rigid PVA crystals which were 
difficult to grind for analysis. 
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Figure 3.9. IR spectra of MEF polymorphs: (a) pure Form I, (b) pure Form II; 
spectra of particles prepared (c) in the absence of additives, (d) in the presence of 
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HPMC, (e) in the presence of PVA, (f) in the presence of DOSS; and spectra of 
additives: (g) pure HPMC, (h) pure DOSS. 
3.3.3. Influence of subsequent addition of HPMC and PVA 
To prevent polymorphic transformation of the nanoparticles prepared with DOSS, 
combinations of additives were examined. A combination of DOSS with HPMC or 
PVA in the antisolvent to which the solvent solution was injected led to increased 
particle size in suspension (compared at 1 minute aging time) compared to the size 
when only DOSS was present in the antisolvent (Figure 3.10). However, when 
HPMC or PVA solution was injected into the nanosuspension (prepared with the 
initial use of DOSS only) after 5 seconds aging time, the particle size in suspension 
was the same as with DOSS only (compared at 1 minute aging time).  
 
Figure 3.10. Volume-weighed mean size, D[4,3], of MEF suspensions prepared with 
the initial presence of different additives or with the initial presence of DOSS and 
subsequent (s.) injection of a second, concentrated HPMC or PVA solution to the 
suspension at 5 s aging time. Particle size was measured after 1 minute aging time. 
SEM images of the particles prepared in the presence of DOSS with HPMC or PVA 
and isolated after 1 minute aging showed the absence of well formed crystals (Figure 
3.11). PXRD characterization showed similar peak broadening and thus, reduced 

































Figure 3.11. (a) SEM micrographs and (b) PXRD diffractograms of MEF particles 
prepared with the initial presence of additive combinations. Particles were isolated 
after 1 minute aging time.  
The particle size over time in suspension, prepared in the presence of DOSS, with or 
without the subsequent addition of HPMC or PVA, is shown in Figure 3.12. In the 
presence of DOSS only, the initial particle size (312 nm) started to increase after 10 
minutes aging time, reaching 788 ± 4 nm after 80 minutes. This size only slightly 
increased during further aging, to 838 ± 21 nm after 18 hours. In contrast, the size of 
the particles in suspension prepared with the further addition of HPMC after 5 
seconds aging did not change during the studied 120 minutes and increased only to 
365 ± 18 nm after 18 hours. Similarly to the subsequent addition of HPMC, the 
subsequent addition of PVA also improved the size stability of the system, with only 
a moderate increase in the size during the first 120 minutes aging. However, the size 
of these particles increased to 681 ± 4 nm after 18 hours.  
 





Figure 3.12. Volume-weighed mean size, D[4,3], of MEF suspensions over time, 
prepared with the initial presence of DOSS only or with the initial presence of DOSS 
and subsequent addition of PVA or HPMC after 5 s aging time. The particle size in 
suspension after 18 hours aging is also indicated. 
 
Figure 3.13. SEM micrographs of MEF particles prepared with the (a-c) initial 
presence of DOSS, (d-f) initial presence of DOSS and subsequent addition of HPMC 
at 5 seconds aging time and (g-i) initial presence of DOSS and subsequent addition 

















DOSS + s. HPMC (5 s)
DOSS + s. PVA (5 s)
3 µm 3 µm 3 µm 
3 µm 3 µm 3 µm 
(d) 
3 µm 3 µm 3 µm 
(a) (b) (c) 1 min 60 min 120 min
1 min 60 min 120 min
1 min 60 min 120 min
(e) (f) 
(g) (h) (i) 
838 ± 21 nm at 18 h 
681 ± 4 nm at 18 h 
365 ± 18 nm at 18 h 
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In the presence of DOSS only, the size of the crystals isolated after certain aging 
times increased with time, with the appearance of larger crystals having a rod-like 
habit and the disappearance of smaller ones initially isolated from the suspension, 
Figure 3.13. After 120 minutes, only larger crystals were present in the sample. In 
contrast, when HPMC or PVA was added to the suspension after 5 seconds aging 
time, the size and habit of the isolated crystals did not change during the studied 
period.  
PXRD diffractograms of the particles prepared in the presence of DOSS, with or 
without the subsequent addition of HPMC or PVA are presented in Figure 3.14. In 
the presence of DOSS, as shown earlier, the isolated particles were a mixture of the 
metastable Form II and the stable Form I after 1 minute aging time. The diffraction 
peaks indicating Form II content gradually decreased over time and completely 
disappeared after 60 minutes of aging in suspension. It should be noted that the 
PXRD profiles do not correspond exactly to the rate of transformation in suspension 
since the transformation also occurs during the isolation and drying processes. The 
size change of the particles in suspension levels off after 80 minutes aging time 
(Figure 3.12), indicating the end of transformation in suspension. In addition, the 
SEM images (Figure 3.13), where only a small amount of suspension was isolated to 
facilitate faster filtration and drying, show smaller (starting material) and larger 
(transformed material) crystals even at 60 minute aging time, indicating that the 
transformation is not completed. 
When HPMC or PVA was added to the suspension, prepared with the initial presence 
of DOSS, after 5 seconds aging, the particles isolated after 1 minute aging time had 
significantly lower Form I content. This low Form I content did not change during 
the studied aging time when HPMC was added to the suspension but did increase 
slowly when PVA was added. In contrast to the particles prepared with the initial 
presence of the polymers (Figure 3.11), the particles prepared with later addition of 
HPMC and PVA had sharp PXRD peaks, indicating high crystallinity of the MEF 
particles. In addition, IR analyses of the isolated particles confirmed the absence of 
polymeric additives in these samples (Appendix A, Figure A3.4). This is consistent 





























































Figure 3.14. PXRD diffractograms of isolated MEF particles prepared with the (a) 
initial presence of DOSS, (b) initial presence of DOSS and subsequent addition of 
HPMC after 5 seconds aging time and (c) initial presence of DOSS and subsequent 
addition of PVA after 5 seconds aging time. Crystals were isolated after different 
aging times. Asterix indicates the diffraction peaks corresponding to Form I. 
3.4. DISCUSSION  
Antisolvent precipitation is a crystallisation method which can generate highly 
supersaturated solutions, leading to the formation of small crystals. Large differences 
in the drug solubility in the solvent and in the antisolvent lead to a steep solubility 
decrease with increasing amount of antisolvent. Upon mixing, this creates a high 
supersaturation. High supersaturation promotes rapid nucleation resulting in the 
formation of a large number of small crystals [3][6][23]. The influence of the studied 
process parameters on the size of the isolated MEF crystals (Figure 3.2) can be 
explained in terms of change of supersaturation. Higher drug concentration directly 
leads to higher supersaturation, while higher antisolvent to solvent ratio and lower 
temperature increases supersaturation by decreasing the solubility of the drug. In 
addition, more efficient mixing leads to a faster generation of supersaturation. 
Although the change of process parameters greatly decreased the size of the 
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produced crystals, submicron crystals of MEF could not be formed in the pure 
DMA – water systems.  
From all the pure DMA – water systems, a mixture of the stable Form I and the 
metastable Form II crystals were isolated, with significantly less intense PXRD 
peaks corresponding to the Form I crystals than to Form II (Figure 3.3). As stated by 
Ostwald’s rules of stages [24], when high supersaturation is used during 
crystallisation, a metastable polymorph is often formed at first. From the point of 
view of increased dissolution rate, the metastable form is favorable since it has 
higher solubility than the stable form [19]. However, a metastable form may undergo 
polymorphic transformation and if this happens, the control over the size distribution 
may be lost. It has been reported that the transformation of MEF Form II to MEF 
Form I in the presence of solvent is affected by the solubility of MEF in the solvent 
[20]. This transformation occurs completely in weeks in pure water at 40 °C (0.8 
µg/mL at 40 °C) but in hours in ethanol (10.45 mg/mL at 40 °C) [20]. In the system 
studied in this work, it has not yet been established if both polymorphs nucleate 
simultaneously or polymorphic transformation led to the presence of both 
polymorphs. However, there is no indication that samples prepared at lower 
supersaturation levels and having larger crystal sizes have a higher stable form 
content (Figure 3.3). This suggests that Form I crystals are formed as a result of 
transformation from the originally nucleated Form II crystals while in suspension 
and/or during the drying process.  
Eight additives of different chemical structure were selected to control the size and 
stability of MEF particles prepared by antisolvent precipitation. The range of particle 
size in suspension (Figure 3.4) and variations in crystal habit, size (Figure 3.6), and 
polymorphic form (Figure 3.7) of the isolated particles observed indicate that the 
presence of additives greatly influences the crystallization process and particle 
stability. Additives from the same group (non-ionic polymers, non-ionic block-
copolymers, non-ionic surfactants, anionic surfactants) affected the properties of the 
particles in a similar way, even when they were not closely related structurally. A 
comparison of the particle size in suspension (Figure 3.4) and the size of the isolated 
particles at different aging times (Figure 3.6 and Figure A3.2) indicates that 
individual particles are present in suspension in the presence of Pluronics and 
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surfactant additives, whereas the individual particles agglomerate in the presence of 
HPMC and PVA during aging.  
Of the additives studied, DOSS was the most effective for the preparation of MEF 
nanoparticles (Figure 3.5). DOSS is listed as a ‘Generally Recognised as Safe’ 
(GRAS) additive by Food and Drug Administration and it is present in at least two 
commercial nanocrystal drug formulations, Tricor® and Megace ES®. DOSS is an 
anionic surfactant having two hydrophobic tails and a hydrophilic inner part (Figure 
3.1). It may adsorb to the surface of MEF nanoparticles through hydrophobic 
interaction but it also has hydrogen bond acceptors that can interact with the acid or 
amine moieties of MEF. Adsorption of docusate ions on the crystal surface, 
demonstrated by the increased zeta potential of the particles, resulted in a reduced 
size of the individual crystals at 1 minute aging time compared to in their absence 
(Figure 3.6) and stabilised the suspension against particle agglomeration through 
electrostatic stabilisation [25] (Figure 3.5 and 3.6). The reduced crystal size indicates 
that DOSS promotes the nucleation of MEF Form II crystals. Theoretical 
calculations [26] and molecular dynamics simulations [27] proposed that surface 
active molecules can accelerate the nucleation process by reducing the interfacial 
energy between the nucleus surface and the solution through adsorption. As a result 
of higher nucleation rate, a larger number of smaller crystals form. We rule out the 
possibility that the smaller crystal size observed in the presence of DOSS relates to 
incomplete consumption of supersaturation at early aging times, since the 
concentration of MEF in the filtrate after separating off the particles was negligible 
compared to the initial solution concentration (Table A3.2 in Appendix A). 
In the presence of DOSS, a mixture of the stable Form I and the metastable Form II 
crystals were isolated, with similar intensity of the PXRD peaks corresponding to the 
different polymorphs present after 1 minute aging time (Figure 3.7). Yang et al. [28] 
observed simultaneous formation of MEF Form I and Form II crystals on self-
assembled monolayers and the ratio of the two forms could be varied by changing 
the functionalisation of the monolayer. However, the rapid polymorphic 
transformation observed herein in the presence of DOSS (Figure 3.14) suggests that 
the large amount of isolated Form I crystals is due to the promotion of the 
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transformation of Form II crystals to Form I by DOSS rather than the influence of 
DOSS on the phase purity at the nucleation stage.  
Transformation of Form II crystals to Form I in the presence of DOSS altered not 
just the phase purity and habit but also increased the size of the product crystals. If 
the transformation can be prevented, the size of the crystals can be stabilised, 
extending the time window for isolation of the nanoparticles. From the single 
additives tested during this study, the presence of macromolecules retarded (HPMC, 
PVA, PF127) or had no effect (PF68) on the transformation of MEF Form II crystals 
compared to in their absence, whereas anionic surfactants such as DOSS and SDS 
promoted the transformation (Figure 3.7). It should be noted that crystals prepared in 
the presence of the nonionic surfactants, Tween 20 and 80, were isolated as pure 
Form I already at 1 min aging time. However, we have no clear evidence of direct 
nucleation of the stable Form I crystals and for the other surfactant additives we 
observed the nucleation of Form II crystals that rapidly transformed to Form I. Thus, 
we hypothesize that Tweens promote the polymorphic transformation rather than 
alter the polymorphic outcome at the nucleation stage. These results demonstrate that 
macromolecules are more effective in preventing polymorphic transformation and 
can be used in combination with DOSS to stabilise the system. 
The presence of HPMC and PVA in the antisolvent reduced the crystallinity of Form 
II particles, characterized by PXRD and DSC (Figure 3.7 and 3.8). This effect cannot 
be attributed simply to the macromolecular nature of HPMC and PVA, since PXRD 
peak broadening was not observed in the presence of Pluronics, which have similar 
molecular weight to PVA. Thus, the reduced crystallinity of the particles, observed 
only for these additives, implies a more specific interaction of HPMC and PVA 
influencing/inhibiting the formation of Form II crystals. The interaction of HPMC or 
PVA and MEF, that is responsible for the inhibition of the formation of highly 
crystalline metastable Form II crystals, is likely to retard the nucleation of the stable 
Form I crystals too. In addition to the retardation of nucleation, these polymers might 
also inhibit the growth of Form I crystals. Although it is not determined here whether 
the inhibition relates to nucleation or growth or both, the results reveal an overall 
slower polymorphic transformation of Form II particles in the presence of these 
additives (Figure 3.7). 
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In parallel to the presence of HPMC and PVA in the particles, indicated both by the 
surface roughness of the particles and the obtained IR spectra, the hydrogen bonding 
interactions also changed in the particles (Figure 3.9). The shift of the main band 
corresponding to the carbonyl stretch towards higher wavenumbers shows reduced 
hydrogen bonding density in the particles compared to the original crystalline 
structure [29]. Since both polymers are able to form hydrogen bonds with MEF, the 
opposite trend could be expected. However, incorporation of the polymers into the 
particle disrupts the crystalline structure, reducing the crystallinity and the density of 
hydrogen bonded MEF dimers originally present in the crystal. Although it is 
difficult to determine the nature of the interaction between the polymers and MEF 
from the IR spectra due to the changed crystallinity, it is clear that these 
macromolecules have an interaction with MEF which led to the incorporation of 
them into the particles. Our finding correlates well with the work of Anwar et al. 
[27], who proposed, based on molecular dynamics simulations, that additives which 
are able to disrupt the emerging nucleus structure can inhibit or retard the nucleation 
process.  
Based on the results using single additives in the antisolvent, combinations of DOSS 
with HPMC or PVA were used with the aim to prepare nanocrystals with improved 
size and polymorphic stability over time. A comparison of the particle size in 
suspension (Figure 3.10) and the crystallinity of the isolated particles (Figure 3.11) 
prepared in the presence of DOSS with or without the polymers verifies that the 
presence of these polymers during nucleation of MEF inhibits the formation Form II 
nanoparticles.  
In contrast, when the HPMC or PVA is added to the suspension prepared with DOSS 
after nucleation, (i.e. stepwise use of additives), the initial small particle size is 
retained and the stability of the system is significantly improved (Figure 3.12). The 
interaction of HPMC and PVA with MEF reduced the rate of solution mediated 
polymorphic transformation, preserving the size (Figure 3.13) and polymorphic form 
(Figure 3.14) of the crystals over a significantly longer period of time. This resonates 
with the observation of Tian et al., that polymers with hydrogen bonding ability and 
sufficient hydrophobicity can completely inhibit the transformation of 
carbamazepine [30].  
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High crystallinity of the particles (Figure 3.14) and the absence of polymers in the 
particles (Figure A3.4 in Appendix A) prepared with the stepwise addition of 
additives indicate that the additives do not incorporate into the crystal structure when 
added to the suspension after nucleation of MEF crystals. This verifies that 
incorporation of the additives in the initial presence of HPMC or PVA is due to 
molecular interaction of the polymer with MEF and not the result of the co-
precipitation of the polymer because of exceeding the solubility of the polymer in the 
final mixture. 
Although both HPMC and PVA improved the stability of the suspension, HPMC was 
found to be more effective. The superiority of HPMC as an additive can be explained 
by its bulky chain structure [31], by which it may disrupt the packing of the 
emerging nucleus and retard the transfer of molecules onto the surface of the nucleus 
or growing crystal.  
The use of stepwise additive addition significantly extended the time window for 
isolation, improving the feasibility of the process on an industrial scale. The initial 
presence of DOSS promoted the nucleation, while the subsequent addition of HPMC 
greatly delayed polymorphic transformation. This study demonstrated that 
appropriate timing of each additive solution can exploit the favorable properties of 
each additive, allowing for a greater control over the process.  
3.5. CONCLUSIONS  
Using additives to separately target nucleation and particle growth/transformation led 
to improved mefenamic acid nanoparticle manufacturing. In the absence of additives, 
the size of the mefenamic acid crystals was reduced by increasing the supersaturation 
through increased MEF concentration in the antisolvent – solvent mixture, increased 
antisolvent to solvent ratio, lower temperature or increased mixing. The presence of 
additives greatly influenced the crystallisation and particle stability affecting particle 
size in suspension and the size, habit and polymorphic form of the isolated particles. 
Of the eight additives studied, docusate sodium was the most effective for the 
preparation of nanoparticles in suspension (D[4,3] = 312 nm), promoting nucleation 
and preventing particle agglomeration. However, the particle size in suspension 
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gradually increased during aging associated with a polymorphic transformation. In 
contrast, the presence of HPMC and PVA interfered with the formation of 
mefenamic acid particles resulting in larger size and reduced crystallinity compared 
to in their absence. The presence of these polymers did not prevent particle 
agglomeration in suspension, but they did prevent polymorphic transformation 
through inhibiting the nucleation and/or growth of the stable polymorph, Form I. 
Based on the results with single additives, favorable combinations of additives were 
identified. Combining the initial use of DOSS for nucleation control with subsequent 
addition of HPMC for stabilisation of the polymorphic form allowed for the 
preparation of stable suspension of MEF nanocrystals. This study demonstrates that 
the influence of different additives on the different mechanisms involved in 
manufacturing of nanocrystal suspensions varies, and that particular features of 
different additives can be exploited by appropriate timing of the addition of each 
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In Chapter III, an anionic surfactant, docusate sodium (DOSS), had to be added to 
produce nanocrystals of a poorly water-soluble compound, mefenamic acid (MEF), 
during an antisolvent precipitation process in 5 % dimethylacetamide (DMA) –
 95 % water system. Since the final size of the nucleating crystals is governed by the 
number of formed nuclei and thus, the nucleation rate, the reduction of the crystal 
size suggested that DOSS accelerated the nucleation of MEF. The approximately 
threefold reduction of the crystal volume in the presence of 1 mg/mL DOSS 
corresponds to a threefold increase in the number of formed nuclei, suggesting an 
approximately threefold increase of the nucleation rate. An increase in nucleation 
rate by the addition of additives is less commonly encountered than the opposite, so 
experimental evidence that the nucleation rate actually increased is needed. 
The mechanisms by which molecular additives promote the nucleation of a 
molecular compound is a topic of intensive interest in the crystallisation community, 
as discussed in section 2.5.1. Computational and theoretical studies [1][2][3][4] 
propose that surfactant type or surface active oligomeric additives can reduce the 
nucleus – solution interfacial energy and thus, reduce the nucleation work upon 
adsorption to the interface. Experimentally, the influence of a soluble additive can be 
studied by performing induction time experiments that is determining the time 
between the creation of supersaturation for crystallisation and the detection of the 
first crystals. Then, analysis of the results within the classical nucleation theory may 
shed light on the predominant mode of action of the additive. Conducting induction 
time experiments, Kim and co-workers [5] found that amphiphilic additives 
promoted the nucleation of the hexahydro-1,3,5-trinitro-1,3,5-triazine molecule. 
However, the results showed an increasing nucleation rate over time in contrast to a 
stationary rate assumed by the classical nucleation theory and thus, they were unable 
to analyse the results within this context. With similar experiments, Poornachary et 
al. [6] found that polyvinylpyrrolidone (PVP) promoted the nucleation of naproxen 
crystals by increasing the pre-exponential factor with an insignificant change in the 
thermodynamic parameter and thus, interfacial energy for nucleation. The authors 
concluded that PVP acted as a nucleation centre in the crystallisation process.  
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In order to produce nanocrystals of MEF, a very high supersaturation needs to be 
generated. This was achieved by using a high water concentration as MEF is 
essentially insoluble in water. However, at these conditions the induction time is 
extremely short and thus difficult to measure with sufficient accuracy. In addition, 
primary nucleation is a highly stochastic process and thus the nucleation rate at each 
condition must be recorded in repeated experiments. Commonly this is done in 
parallel cooling crystallisation experiments where 10-30 experiments on the millilitre 
scale are observed simultaneously at isothermal conditions after the creation of 
supersaturation [7][8][9], and where the cooling and reheating can be cycled to 
collect perhaps a hundred recordings of the induction time at each condition. 
However, supersaturation generation by cooling can only be used for induction times 
in the order of minutes and longer, at lower supersaturations and water content of the 
solutions, and thus not for the supersaturation experiments used in the nanocrystal 
manufacturing method for mefenamic acid. Measurement of shorter induction times 
at higher supersaturations, in solutions having a higher concentration of water, 
requires an antisolvent method. However, to operate 50-100 repeated antisolvent 
experiments is of course much more demanding as the antisolvent needs to be 
injected in every individual vial, and the experiment cannot be repeated without 
replacing the solution with fresh material. 
In this chapter, the influence of DOSS on the nucleation of a MEF solution is studied 
with the aim being to elucidate the action of DOSS in the nanocrystal formation 
process of MEF. A series of induction time experiments were performed at 
isothermal conditions in the absence or presence of DOSS, varying the 
supersaturation and the ratio of the drug to the additive. Initially, supersaturation was 
created using the conventional cooling crystallisation method in 70 % DMA –
 30 % water solvent system. This allowed for parallel crystallisation experiments of 
up to 15 vials to be performed and recycling of the solution, significantly reducing 
chemical waste and labour expenses. However, no influence of DOSS on the 
nucleation rate was found perhaps related to the much higher DMA content and 
lower supersaturations compared to the originally used conditions during the 
preparation of MEF nanocrystals. A more laborious antisolvent crystallisation 
method [6], where the solutions had to be mixed in each separate vial to achieve a 
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desired composition, allowed for the study of significantly shorter induction times in 
40 % DMA – 60 % water solvent mixtures and at higher levels of supersaturation. 
Under these latter conditions, DOSS enhanced the nucleation of MEF. The results 
are analyzed within the framework of the classical nucleation theory, and a 
mechanism for the nucleation enhancement and the influence of solvent composition 
is proposed. 
4.2. MATERIALS AND METHODS 
4.2.1. Scope of experimental work 
The overall scope of the experimental work is as follows: First, solubility of MEF 
polymorphs (stable Form I and where relevant, metastable Form II) is determined in 
the two studied solvent systems, in 40 %  DMA – 60 %  water and in 70 % DMA –
 30 % water, in the presence and absence of the surfactant docusate sodium and at the 
corresponding crystallisation temperatures. Then a series of induction time 
experiments is conducted under isothermal conditions in 40 % DMA – 60 % water 
(25 °C) and in 70 % DMA – 30 % water (15 °C), in the presence and absence of 
docusate sodium, generating supersaturation by antisolvent and cooling 
crystallisation, respectively. For both solvent systems at given conditions, the 
crystallised solid from a number of vials is isolated for determination of the 
polymorphic form. In 40 % DMA – 60 % water, the timescale of transformation of 
Form II to Form I is also studied. 
4.2.2. Materials 
Mefenamic acid (MEF, Form I, > 98 %), N,N-dimethylacetamide (DMA, > 99.9 %), 
acetonitrile (ACN), acetic acid, sodium docusate (dioctyl sulfosuccinate sodium salt, 
DOSS), and sodium acetate were obtained from Sigma Aldrich. Tetrahydrofuran 
(THF) was purchased from VWR. Deionized water was used for aqueous solutions 
(18 MΩ, ELGA, Purelab Ultra). All chemicals were used as received. The metastable 
polymorphic form, MEF Form II, was prepared as a reference material by heating the 
as received MEF Form I to 160 °C for 48 hours [10]. The structural purity of the 
product was examined by PXRD and FTIR.  
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4.2.3. Solubility studies 
The solubility of the stable MEF polymorph, Form I in 40 % DMA – 60 % water 
(v/v) was determined at the crystallisation temperature (Tcryst) of 25 °C in the absence 
and presence of 0.2 mg/mL DOSS from six separate solubility experiments. Here 
v/v % represents the volume fraction of solvents mixed for creating the specific 
cosolvent system. The solubility of Form I in 70 % DMA – 30 % water (v/v) was 
measured at the crystallisation temperature (Tcryst) of 15 °C in the presence of 
0-5 mg/mL DOSS, as well as at 20 °C, 30 °C and 35 °C in the absence of DOSS to 
estimate the temperature (Tsat) at which a solution with a given concentration is 
saturated. In this solvent system, three separate solubility experiments were done at 
each condition of DOSS concentration and temperature. In all cases, solutions were 
saturated by adding an excess of Form I solid to the corresponding solvent mixture 
and placing into a water bath (Grant GR150, accuracy ± 0.1 °C) under magnetic 
stirring at 400 rpm. After 24 h, the stirrer was switched off and the suspensions were 
left to settle for 24 h. From each solution a 2 mL sample was then filtered with nylon 
(with 40 % DMA) or polytetrafluoroethylene (PTFE) (with 70 % DMA) syringe 
filters (0.2 µm pore size, VWR), discarding the first mL to avoid possible adsorption 
of the MEF molecules to the filter membrane. While a hydrophilic nylon membrane 
was suitable for filtering solutions containing 60 % water, an organic solvent 
resistant PTFE was used to avoid possible degradation of the filter material with 
70 % DMA. In case of both solvent systems, the filtrate was diluted with 
70 % DMA – 30 % water and analyzed using an Agilent high performance liquid 
chromatography system (HPLC) at a detection wavelength of 285 nm. The mobile 
phase consisted of 55 % sodium acetate buffer at 50 mM, pH 5 and 45 % ACN:THF 
(23:7) solvent mixture. The chromatographic separation was carried out using a 
reverse phase C8 column (250 mm x 4.6 mm) and 1 mL/min flow rate. The volume 
of the injected sample was 20 µL. Powder X-ray diffraction experiments verified that 
the crystalline state of the suspended MEF Form I did not change during the 
equilibration.  
The determination of the solubility of the metastable Form II polymorph is more 
challenging because of the tendency for polymorphic transformation Thus in the 
present work, the solubility of Form II crystals was estimated from the mole fraction 
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solubility ratio (x II/ x I) determined by Romero et al. [11] at 25.0 ºC in different 
solvents, as this value is almost independent of the choice of solvent, representing the 
relative stability of the forms at a certain temperature. The mole fraction solubility 
ratio of MEF Form II and Form I at 25.0 ºC was reported to be 1.37 in water, 1.40 in 
ethanol and 1.28 in ethyl acetate [11]. Considering that polymorphic transformation 
is the fastest when the solubility is the highest, i.e. in ethyl acetate [11], and the 
solubility determination is more uncertain at low solubility, i.e. in water [11], the 
highest mole fraction solubility ratio measured in ethanol, 1.40, has been selected for 
the solubility calculation of MEF Form II at 25.0 ºC.  
Table 4.1. Solubility of MEF in 40 % DMA – 60 % water at 25 °C and in 
70 % DMA – 30 % water at 15 °C in the absence and presence of different 
concentrations of DOSS. Standard deviation is calculated from six (40 % DMA –




Solubility in 40 % DMA – 60 % w 
at 25 °C (mg/mL) 
Solubility in 70 % DMA – 30 % w 
at 15 °C (mg/mL) 
Form I Form II Form I 
0 0.065 ± 0.003 0.091 ± 0.004* 3.80 ± 0.01 
0.1 - - 3.81 ± 0.01 
0.2 0.065 ± 0.001 0.091 ± 0.002* - 
1.0 - - 3.81 ± 0.03 
2.5 - - 3.84 ± 0.04 
5.0 - - 3.92 ± 0.03 
* calculated from Form I solubility using the mole fraction solubility ratio of x II/ x I = 1.4 
In 40 % DMA – 60 % water at 25.0 ºC, the solubility of the stable MEF Form I was 
0.065 ± 0.003 mg/mL, and remained the same in the presence of 0.2 mg/mL DOSS 
(Table 4.1). The solubility of the metastable MEF Form II was calculated to be 
0.091 ± 0.004 mg/mL. In 70 % DMA – 30 % water the solubility of MEF Form I at 
15.0 ºC was 3.80 ± 0.01 mg/mL and did not change in the presence of 1 mg/mL 
DOSS but increased slightly to 3.92 ± 0.03 mg/mL in the presence of 5 mg/mL 
DOSS. The solubility in 70 % DMA – 30 % water in the absence of DOSS 
determined at different temperatures are graphed on Figure A4.1 (Appendix A) along 
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with an exponential fit to calculate Form I saturation temperatures for any given 
concentration relevant to supersaturation generation by cooling crystallisation. 
4.2.4. Induction time experiments  
Induction time refers to the time elapsed from the moment of the creation of 
supersaturation until the detection of the first crystals. Two different procedures, 
antisolvent crystallisation (40 % DMA – 60 % water) and cooling crystallisation 
(70 % DMA – 30 % water), were used to generate supersaturation. The program of 
induction time experiments is presented in Table 4.2, including the temperature of 
crystallisation, the polymorphic outcome and supersaturations calculated by dividing 
the molar concentration (mol/L) of the molecules in the supersaturated solution with 
the corresponding equilibrium concentration presented in Table 4.1. Note that the 
ratio of concentrations in the unit of mol/L for the same compound is equal to the 
ratio of concentrations in the unit of mg/mL, which concentration unit is also used 
herein for easier representation of the data. Throughout the paper, S I denotes 
supersaturation calculated with respect to Form I, whereas S II denotes 
supersaturation calculated with respect to Form II. Polymorphic behavior of the 
systems, providing a basis for the calculation of supersaturation, is presented later, in 
section 4.3.1. In both systems, the concentration of DOSS was selected to achieve 
molar ratios comparable to the originally used nDOSS/nMEF = 0.29 during the 
preparation of MEF nanocrystals in 5 % DMA – 95 % water (Chapter III).  
In the case of the 40 % DMA – 60 % water solvent system, supersaturation 
(S II = 4.40-2.20) was created by antisolvent crystallisation at Tcryst=25.0 °C. MEF 
solution (solution 1) was prepared in 80 % DMA – 20 % water (v/v) and filtered with 
a PTFE syringe filter (0.2 µm, VWR) after overnight stirring. The antisolvent 
solution (solution 2) consisted of 5.9 mL deionised water or aqueous DOSS solution 
premixed with 3.6 mL DMA. When DOSS was used, the antisolvent solution was 
filtered with a nylon syringe filter (0.2 µm, VWR) to remove particulate impurities. 
For an induction time experiment, 0.5 mL MEF solution (solution 1) was pipetted 
into 9.5 mL antisolvent solution (solution 2) giving a final solvent composition of 
40 % DMA – 60 % water. The mixed solution was stirred at 300 rpm using a 
magnetic stir bar and the induction time was recorded with a camera. The visually 
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detectable level of the mixing of the two phases was complete within 4 s. Since the 
mixing of DMA and water is highly exothermic, premixing of the major part of 
DMA and water as the antisolvent solution prior the addition of MEF solution 
allowed for the reduction of the initial temperature rise to less than 0.2 °C. The 
recorded videos were analyzed by the naked eye, carefully comparing snapshots 
prior to and after the visual appearance of crystals. The uncertainty of the detection 
technique itself, estimated from repeated analysis of the induction time video for a 
given vial of nucleating solution, is 3-4 seconds at S II = 4.40, increasing to 5-10 s at 
S II = 2.20. The use of lower supersaturations was restricted due to the decreasing 
turbidity of the system as a result of the lower mass crystallised. A minimum of 59 
data points were measured for each condition to account for the stochastic nature of 
nucleation. 
In case of 70 % DMA – 30 % water, supersaturation (S I = 1.99-1.53) was generated 
by cooling the solution below its saturation temperature, to Tcryst = 15 °C. A 250 mL 
stock solution was prepared by dissolving a known amount of MEF in the premixed 
solvent mixture at a Tdiss dissolution temperature, 16 °C above the corresponding 
saturation temperature (Tdiss = Tsat+16 °C) using submersible magnetic stirrer plate 
for mixing (400 rpm, 4 h). Based on solubility results (Figure A4.1 in Appendix A), 
Tdiss was 40.0 °C, 42.8 °C and 45.0 °C for S
 I = 1.53, S I = 1.75 and S I = 1.99, 
respectively. Then, the solution was filtered with preheated syringes equipped with 
PTFE filters (0.2 µm, VWR) to eliminate particulate impurities. This batch solution 
was subjected to two crystallisation cycles prior recording any induction times (pre-
treatment cycles) in order to overcome history of solution/filtration effects: first 
crystallisation at 5 °C followed by dissolution of the crystals at Tdiss (4 h), then 
crystallisation at Tcryst = 15 °C followed by dissolution of the crystals at Tdiss (3 h). 
Fifteen mL solutions were then distributed into 15 preheated vials containing a 
magnetic stir bar and left to equilibrate for another 2 h at Tdiss. To start the induction 
time experiments, the vials were placed into a waterbath at Tcryst = 15 °C and stirrer 
speed of 250 rpm, and a high resolution camera was started to record the induction 
time by visual inspection. Due to the 3-4 min initial cooling period to the 
crystallisation temperature, also measured as a part of the induction time, only 
supersaturations giving sufficiently large induction times (> 10 min) could be studied 
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using this method to ensure that nucleation occurs at isothermal conditions. After 
crystallisation, the vials were placed back into the waterbath at Tdiss for dissolution 
(5 h) and the crystallisation cycle was repeated (Tcryst –Tdiss – Tcryst and so on) to 
collect a minimum of 60 induction time data for each condition.  
Table 4.2. Induction time experiments performed, temperature of crystallisation 
(Tcryst), concentration of MEF (cMEF) and DOSS (cDOSS) in the final solvent mixture, 















































5.0 0.41 1.70I 
5.81 0.0 0.00 Form I 1.53I 
I S is calculated based on Form I solubility 
II S is calculated based on Form II solubility 
4.2.5. Isolation and characterisation of the crystals  
Isolation. In the case of 40 % DMA – 60 % water solvent system, two drying 
methods have been used to understand the polymorphic behavior of the systems. (1) 
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At S II = 4.40 in the absence of DOSS, crystals were isolated by filtration at different 
times (8 min, 15 min and 3.5 hours) after the first detection of crystallisation and 
dried under high vacuum (< 27 Pa) at room temperature for 16 h. (2) At S II = 4.40 
and S II = 2.20, in the presence of 0.0-0.2 mg/mL DOSS, crystals were isolated by 
filtration, 8 min (in case of S II = 4.40) or 15 min (in case of S II = 2.20) after the first 
detection of crystallisation and dried at 50 °C for 1 h. Due to the very low 
crystallising mass, these selected times were required to ensure enough sample for 
characterisation. While drying at room temperature was employed to slow down 
polymorphic transformation during drying, the obtained crystals were partially 
defected because of the high vacuum. Thus, the second drying method using higher 
temperature but atmospheric pressure was used further on to avoid sublimation of the 
crystals. In case of 70 % DMA – 30 % water, crystals were isolated by filtration, 8 
min (S I = 1.99) or 15-20 min (S I = 1.75 and S I = 1.70) after the first detection of 
crystallisation and dried at 50 °C for 1 hours.  
Infrared spectroscopy (IR). The polymorphic form of the crystals, in cases of small 
crystallisation yields, was characterized by Fourier transform infrared spectroscopy, 
employing a Perkin Elmer Spectrum 100 ATR FTIR. Spectra were recorded between 
650-4000 cm-1 using 2 cm-1 spectral resolution and 32 scan per sample. Three 
samples were characterized at each condition unless otherwise stated.  
Powder X-ray diffraction (PXRD). The polymorphic form of the crystals nucleated in 
70 % DMA – 30 % water at S I = 1.99, having a larger crystallisation yield, was 
verified using a Philips PANAlytical X’pert powder X-ray diffractometer. The 
sample was placed between amorphous tapes and measured in transmission geometry 
using Ni filtered Cu Kα radiation (λ=1.54 Å), 40 kV accelerating voltage and 40 mA 
anode current. The diffraction pattern was collected between 5˚ and 30˚ (2θ) and the 
separately measured diffraction pattern of the amorphous tape was subtracted. 
Scanning electron microscopy (SEM). The size and habit of the isolated crystals were 
analysed by a HITACHI SU-70 scanning electron microscope at 3 kV. To prepare 
the samples, a small amount of isolated particle was placed onto an adhesive carbon 
tape attached to a cylindrical aluminum sample holder and gold sputtered at 20 mA 
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for 1 minute using an EMITECH K550. Two samples were characterized at each 
condition. 
4.3. RESULTS 
4.3.1. Polymorphic behaviour of the systems 
IR spectra of the crystals nucleated in 40 % DMA – 60 % water at S II = 4.40 in the 
absence of DOSS, isolated at different times after the detection of crystallisation and 
dried under high vacuum at room temperature are presented in Figure 4.1. The stable 
Form I and the metastable Form II polymorphs can be distinguished by the band 
position associated with the amine stretch [10][12], being 3308 cm-1 with a shoulder 
at 3344 cm-1 for Form I and a single peak at 3344 cm-1 for Form II. Isolated after 8 
min aging time, this drying condition provided samples containing only Form II 
crystals or Form II crystals with a very small amount of Form I crystals. With 
increasing the aging time to 15 min, the amount of Form I crystals in the sample 
increased, and after 3.5 h aging pure Form I crystals or Form I crystals with a very 
small amount of Form II were obtained. This indicates that the metastable Form II 
crystals are nucleating initially and the stable Form I crystals appear as a result of 
polymorphic transformation, with a short timescale for complete transformation.  
An example IR spectra of the crystals nucleated in 40 % DMA – 60 % water at 
S II = 4.40 and S II = 2.20 in the presence of 0.0-0.2 mg/mL DOSS and dried at 50 °C 
is shown in Figure 4.2, whereas additional spectra of repeated samples are shown in 
Figure A4.2 (S II = 4.40) and in Figure A4.3 (S II = 2.20) in Appendix A. Looking at 
S II = 4.40 in Figure 4.2 and Figure A4.2, several samples contain only Form II 
crystals and in case of the mixtures, Form II crystals are dominating with a small 
amount of Form I. Compared to the samples dried under vacuum at room 
temperature (Figure 4.1), samples dried at 50 °C contained more From II crystals 
when isolated after the same aging time of 8 min, indicating a faster polymorphic 
transformation at the latter drying condition. At S II = 2.20 shown in Figure 4.2 and 
Figure A4.3, the majority of the isolated samples are a mixture of Form II and Form I 
crystals (eight out of nine samples) with one exception at 0.2 mg/mL DOSS being 
only Form I. The higher ratio of Form I crystals in these samples as opposed to at 
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S II = 4.40 with the same drying condition can be the result of longer suspension 
aging time, being 15 min as opposed to 8 min at S II = 4.40. Thus from this and from 
the short timescale of the transformation observed at S II = 4.40 with the drying 
method using vacuum (Figure 4.1) it is reasonable to assume that the high amount of 
Form I crystals in the samples at S II = 2.20 is the result of the transformation of the 
originally nucleating Form II crystals. Therefore supersaturation is calculated with 
respect to Form II solubility. At both supersaturations, no clear influence of DOSS 
on the polymorphic form was observed.  
 
Figure 4.1. IR spectra of pure MEF polymorphs and MEF crystals nucleated at 
S II = 4.40 in the absence of DOSS, isolated at different times after the detection of 
crystallisation and dried under high vacuum at room temperature. S II is calculated 
based on the solubility of the nucleating Form II crystals. 
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Figure 4.2. IR spectra of pure MEF polymorphs and MEF crystals nucleated in the 
absence or presence of DOSS at different supersaturations in 40 % DMA – 60 % 
water. At S II = 4.40, crystals were isolated at 8 min aging time, whereas at S II = 2.20, 
crystals were isolated after 15 min aging time, and crystals were dried at 50 °C. S II is 
calculated based on the solubility of the nucleating Form II crystals.  
In 70 % DMA – 30 % water, in the pure MEF system at S I = 1.99, Form I crystals 
were isolated (Figure 4.3). Since Form I crystals have a weak adsorption band in the 
IR spectra at the same position as the main band of Form II crystals, 3344 cm-1, the 
absence of Form II crystals in the sample was verified using PXRD (Figure A4.4 in 
Appendix A). At S I = 1.75, the addition of 1 mg/mL and 5 mg/mL DOSS did not 
have an influence on the polymorphic form of the crystals, yielding Form I crystals 
in each case (Figure 4.3). Since only the stable polymorphic form was isolated at 
S I = 1.99 and S I = 1.75, the crystals at S I = 1.53 are also expected to be Form I. 
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Therefore supersaturation is calculated with respect to Form I solubility in 
70 % DMA – 30 % water systems. 
 
Figure 4.3. IR spectra of pure MEF polymorphs and MEF crystals nucleated in the 
absence or presence of DOSS at different supersaturations in 70 % DMA – 30 % 
water. At S I = 1.99, crystals were isolated at 8 min aging time, whereas at S I = 1.75 
and 1.70, crystals were isolated after 15-20 min aging time. S I is calculated based on 
the solubility of the nucleating Form I crystals. 
Figure 4.4 presents SEM images of the crystals obtained from 40 % DMA –
 60 % water. Based on IR, most of the samples presented herein are a mixture of 
Form I and Form II crystals (except at S II = 4.40, 0.1 mg/mL DOSS) with the images 
focusing on the initially nucleating Form II crystals. In the absence of DOSS, Form 
II crystals had parallelepiped habit at both S II = 4.40 and S II = 2.20, having more 
evolved facets at S II = 2.20. The presence of DOSS, irrespective of the concentration 
used, did not have a noticeable influence on the habit indicating no specific face for 
Wavenumber (1/cm)
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adsorption of the surfactant molecule. The habit of Form I crystals present in the 
same samples, when found in the case of polymorph mixtures, was distinctly 
different being plate-like at all studied conditions (Figure A4.5 in Appendix A). 
Similarly, in 70 % DMA – 30 % water at S I = 1.75 in the absence of DOSS, the habit 
of the Form I crystals was plate-like, and did not change upon the addition of 
1 mg/mL or 5 mg/mL DOSS (Figure 4.5). 
 
Figure 4.4. SEM images of MEF crystals prepared in the absence or presence of 
DOSS in 40 % DMA – 60 % water, at S II = 4.40 (isolated at 8 min) and at S II = 2.20 
(isolated at 15 min). Based on IR, samples are a mixture of Form I and Form II 
crystals except at S II = 4.40, 0.1 mg/mL DOSS, with the images focusing on mainly 
Form II crystals (parallelepiped shape). S II is calculated based on Form I solubility. 
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Figure 4.5. SEM images of crystals prepared in the absence and presence of DOSS 
in 70 % DMA – 30 % water. Crystals were isolated after 15-20 min aging and are 
pure Form I. S I is calculated based on Form I solubility. 
4.3.2. Induction time probability distributions 
Figure 4.6 shows the experimental probability distribution of induction times of MEF 
in 40 % DMA – 60 % water at S II = 4.40-2.20 in the absence or presence of 
0.1 mg/mL and 0.2 mg/mL DOSS. For each system, the induction times and the 
width of the distributions are systematically increasing with decreasing 
supersaturation, where the scattering of the data is attributed to the inherent 
stochasticity of nucleation events [13][14][15]. In the absence of DOSS, the 
measured induction times were in the range of 27 s - 74 s at S II = 4.40 and increased 
to 92 s - 370 s with decreasing the supersaturation to S II = 2.20. In the presence of 
DOSS, overall shorter induction times were measured at each supersaturation 
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Figure 4.6. Experimental probability distribution of induction times of MEF in the 
absence or presence of DOSS at different supersaturations in 40 % DMA – 60 % 
water. Blue triangle ( ): pure MEF; orange circle ( ): MEF with 0.1 mg/mL DOSS; 
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section 4.3.3, is also shown. S II is calculated based on the solubility of the nucleating 
Form II crystals. 
In a 70 % DMA – 30 % water solvent mixture, presented in Figure 4.7, the induction 
times varied from ten minutes to hours at S I = 1.99-1.53, in contrast to induction 
times of couple of ten seconds to minutes measured in 40 % DMA – 60 % water 
systems at higher supersaturations. At S I = 1.75, the addition of 1 mg/mL DOSS only 
slightly shifted the distribution to longer induction times compared to the pure 
system. In the presence of 5 mg/mL, the supersaturation decreased from S I = 1.75 to 
S I = 1.70 at the same concentration of MEF due to the increase in solubility. The 
corresponding induction time distribution was slightly shifted to longer induction 
times compared to the two systems at S I = 1.75. 
 
Figure 4.7. Experimental probability distribution of induction times of MEF in the 
absence or presence of DOSS at different supersaturations in 70 % DMA –
 30 % water. Dark blue triangle ( ): pure MEF at S I = 1.99; blue circle ( ): pure 
MEF at S I = 1.75; light blue square ( ): pure MEF at S I = 1.53; orange rhombus ( ): 
MEF with 1 mg/mL DOSS at S I = 1.75; red triangle ( ): MEF with 5 mg/mL DOSS 
at S I = 1.70. Fit to equation 4.1, described in section 4.3.3, is also shown. S I is 
calculated based on the solubility of the nucleating Form I crystals.   
4.3.3. Nucleation rate determination 
Assuming independent nucleation events and a single nucleus mechanism, the 



















distribution, where the probability of detection of a nucleation event P(t) within a 
time t is [9][16][17]: 
   1 exp( ( ))gP t J V t t      (4.1)  
Where J is the nucleation rate, V is the solution volume and tg is the growth time. The 
growth time accounts for the time difference between the detection of nucleation (t) 
and the actual nucleation event (t-tg), with the assumption that the shortest nucleation 
time is 0 s (t=tg). Tables 4.3 and 4.4 summarize J and tg obtained from fitting 
equation 4.1 to the experimental probability distributions presented on Figure 4.6 and 
4.7, respectively. In 40 % DMA – 60 % water, R2 values describing the quality of the 
fit were in the range of 0.89-0.99, being lower at higher supersaturations, whereas in 
70 % DMA – 30 % water, a fairly good R2 ≥ 0.95 was found at all conditions. 
In 40 % DMA – 60 % water (Table 4.3), in the presence of DOSS, the nucleation 
rate increased by 37-51 %, while the growth time decreased by 13-22 % compared to 
the pure system in the range of S II = 2.20-3.30, with no major difference between the 
studied DOSS concentrations. At S II = 4.40, the experimental induction time 
distributions from Figure 4.6 shows the same trend. However, the analyses, Table 
4.3, lead to lower nucleation rate at S II = 4.40 in the presence of 0.1 mg/mL DOSS 
than in the presence of 0.2 mg/mL DOSS or in the absence of DOSS. These outlying 
data points arise from the increasing uncertainty of the results with increasing 
supersaturation and the lowest accuracy of the Poisson fit at S II = 4.40 in the 
presence of 0.1 mg/mL DOSS (R2=0.89).  
As a comparison, to verify the same influence of DOSS at S II = 4.40 as at 
S II = 3.30-2.20, we also determined J from fitting a lognormal cumulative 
distribution function (LCDF) [8][18]:  
   0.5erfc(-(ln ) / 2)P t t     (4.2)  
to the cumulative induction time distributions, where the location parameter η can be 
translated to the geometric mean (= median induction time, t50) by exp (η)
  = t50 and 
the scale parameter σ to the geometric standard deviation (σ*) by exp (σ)  = σ*. The 
nucleation rate, included in Table 4.3, can be calculated from the median induction 
time and solution volume by J=1/t50V. Compared to J values obtained using the 
CHAPTER IV 
104 
Poisson function 4.1, using LCDF resulted in a similar trend in the range of 
S II = 2.20-3.30, with values being 47-55 % smaller. This trend also extended to 
S II = 4.40, showing higher and comparable nucleation rates in the presence of both 
concentration of DOSS than in the absence of it. The difference in the nucleation 
rates calculated by fitting a Poisson distribution and the LCDF derives primarily 
from the fact that the latter method assumes that the time to grow to visibility is 
negligible. Thus, the nucleation time is approximated by the induction time, and the 
nucleation rate is calculated from the median induction time. This results in larger 
nucleation times and thus, lower nucleation rates.  
Table 4.3. Nucleation rate, J, and growth time, tg, of MEF at different S
 II in the 
absence or presence of DOSS in 40 % DMA – 60 % water, from fitting to the 
Poisson function 4.1. As a comparison, the median induction time t50
a and the 
nucleation rate Ja from fitting to the LCDF function 4.2 is also shown. S II is 















4.40 0.0 0.00 6270 28.8 40.9 2448 
4.40 0.1 0.14 5784 20.8 33.5 2982 
4.40 0.2 0.27 7025 23.0 33.8 2956 
3.30 0.0 0.00 2861 40.6 65.6 1524 
3.30 0.1 0.18 4061 33.9 52.6 1901 
3.30 0.2 0.36 4027 34.7 52.9 1890 
2.64 0.0 0.00 1859 66.3 106.2 941 
2.64 0.1 0.23 2799 51.6 78.8 1267 
2.64 0.2 0.45 2606 50.7 78.9 1267 
2.20 0.0 0.00 1109 111.4 177.1 565 
2.20 0.1 0.27 1517 96.8 145.2 689 
2.20 0.2 0.54 1524 90.5 141.3 723 
In 70 % DMA – 30 % water at S I = 1.99-1.53 (Table 4.4), the nucleation rates 
determined by fitting the Poisson function were orders of magnitude lower and the 
growth times larger compared to those measured at higher supersaturations in 40 % 
DMA – 60 % water. At S I = 1.75, compared to the pure system, the addition of 1 
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mg/mL DOSS only slightly decreased the nucleation rate by 7 %, but increased the 
growth time by 20 %. At S I = 1.70 in the presence of 5 mg/mL DOSS, the nucleation 
rate was further decreased and the growth time increased, possibly just because of 
the lower supersaturation.  
Table 4.4. Nucleation rate, J, and growth time, tg, of MEF at different S
I 
supersaturations in the absence or presence of DOSS in 70 % DMA – 30 % water, 










1.99 0.0 0.00 104.2 1128 
1.75 0.0 0.00 28.9 1638 
1.75 1.0 0.08 26.8 1972 
1.70 5.0 0.41 25.7 2259 
1.53 0.0 0.00 8.6 5239 
4.3.4. Calculation of pre-exponential factor and interfacial energy 
In order to calculate the pre-exponential factor A and interfacial energy γ of the 









   (4.3) 
This shows that a plot of ln (J/S) versus T-3ln-2 S should result in a straight line with 











  (4.4) 
Figure 4.8a and Figure A4.6 in Appendix A show this fit for the nucleation rates 
measured in 40 % DMA – 60 % water excluding and including S II = 4.40 in the 
linear fit, respectively, whereas Figure 4.8b presents the plot in both solvent systems 
and shows the fit for pure MEF in 70 % DMA – 30 % water. The nucleation 
parameters calculated from the fits are summarised in Table 4.5.  
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In 40 % DMA – 60 % water, the nucleation parameters were calculated excluding 
and including the outlying S II = 4.40 in the linear regression. Excluding S II = 4.40 
from the linear regression provided an excellent linear correlation for all the three 
systems (0.98 ≤ R2). From the fits, the pre-exponential factor A was calculated to be  
1324 1/m3s in the absence of DOSS and increased to 2007 1/m3s and 1904 1/m3s 
with the addition of 0.1 mg/mL and 0.2 mg/mL DOSS, respectively. In contrast, the 
interfacial energy γ (with respect to Form II) was similar in the absence or presence 
of DOSS, being 2.92 - 3.00 mJ/m2. Including S II = 4.40, the fit was less good 
(0.91 ≤ R2) and the derived A and γ values did not show a clear trend with changing 
the concentration of DOSS from 0 to 0.2 mg/mL. Thus nucleation parameters at 
40 % DMA – 60 % water are determined using the Poisson fit, excluding the data 
points at S II = 4.40, which may deviate because uniformity of supersaturation might 
not be achieved at the shortest induction times. The mixing of the solvent and 
antisolvent solutions is visually detectable for approximately 4 s after solution 
injection, and molecular level mixing should be somewhat longer than this. As a 
comparison, at the highest supersaturation of S II = 4.40, the shortest induction time 
data is 16 s, whereas at the second highest supersaturation of S II = 3.30 this data is 
27 s, being considerable longer. 
As an estimation for the error of calculating the solubility of Form II and the 
corresponding S II from the mole fraction solubility ratio of xII/xI = 1.4, A and γ values 
have been recalculated using xII/xI = 1.3 and xII/xI = 1.5. The obtained results are 
qualitatively the same, with A and γ values being 2.0-2.3 % smaller and 7.9 % larger 
at xII/xI = 1.3, respectively, and 1.9-2.2 % larger and 7.4 % smaller at xII/xI = 1.5, 
respectively, and showing no influence of DOSS on γ. 
As can be seen from Table 4.5, the same trend in Aa and similar γa values were found 
when the parameters were calculated from plotting the nucleation rates determined 
from fitting to LCDF (Ja) in the whole range of studied supersaturations, S II = 2.20-
4.40, as for A and γ over S II = 2.20-3.30. This verifies that DOSS only has an effect 






Figure 4.8. Plot of ln (J/S) versus T-3ln-2S for the determination of the pre-
exponential factor A and interfacial energy γ of the nucleation by fitting equation 4.3, 
showing (a) data points in 40 % DMA – 60 % water including data in the linear fit at 
S II = 2.20-3.30 and (b) all data points and the fit for pure MEF in 70 % DMA –
 30 % water. In 40 % DMA – 60 % water, Form II crystals nucleate and data is 
plotted using S II, whereas from 70 % DMA – 30 % water Form I crystals are isolated 
and data is plotted using S I. 
In 70 % DMA – 30 % water, in the absence of DOSS, the pre-exponential factor was 
found to be A = 160 1/m3s and the interfacial energy was calculated to be 
γ = 2.86 mJ/m2 with respect to Form I. The data points with 1 mg/mL DOSS at 
S I = 1.75 and 5 mg/mL DOSS at S I = 1.70 are lying along the fitted line of the pure 
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pure MEF, 70 % DMA -
30 % water
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Table 4.5. Pre-exponential factor, A, and the interfacial energy, γ, determined for 
the nucleation of MEF Form II in 40 % DMA – 60 % water and MEF Form I in 
70 % DMA – 30 % water, in the absence or presence of DOSS. In 40 % DMA –
 60 % water, fit was determined over S II = 2.20-4.40 or S II = 2.20-3.30 and as a 
comparison, Aa and γa values obtained using Ja from the fit with LCDF (equation 4.2) 

















40 % DMA 
– 60 % water 
S II = 2.20-4.40 S II = 2.20-3.30 S II = 2.20-4.40 
Pure MEF 1800 3.25 0.91 1324 2.92 1.00 742.9 3.03 1.00 
+ 0.1 mg/mL 
DOSS 
1795 2.87 0.96 2007 3.00 0.98 928.0 3.02 0.99 
+ 0.2 mg/mL 
DOSS 
2099 3.07 0.99 1904 2.96 1.00 891.8 2.94 1.00 
70 % DMA 
– 30 % water 
- S I = 1.53-1.99 - 
Pure MEF - 160 2.86 0.95 - 
4.4. DISCUSSION 
The main objective of the present work is to investigate how the addition of DOSS 
influences the nucleation of MEF, and in particular to seek validation of the 
hypothesis that the reason why DOSS promotes the formation of nanocrystals of 
MEF in a 5 % DMA – 95 % water (S approximately in the order of 7000) antisolvent 
process is that DOSS promotes the nucleation of MEF under these conditions. The 
isothermal antisolvent crystallisation protocol employed here, though being 
laborious, allowed for the rapid creation of uniform supersaturation and investigation 
of induction times as short as a couple of ten seconds, as opposed to the shortest 
induction times of ten minutes obtained in the traditional cooling crystallisation 
experiments. The antisolvent experiments were performed at lower DMA content 
(40 %) and higher supersaturations: 2.20 ≤ S II ≤ 4.40, compared to the cooling 
crystallisation experiments at 70 % DMA, and 1.53 ≤ S II ≤ 1.99. In the antisolvent 
experiments, being closer to the original nanocrystallisation conditions, the presence 
of 0.1 mg/mL and 0.2 mg/mL DOSS enhanced the nucleation of MEF crystals by 
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increasing the pre-exponential factor A by approximately 50% (excluding the data 
points at S II = 4.40), with no change in the interfacial energy γ. 
Within the frame work of the classical nucleation theory, the increase in A in the 
presence of DOSS, observed in the 40 % DMA – 60 % water mixture, is the result of 
an increase of the monomer attachment frequency or in the concentration of 
nucleation sites (f*C0) as the Zeldovich factor, equation 2.7, does not change since 
the interfacial energy has been shown to remain essentially unchanged. The 
attachment frequency parameter, given by equation 2.8, relates to the rate of 
transport of molecules to the critical nucleus surface and the likelihood of actually 
attaching and sticking to the surface. Thus it depends on the diffusion coefficient and 
the nucleus surface area. The latter remains unchanged if the interfacial energy is 
uninfluenced. Other parameters remain unchanged (molecular volume, equilibrium 
solute concentration, supersaturation, temperature) or are as a first approximation 
assumed to be unchanged (sticking coefficient) with the addition of DOSS in 
40 % DMA – 60 % water. The diffusion process describes the transport of the solute 
molecules from the solution to the surface of the nucleus, and includes desolvation 
and required conformational changes. Thus, the increase in A in the presence of 
DOSS may reflect that the transport process is facilitated. 
As shown in Figure 4.9, the mefenamic acid molecule has hydrogen bond accepting 
and donating functionalities, but also has large hydrophobic surface patches. In 
water, the MEF solubility is very low, because the hydrophobic parts of the molecule 
will force an entropically unfavorable structuring into the surrounding water 
molecules. The solubility is significantly improved by addition of DMA, but even in 
40 % and 70 % by volume DMA – water mixtures the solubility of Form I is only 






Figure 4.9. Molecular structure of water, DMA, MEF and DOSS, highlighting the 
type of functionalities in the molecules. 
DMA is a polar aprotic solvent having a large dielectric constant and a sizeable 
dipole moment. The normalised solvent polarity parameter, ET
N, is 0.38 [19] and the 
octanol/water logP value is -0.77 [20]. However, even though DMA and water are 
fully miscible, the solution is not well mixed on the molecular level [21]. At DMA in 
water concentrations of our previous nanocrystallisation experiments: 
5 % v/v DMA = 1.0 mole %; the tetrahedral structure of normal water predominates 
in the solution, and the radial distribution function (RDF) reveal the same data as in 
pure water. At the DMA concentration of the anti-solvent nucleation experiments of 
the present study: 40 % v/v = 11.4 mole %, this water structure starts to disappear, 
and clusters of DMA molecules begin to form. DMA molecules aggregate with the 
dipole-dipole interactions between DMA molecules to form DMA clusters stabilized 
in water by the hydrophobic effect and by strong hydrogen bonding with water over 
the carbonyl group. Thus in comparison, the force of interaction between DMA 
molecules is fairly weak. At the conditions of the cooling nucleation experiments of 
the present work: 70 % v/v DMA = 31.1 mole %, the RDF of pure DMA gradually 
dominates. Being an amphiphilic solvent, DMA has hydrophobicity in the methyl 
groups and can thus facilitate the solvation of the hydrophobic parts of MEF, which 



















have to order turning the polar side outwards, potentially hydrogen bonding with 
water. The unfavorable entropy decrease in the solvent molecules surrounding the 
hydrophobic parts of the MEF molecule should however be less than in pure water. 
The docusate ion has hydrogen bond accepting functionality that may bond to water 
and MEF but there is no hydrogen bond donating functionality (Figure 4.9). The 
docusate ion has a large hydrophobic surface, and is expected to more favorably 
solvate the corresponding MEF molecular surface when introduced into the solution, 
and thus replace the less favorable solvation by water and DMA molecules. 
Hydrophobic interaction is not associated with particular forces between MEF and 
DOSS, and hence because of the weak interaction with DOSS the desolvation is 
facilitated. Accordingly, the attachment frequency factor becomes higher and the 
nucleation becomes facilitated. It appears as if it is more the role of the water that is 
important, since with increasing DMA content from 40 % to 70 %, the favourable 
effect on the nucleation of adding DOSS seems to disappear.  
In Chapter III, it has been hypothesized that DOSS promotes the formation of 
nanocrystals of MEF in a 5 % DMA – 95 % water. While, unfortunately, we do not 
have the experimental capability to investigate the rate of nucleation at the very high 
supersaturations in 5 % DMA, the present work has shown that even at the very 
much lower supersaturations where we are capable of making actual nucleation 
experiments a promoting effect can be detected. Since the effect was found to relate 
to the large water content at 40 % DMA and decreases with increasing ratio of DMA 
in the solvent mixture, it is expected to be even stronger at 5 % DMA, thus 
supporting the hypothesis that DOSS promotes formation of smaller nanocrystals by 
increasing the rate of nucleation.  
It should be recognized though that in parallel to the increase in DMA content from 
5 % to 70 %, the supersaturation employed during the crystallisation experiments 
also decreases perhaps even leading to a change from homogeneous to heterogeneous 
nucleation, and the polymorphic form nucleating changed from the metastable Form 
II (5 %, 40 % DMA) to the stable Form I (70 % DMA). In addition, while the DOSS 
concentration employed in 40 % DMA – 60 % water system is only 0.1 - 0.2 mg/mL, 
the DOSS/MEF molar ratio is 0.14-0.54 (Table 4.2), which perhaps explains why the 
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Figure 4.10.  Centrosymmetric dimer of MEF molecules in (a) Form I and (b) Form 
II crystal structure, the latter showing a disorder in the imino bridge and alkylated 
phenyl rings [22]. (c) Simulation of the plate-like morphology of Form I crystals and 
(d) surface group orientation on the slow growing (100) face [23]. 
Without the boundaries of the classical nucleation theory, the situation can be 
examined from a crystal structure point of view. The two structures of MEF feature 
the centrosymmetric hydrogen bonded dimerisation, and the dimers are basically 
arranged in stacks linked through C-H…pi interactions involving aromatic C-H and 
the alkylated phenyl ring [22], Figure 4.10. These stacks are then arranged parallel in 
the crystal structure held together by van der Waals bonding. Presumably, the 
strongest bonding is the H-bonding between the carboxylic acid groups in the dimers, 
followed by the bonding between the dimers in the stack. The weakest bonding (per 





shape simulations within the Material studio software, using the attachment energy 
method [23]. The shape of Form I crystals is plate-like and the axis of the stacks is 
parallel to the big flat slow growing surface.  
In building the nucleus, we would expect the sequence: dimer formation, stacking 
and stack binding. In pure water the aggregation of MEF molecules should be 
significantly influenced by hydrophobicity, i.e. reducing the exposure of the 
hydrophobic surfaces of the molecule to water. The dimer hydrogen bonding does 
not contribute to this, and thus dimers should not be expected to dominate in the 
solution. The hydrophobicity will somewhat promote the formation of the stacks, but 
will still leave a significant portion of the hydrophobic surface exposed. The binding 
of the stacks together will reduce the total hydrophobic surface area exposed to 
water. Adding DMA to a water solution will to some extent (as is illustrated by the 
increase in solubility) facilitate the solvation of the hydrophobic parts of MEF, and 
thus somewhat reduce the unfavorable conditions for dimer formation and stacking. 
Introducing docusate sodium into this may further facilitate dimerisation and 
stacking of MEF molecules in the solution, and thus promote nucleation.  
In solvating the hydrophobic surface of MEF, DOSS will turn its own hydrophilic 
hydrogen bond accepting surface towards water/DMA. This will reduce the 
thermodynamically unfavorable contact between hydrophobicity and hydrophilicity, 
and facilitate the formation of dimers. If the formation of dimers is facilitated and 
become the units being transported, addition of DOSS will promote the nucleation. 
As no measurable decrease was observed in the solid-liquid interfacial energy at 
these concentrations of DOSS (Table 4.5), the governing factor cannot be claimed to 
be improved solvation of the surface of the nucleus by DOSS. In relation to this, it is 
noteworthy that in 40 % DMA – 60 % water, the solubility of MEF in the presence 
of 0.2 mg/mL DOSS is essentially unchanged from the value in the absence of DOSS 
(0.065 ± 0.001 mg/mL and 0.065 ± 0.003 mg/mL respectively at 25 °C), and in the 
70 % DMA – 30 % water mixture there is a very slight increase from 
3.80 ± 0.01 mg/mL at 15 °C in pure solvent mixture to 3.92 ± 0.03 mg/mL in the 
presence of 5 mg/mL DOSS (Table 4.1).  
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Transport and attachment of molecules is required for both the formation of the 
critical nucleus as well as for the growth of the nuclei to detectable size. 
Accordingly, if the rate of molecule attachment is governing, the increase in 
nucleation rate should correspond to a decrease in time for crystal nuclei to grow to 
become visible. In fact, in the present work, the growth time tg is decreased in the 
presence of DOSS in 40 % DMA – 60 % water over the entire supersaturation range 
examined. The same relation has been found previously [24] for p-aminobenzoic 
acid in different solvents, and it was concluded that desolvation of the carboxylic 
acid group and formation of carboxylic acid dimers is the rate limiting step for 
nucleation as well as for crystal growth. Studies showing molecular additives to 
increase the nucleation rate are rather scarce, but it has been found [25]  that tailor-
made additives can accelerate the growth of γ-glycine along the fast growing pole by 
disruption of the solvation, and that crystal growth of L-alanine [26] is accelerated in 
the presence of L-valine enhancing the rate of surface diffusion.  
Another possible mechanism for nucleation rate improvement in the presence of 
DOSS could be a templating effect of DOSS micelles or single DOSS ions, 
facilitating the arrangement of MEF molecules to form a nucleus and thus, increasing 
the pre-exponential factor A. However, in 40 % DMA – 60 % water, micelle 
formation cannot be detected at the DOSS concentrations employed (Figure A4.7). In 
addition, an increasing nucleation promotion effect with increasing DOSS 
concentration would be expected if DOSS ions acted as nucleation centre which was 
not found at the concentrations examined here.  
4.5. CONCLUSIONS  
In antisolvent crystallisation at 40 % DMA – 60 % water and supersaturations of 
S II = 4.40-2.20, DOSS enhanced the nucleation rate of MEF. Within the classical 
nucleation theory, this increase is due to an increase in the pre-exponential parameter 
A by 52-44% at 0.1 mg/mL and 0.2 mg/mL DOSS, respectively, while the interfacial 
energy γ remains essentially unchanged. The analysis leads to the hypothesis that the 
increase in A is due to an increase in the attachment frequency of MEF molecules to 
the growing nucleus, as a result of a facilitated desolvation of MEF in the presence of 
DOSS. This is supported by the fact that also the time of growth to visibility tg is 
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observed to decrease in the presence of DOSS. In the analysis, it is further 
recognised that DOSS may facilitate the formation of MEF dimers, a key element of 
the crystal structure. At 70 % DMA – 30 % water and supersaturations of SI=1.99-
1.53, the influence of DOSS is very small, suggesting that it is in the presence of 
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CHAPTER V  
DALCETRAPIB – MONTMORILLONITE 




5.1.  INTRODUCTION 
As an alternative to nanosuspensions, nanoparticles may be converted to a solid 
dosage formulation for long term stability and for patient convenience. During this 
conversion, the small particle size and phase properties must be maintained to 
preserve the improved dissolution properties of the nanoparticles. Summarised in 
section 2.6, extensive research has been conducted using freeze drying and spray 
drying techniques for the isolation of nanoparticles [1][2][3][4]. It has been found 
that a redispersable product might be obtained with the use of suitable 
cryoprotectants, lyoprotectants and matrix formers [1][2]. However, freeze drying is 
a slow and expensive technique [3], while spray drying may promote degradation or 
phase change when elevated temperatures are used [5].  
As an alternative nanoparticle isolation strategy, Khan et al. [6] introduced the use of 
insoluble dibasic calcium phosphate as a carrier for the recovery of additive 
stabilised ibuprofen and glibenclamide nanoparticles from suspension using a simple, 
industrially feasible filtration process. Although the improved dissolution properties 
of the particles were retained in the dried form, the method was limited by the low 
drug loading of 0.35 w/w %. Tierney et al. [7] further developed this concept using 
montmorillonite clay particles for the isolation of fenofibrate and mefenamic acid 
nanoparticles that did not require the use of soluble additives in an antisolvent 
precipitation process. In their study, surface functionalization of the negatively 
charged carrier using a positively charged cationic polymer, protamine sulphate salt, 
was necessary to improve drug loading up to 9.1 w/w % while maintaining the 
enhanced dissolution rates due to the high surface area of the nanoparticles. 
The above mentioned studies introduced the promising concept of carrier mediated 
nanoparticle isolation, combining simplicity with industrial relevance. However, how 
the presence of soluble additives and the functionalisation of the carrier particle 
surface affect the preparation of highly loaded drug – carrier nanocomposite 
microparticles while maintaining high dissolution rates need to be explored further. 
The carrier particles appear to stabilise nanoparticles during the antisolvent 
precipitation process [7], when present during or just after nucleation, without the 
need for soluble additives. In contrast, some other nanoparticle processes such as wet 
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milling may still require the use of additives if the nanosuspension is not stable 
during the milling stage, prior to introducing the insoluble carrier [6]. Thus from a 
practical point an important question is how the presence of additives influences the 
crucial element of nanoparticle attachment, governing the achievable drug loading of 
the final product. Montmorillonite carrier particles had to be functionalised to 
preserve the dissolution rates at increased drug loadings for fenofibrate [7] but it is 
unclear whether this is necessary for all drugs or is drug specific.  
This chapter focuses on the filtration based carrier particle supported isolation of 
nanoparticles, and explores the factors affecting the maximum achievable drug 
loading of the prepared nanocomposite microparticles while maintaining high 
dissolution rates. Because of the very low solubility of the model compound 
dalcetrapib in water, the formation of nanoparticles by an antisolvent process is not 
difficult which allows us to focus on the nanoparticle isolation aspects. At first the 
antisolvent precipitation of dalcetrapib nanoparticles is experimentally examined in 
the absence of the carrier montmorillonite (MMT) microparticles to identify suitable 
conditions for the main investigation on the use of MMT and various additives. Then 
the influence of drug loading and presence of soluble additives on nanoparticle 
attachment onto the carrier microparticles and on the dissolution behaviour of the 
fresh suspension is investigated. Finally, the dissolution and solid state properties of 
the dried nanocomposite microparticles are characterised and the influence of drug 
loading on the stability during the isolation and drying process is identified. 
Dalcetrapib (DCP) is a poorly water soluble (~0.02 µg/mL [8]) cholesterol ester 
transferase protein inhibitor [9], that was in clinical development for treating 
cardiovascular diseases by Roche until 2012. Although the original trials did not 
show a clinical efficacy, it has been found recently that the drug could potentially be 
beneficial for a genetic subgroup [10]. To our knowledge, a nanoparticle formulation 
of the drug does not exist.  
The carrier microparticle MMT, an insoluble aluminosilicate clay, is widely used in 
the pharmaceutical industry as a traditional excipient [11] and also extensively 
studied for use in modified drug delivery systems [12][13][14] due to its low cost, 
non-toxicity and easy modifiability.  
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5.2.  MATERIALS AND METHODS 
5.2.1. Materials 
Dalcetrapib (DCP, Form A) was kindly donated by Roche. Ethanol (>99.9) was 
purchased from Lennox. Methanol (HPLC grade) and sodium chloride (NaCl) was 
obtained from Fisher. Montmorillonite K10 (MMT, average size: 28.0 µm ± 1.3 µm 
[7]), protamine sulphate salt (PA), polyvinylpirrolidone (PVP, 40kDa) 
hydroxypropylmethylcellulose (HPMC, 15 cP), Pluronic® F127 (PF127), Tween 20, 
sodium docusate (dioctyl sulfosuccinate sodium salt, DOSS), hydrochloric acid 
(HCl) and sodium dodecyl sulphate (SDS) was purchased from Sigma Aldrich. 
Deionised water was used for aqueous solutions (18 MΩ. Elga, purelab Ultra). All 
chemicals were used as received. The molecular structure of DCP is presented in 
Figure 5.1.  
 
Figure 5.1. Molecular structure of DCP 
5.2.2. Preparation of DCP nanoparticles and DCP – MMT nanocomposite 
microparticles 
DCP nanoparticles were prepared by an antisolvent precipitation method and isolated 
using MMT as carrier microparticles. In a typical experiment, DCP solution was 
prepared by dissolving 60 mg/mL DCP in ethanol overnight with agitation (400 rpm, 
25.0 °C). The antisolvent was 9 mL water with 100 – 1350 mg MMT, equilibrated 
under agitation (1000 rpm, 5 °C) for at least 2 h prior to the preparation of DCP 
nanoparticles. DCP nanoparticles were prepared by the quick injection of 1 mL DCP 
solution at 25.0 °C into the antisolvent at 5.0 °C under magnetic stirring (1000 rpm). 
After 1 min aging time, the suspension was filtered using a Whatman grade 1 filter 
paper (10 µm filter pore), and the filter cake was washed with 5 mL water and dried 
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under high vacuum (< 27 Pa) at room temperature for more than 16 hours. Aging 
time refers to the time elapsed from the injection of drug solution into the antisolvent 
until sampling the suspension for characterisation or isolation of the particles. Dried 
samples were then stored at room temperature and characterised within a couple of 
days. A control DCP suspension in the absence of MMT was prepared the same way; 
however, in this case, isolation of the particles was not possible. Exceptions from this 
procedure were made when the influence of process parameters and aging time, and 
the influence of soluble additives were studied, detailed below. The program of the 
experiments is summarised in Table 5.1, highlighting the aim of the sub-studies. 
At first, the influence of the concentration of DCP in the solvent (cDCP) and the 
antisolvent to solvent ratio (AS/S) was studied in the absence of MMT or soluble 
additives. The experiments were performed at a total final suspension volume of 10 
mL and the size of nanoparticles in suspension was characterized at 1 min aging 
time. From these experiments, the concentration of cDCP = 60 mg/mL and AS/S = 9 
were selected for further studies. The short term stability of the particles in 
suspension prepared with the selected conditions was assessed by measuring the 
particle size at different aging times.  
When soluble additives were used, they were either present in the antisolvent for 
more than 2 hours prior the injection of the drug solution or added to the suspension 
as a 1 mL concentrated additive solution in water at 15 s aging time. The amount of 
each additive was 2.2 mg/g MMT, unless otherwise specified. When the influence of 
timing of MMT addition on the nanoparticle attachment was investigated, MMT was 
added as a powder at 15 s aging time, and the suspension was left stirring for an 
additional 1 min.  
The mass of DCP nanoparticles that attached onto MMT particles was indirectly 
determined by measuring the drug content in the filtrate after filtration. While MMT 
particles (average size of 28 µm) or MMT attached DCP nanoparticles are retained 
by a filter with a pore size of 10 µm, DCP nanoparticles that are not attached onto 
MMT can pass through. Centrifugation was also used to confirm that the carrier 
particles do not act as filtration aid but adsorb DCP nanoparticles from suspension.  
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Table 5.1. Experimental program, highlighting the aim of sub-studies. AS –
 antisolvent, S – solvent, AS/S – antisolvent to solvent ratio, cDCP – DCP 
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*present in AS prior the injection of drug solution or added at 15 s aging time into the suspension 
Suspensions of DCP – MMT nanocomposite microparticles were centrifuged for 1 
min at 10000 rpm using a Micro Star 12 Microcentrifuge, which conditions enabled 
for complete settling of MMT particles in the absence of DCP, both in the absence 
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and presence of soluble additives. The filtrate or supernatant was diluted tenfold with 
methanol to dissolve any DCP particles present and its concentration was determined 
by measuring the absorbance at λ=246 nm using a Shimadzu UV – VIS 
spectrophotometer. The percentage of isolated DCP nanoparticles, assumed to attach 
onto MMT when present, and DCP loading of the composite, that is defined as the 
actual percentage of DCP nanoparticles in DCP – MMT nanocomposite 
microparticles, were calculated as the following:  
mDCP isolated (mg) = mDCP total – mDCP filtrate or supernatant (5.1) 
isolated DCP (w/w%) = (mDCP isolated/mDCP total) x 100 (5.2) 
DCP loading (w/w %) = (mDCP isolated / (mDCP isolated + mMMT)) x 100 (5.3)  
5.2.3. Characterisation of DCP nanosuspensions in the absence of MMT 
The size of DCP particles in suspension was characterised by a Malvern Zetasizer 
Nano ZSP, utilizing a dynamic light scattering technique. At a certain aging time, 
suspensions were diluted 80 times with water at 5 °C, filled into a disposable cuvette, 
and the temperature was further equilibrated for 120 s at 5 °C prior the measurement. 
Each sample was measured with three consecutive sub-runs at a scattering angle of 
173° and the average size was recorded as the result of the measurement. A 
monomodal size distribution was obtained unless otherwise specified. 
The zeta potential of DCP nanosuspensions was determined by a Malvern Zetasizer 
Nano ZSP, using a folded capillary cell (cell type: DTS1070). The DCP 
nanosuspension was sampled at 1 min aging time and diluted 20 times using the 
filtrate of a same formulation (filtered after 6-10 min aging time using a 0.2 µm pore 
sized nylon syringe filter). The temperature was equilibrated for 120 s at 5 °C prior 
the measurement. Each sample was measured with three consecutive sub-runs and 
the average was recorded as the result of the measurement. Zeta potentials were 
calculated in the software using the Henry equation with Smoluchowski 
approximation for aqueous suspensions.  




5.2.4. Characterisation of dried DCP – MMT nanocomposite microparticles, 
DCP – MMT physical mixtures and as received DCP 
The polymorphic form was determined using a Philips PANAlytical X’pert 
diffractometer. The sample was placed between amorphous tapes and measured in 
transmission geometry using Ni filtered Cu Kα radiation (λ = 1.54 Å), 40 kV 
accelerating voltage and 40 mA anode current. The diffraction pattern was collected 
between 5˚ and 30˚ (2θ). 
Thermal analysis was performed using a Perkin-Elmer Pyris 1 differential scanning 
calorimeter. To perform the thermographs, powder containing approximately 1 mg 
DCP was placed into a closed aluminum pan, and the sample was characterized from 
15 °C to 95 °C using 30 mL/min N2 gas flow and 50 °C/min heating rate. As a 
control, amorphous DCP was also prepared by cooling the pure melt at a rate of 
50 °C/min from 95 °C to 15 °C and characterized at a second reheat of the sample. 
Calibration was made using indium and the same heating rate. A minimum of five 
individually prepared samples were characterized to determine the onset temperature 
and enthalpy of melting. Enthalpy of melting is reported in respect to the amount of 
DCP in the physical mixture or in DCP – MMT nanocomposite microparticles. 
The particle size distribution of as received DCP crystals was determined using a 
Malvern Morphology G3 in dry mode. Particles were dispersed on a glass slide using 
an SUP dispersion unit and 1 bar pressure, and the length and width of 50000 needle-
like crystals were measured at a magnification of 2.5 to obtain a representative 
number based distribution. D50length and D50width are reported as the length and width 
at which 50 % of the crystals are shorter/thinner.  
5.2.5. Dissolution studies 
The solubility of the as received, stable Form A DCP in dissolution media consisting 
of 0.1 M HCl, 2 g/L NaCl and 2.5 g/L SDS was determined by saturating the solution 
at 37.0 °C. An excess of solid was added to the solution and placed into a water bath 
under magnetic stirring at 400 rpm. After 24 h, the stirrer was switched off and the 
suspensions were left to settle for 24 h. The supernatant was then filtered using a 
nylon syringe filter (0.2 µm pore size, VWR), discarding the first 3 mL to avoid the 
effect of possible adsorption of the DCP molecules to the filter membrane. The 
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filtrate was diluted with the dissolution media fivefold, and the concentration of DCP 
was determined from the absorbance at λ = 244 nm using a Shimadzu UV – VIS 
spectrophotometer.  
The dissolution of DCP nanosuspensions and DCP – MMT formulations was 
measured by adding an equivalent of 12.5 mg DCP of each sample into 500 mL 
dissolution media at 37 °C to maintain sink conditions (solubility: 
153.2 ± 0.2 µg/mL) and stirring with a magnetic stirrer bar at a stirrer speed of 
300 rpm. At specific intervals, a 3 mL aliquot was withdrawn and filtered through a 
nylon syringe filter (0.2 µm pore size, VWR) discarding the first 2 mL of the filtrate 
and analyzed by the above mentioned UV – VIS method without dilution. All 
suspension samples reached 100 ± 5 %, whereas all solid samples reached 100 ± 7 % 
dissolution during the experiments, with the highest error being at low DCP loadings. 
In the cases of suspensions, the deviation from 100 % is likely due to the sampling 
from unstable suspensions, as the relatively large DCP – MMT nanocomposite 
microparticles settled quickly when the stirring was stopped. In case of solid 
samples, a lower water content of the processed MMT compared to the unprocessed 
MMT contributes to the deviation. Thus, for a more accurate comparison of the 
formulations, all dissolution results were normalized to 100 %. For samples prepared 
in the absence of additives, dissolution tests were carried out in triplicate, whereas 
dissolution tests were done twice in the presence of additives.  
5.3. RESULTS  
5.3.1. Free nanoparticles in suspension 
As a first step for the preparation of DCP – MMT nanocomposite microparticles, 
antisolvent precipitation process conditions were optimised in the absence of MMT 
in order to achieve a good yield at a reasonably small particle size. The injection of 
the DCP in ethanol solution into the antisolvent resulted in the immediate 
precipitation of the drug, forming a white suspension. Figure 5.2 presents the particle 
size of DCP nanosuspensions at 1 min aging time, prepared using different DCP 
concentrations in ethanol (cDCP) and different antisolvent to solvent ratios (AS/S). The 
average size of the particles increased with increasing DCP concentration in ethanol. 
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At 30 mg/mL and 60 mg/mL DCP concentrations, monomodal size distributions 
were observed at both AS/S ratios, whereas bimodal distributions were obtained 
when 120 mg/mL was used, indicating particle agglomeration. At a constant 
concentration of DCP in ethanol, increasing the AS/S ratio from 9 to 19 only 
moderately decreased the average size of the particles. At the same amount of DCP 
in the final suspension, e.g. 30 mg at AS/S = 9 and cDCP = 30 mg/mL and also at 
AS/S=19 and cDCP = 60 mg/mL, increasing AS/S increased the size of the particles.  
 
Figure 5.2. Particle size of DCP suspensions at 1 min aging time, prepared using 
different DCP concentrations in ethanol (cDCP) and different antisolvent to solvent 
ratios (AS/S). The measured size distributions were bimodal at cDCP = 120 mg/mL. 
Total volume of AS+S was 10 mL in each case. 
High supersaturations generated in the antisolvent precipitation process are expected 
to promote nucleation and the formation of a large number of small particles 
[15][16]. Supersaturation increase through increasing AS/S ratio, and thus, decreasing 
the solubility of the drug led to particle size reduction. In contrast, increasing 
supersaturation by increasing drug concentration in the solvent resulted in increasing 
particle size due to the increased available mass and a bimodal distribution, because 
of agglomeration. To achieve a higher yield at a similar size, AS/S = 9 was selected 
for further studies. Yield is approximated assuming a negligible DCP solubility in the 
final solution mixture compared to the amount of DCP added. To obtain a reasonable 


















concentration of 60 mg/mL was chosen. At these conditions, the solid load of the 
final antisolvent – solvent mixture is 6 mg/mL. The size of the particles prepared 
using the selected conditions was 429 ± 51 nm after 1 min. The zeta potential of 
these particles was -14.0 ± 2.5 mV.  
The short term stability of the DCP nanosuspension prepared using the selected 
process conditions was studied (Figure A5.1, Appendix A). The size of the particles 
first increased from 429 nm to 693 nm within the first 7 min then gradually 
decreased to 403 nm by 20 min. In parallel to the size change, after 3 min, large, 
visually detectable agglomerates appeared in the suspension, indicating instability 
already after 3 min, which settled quickly after sampling and were not detected by 
the dynamic light scattering. Thus, the DLS technique measured the size of small 
particles coexisting with the large agglomerates (not measurable) at later aging times 
(> 3 min). While stability could be improved in the presence of soluble additives as 
found in several other API systems [17][18], the duration of stability is not critical 
for nanoparticle isolation with MMT as shown later.  
In the absence of MMT, attempts have been made to isolate the nanoparticles at 1 
min aging time; however, none of the traditional methods were successful. The 
nanoparticles blocked the sub-micron pore sized filter membrane (0.2 µm pore size, 
nylon), and were highly unstable during evaporation drying (in oven at 50 °C or 
under vacuum (< 27 Pa) at room temperature) or freeze drying, forming large 
crystals (not shown). Thus, while formation of the nanoparticles was easy to address 
using an antisolvent precipitation process, nanoparticle stabilisation in suspension 
and during isolation is the key challenge to be tackled.  
5.3.2. Nanoparticle attachment onto carrier particles 
In Table 5.2, the dependence of the actual loading of DCP nanoparticles in the DCP 
– MMT nanocomposite microparticles on the amount of MMT present is reported. 
The results show that the loading is very efficient with the MMT, retaining more than 
99 % of the total amount of DCP (60 mg) even with 150 mg of MMT, corresponding 
to 28.4 % drug loading in the composite. In contrast, in the absence of MMT, 75.6 % 
of DCP passed through the filter paper, resulting in a milky filtrate containing the 
nanoparticles. The fact that nanoparticles were attaching onto MMT from suspension 
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was also verified by analysing the supernatant of the corresponding suspensions after 
centrifugation, revealing that 97 % of the total amount of DCP did attach to the 
MMT up to 28.4 % composite loading. In contrast, only 56.1 % of the particles 
separated into the bottom sediment under the same conditions in the absence of 
MMT. 
Table 5.2. Percentage (w/w) of DCP recovered by filtration or by centrifugation at 
60 mg DCP and different amount of MMT in the antisolvent – solvent mixture (AS – 
S), and corresponding DCP loadings in DCP – MMT nanocomposite microparticles 
(w/w %). 
Amount of 
DCP in AS – S   
(mg) 
Amount of 









in DCP – 
MMT* (%) 
60 1350 99.8 ± 0.2 99.8 ± 0.03 4.2 
60 450 99.7 ± 0.2 99.0 ± 0.1 11.7 
60 225 99.2 ± 0.6 97.7 ± 0.2 20.9 
60 190 99.3 ± 0.6 97.6 ± 0.02 23.9 
60 150 99.3 ± 0.3 97.2 ± 0.3 28.4 




24.4 ± 1.6 56.1 ± 3.2 - 
*Calculated based on DCP isolation by filtration 
Figure 5.3 shows the influence of soluble surfactant (DOSS, Tween 20) and 
polymeric (HPMC, PVP, PF127, PA) additives on nanoparticle attachment to MMT. 
High attachment of DCP nanoparticles onto MMT was maintained in the presence of 
Tween 20, PVP, PF127 and PA as single additives, shown by the high percentage of 
isolated particles both by filtration and centrifugation. In contrast, the presence of 
DOSS as a single additive, and in combination with HPMC and with PVP greatly 
reduced the attachment to MMT resulting in only 10.1 %, 28.1 % and 6.7 % of the 
mass of DCP, respectively, separating to the bottom sediment during centrifugation. 
These values being lower than that of the control suspension (56.1 %) indicate that 
not just particle attachment but also the size of the particles is decreased in the 
presence of these additives, and these smaller particles would need more time to 
settle. Interestingly, using filtration instead of centrifugation, a higher amount of 
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DCP was isolated with MMT when DOSS or combination of DOSS with HPMC is 
used. This was accompanied by a slower filtration time of approximately 3 min and 2 
min, respectively, as compared to less than 1 min in the presence of MMT only. In 
contrast, the combination of DOSS with PVP in the presence of MMT allowed for 
the nanoparticles to pass through the filter paper, similarly to the control 
nanosuspension.  
 
Figure 5.3. Influence of different additives on the isolation of DCP nanoparticles 
with MMT particles. Additives added at 2.2 mg/g MMT. Isolation by centrifugation 
(blue bars) or filtration (red bars). 100 % isolation corresponds to a drug loading of 
21.1 % on MMT. Additives and MMT were present initially in the antisolvent, or 
when indicated, additives were injected as 1 ml concentrated solutions or MMT 
added as a powder at 15 s aging time.  
When the combination of DOSS with HPMC or PVP was added to the suspension 
15 s after the injection of the drug solution into the antisolvent containing MMT, 
high percentage of the particles could be isolated both with filtration (> 98.7 %) and 
centrifugation (> 91.5 %) showing that the process of nanoparticle attachment to 
















When MMT was added at 15 s aging time to the nanosuspension prepared in the 
absence of additives, the amount of particles that could be isolated both by filtration 
or centrifugation only reduced by 3 % compared to that when MMT was present 
initially in the antisolvent. In contrast, later addition of MMT to a nanosuspension 
prepared in the presence of Tween 20, PVP or PF127 resulted in the isolation of only 
19.4-66.6 % DCP by centrifugation, as opposed to the isolation of more than 97.5 % 
DCP when both MMT and the additives were present initially.  
5.3.3. Dissolution profiles of drug – carrier nanocomposite microparticles in 
suspension 
In the absence of MMT, the dissolution of the free nanoparticles from a freshly 
prepared suspension was very fast due to the large surface area of DCP 
nanoparticles, being complete within 2.2 min (Figure 5.4). Dissolution of DCP 
nanoparticles attached onto MMT was somewhat slower and the dissolution rate 
decreased with increasing nanoparticle loading of the composite up to 20.9 % DCP. 
Further increase of the loading to 23.9 % and to 28.4 % did not have a significant 
effect on the dissolution profile. Within 15 min, all samples reached 100 % 
dissolution.  
The presence of PA or PVP at an amount of 2.2 mg/g MMT, which did not interfere 
with the high level of nanoparticle attachment, did not show any improvement on the 
dissolution profile of the freshly prepared suspension at 20.9 % drug loading of the 
nanocomposite microparticles, Figure 5.5. In addition, in the case of the positively 
charged surface modifier PA, required for the isolation of negatively charged 
fenofibrate and mefenamic acid nanoparticles [7], no significant improvement was 
found even at a decreased DCP nanoparticle loading of 4.2 % or increased amount of 
PA up to 22 mg/g MMT (Figure A5.2a and A5.2b in Appendix A, respectively). 
Dissolution of DCP nanoparticles from a freshly prepared suspension in the presence 
of MMT was faster with DOSS or with the combination of DOSS and PVP 
compared to that in the presence of MMT only (Figure 5.5). However, in these cases, 
the dissolution rate improvement was associated with the presence of free 
nanoparticles in suspension, not attached onto MMT, as only a small amount of DCP 
particles could be isolated by centrifugation in the presence of DOSS or combination 
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of DOSS and PVP (Figure 5.3). From these results, it is clear that the presence of 
those soluble additives which maintain high nanoparticle attachment to MMT and 
thus, high isolation efficiency, cannot improve the dissolution rate of DCP 
nanoparticles any further. 
 
Figure 5.4. Dissolution behaviour of DCP nanoparticles free in suspension and 
attached onto MMT in suspension at different DCP loadings of the product 
nanocomposite microparticles. 
 
Figure 5.5. Dissolution profiles of fresh DCP suspension and fresh suspensions of 
DCP – MMT nanocomposite microparticles prepared in the presence of selected 
additives, each at 2.2 mg/g MMT. The ratio of DCP to MMT was equal in all the 
suspensions, corresponding to a 21.1 % DCP loading in DCP – MMT nanocomposite 
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MMT + DOSS and DCP with MMT + DOSS + PVP; DCP with MMT and DCP with 
MMT + PVP and DCP with MMT + PA. 
5.3.4. Dissolution profiles of isolated and dried drug – carrier particle 
composites 
DCP – MMT nanocomposite microparticles, free from additional soluble additives, 
were prepared and isolated using a simple and fast filtration process with an 
industrially relevant filter pore size (10 µm). Upon addition to the dissolution media, 
up to DCP loadings of the product composite as high as 20.9 %, the dried sample 
quickly redispersed forming a suspension of DCP loaded MMT composite particles. 
DCP dissolution from the composites was fast, repeatable and comparable, reaching 
80 % within the first 5 min and 90 % within 15 min (Figure 5.6). Further increase of 
the loading to 23.9 % resulted in a slightly slower dissolution, reaching 86.8 % 
within 15 min. However, with increasing the loading to 28.4 % the dissolution 
became more variable and slower. DCP dissolution from these composites was 
superior to the dissolution of the as received DCP crystals (D50length=12.3 µm and 
D50width=6.23 µm, Figure A5.3 in Appendix A), the latter only reaching 11.7 % in 
the first 15 min, Figure 5.6.  
 
Figure 5.6. Dissolution of DCP from isolated and dried DCP – MMT 
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The improved dissolution of the particles from 20.9 % DCP – MMT nanocomposite 
microparticles remained unchanged after 10 weeks of storage at room conditions, 
suggesting reasonable stability in the solid state. (Figure A5.4, Appendix A). 
Comparing the dissolution profiles of DCP – MMT composites in fresh suspensions 
with those of the dried formulations (Figure A5.5, Appendix A), at first the 
dissolution rate is essentially the same at a given drug loading of the composite. 
However, after the initial period, the dissolution of the dried sample became slower 
regardless of loading. While the difference in the percentage of dissolved DCP from 
the fresh suspensions and dried samples was similar and less than 10 % at 15 min for 
4.2 % and 20.9 % DCP loadings, it was more than 30 % at 28.4 % DCP loading, 
indicating a higher instability of this sample during isolation and drying.  
5.3.5. Crystal structure and crystallinity 
To understand the difference in the dissolution profiles of the fresh suspensions and 
dried formulations, the crystallinity of isolated DCP particles at a composite loading 
of 20.9 %, 23.9 % and 28.4 % was characterised using PXRD. The PXRD profile of 
dried DCP – MMT nanocomposite microparticles along with that of the as received 
DCP and physical mixtures of as received DCP with MMT are presented in Figure 
5.7. As received DCP was in the stable polymorphic form, Form A [19][20], with 
characteristic peaks at 8.0°, 17.1°, 18.6°, whereas the presence of MMT in the 
samples is shown by a peak at 26.7°. The diffractograms of all precipitated DCP 
particles showed peaks corresponding to Form A DCP. However, the intensity of the 
peaks was significantly reduced and the intensity ratio of the different peaks (e.g. the 
ratio of the Form A peaks at 8.0° and at 18.6°) was altered compared to that of the 
physical mixtures with the same DCP – MMT ratio, indicating a high amount of 
amorphous content and altered crystal morphology. By plotting the area ratio of the 
DCP peak at 8.0° and that of the MMT peak at 26.7° versus DCP/MMT weight ratios 
in the composite samples (Figure A5.6 Appendix A), a positive deviation from 
linearity was found suggesting an increasing percentage of crystalline DCP content 
with increasing DCP loading from 20.9 % and 23.9 % to 28.4 %.  
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Figure 5.7. PXRD profiles of (a-c) DCP – MMT nanocomposite microparticles: (a) 
20.9 % DCP with MMT, (b) 23.9 % DCP with MMT, (c) 28.4 % DCP with MMT; 
(d-f) physical mixtures of as received DCP and MMT: (d) 20.9 % DCP with MMT, 
(e) 23.9 % DCP with MMT, (f) 28.4 % DCP with MMT; (g) pure as received DCP; 
(h) MMT; (i) background. Intensity of the pure DCP profile has been reduced by a 
factor of 5 for presentation purposes. 
The crystallinity of isolated DCP nanoparticles was also studied by DSC (Figure 
5.8), determining the enthalpy of fusion, ΔHf, summarised in Table 5.3. The onset of 
melting of pure DCP was 67.9 ± 0.8 °C at a heating rate of 50 °C/min and the 
enthalpy of melting was ΔHf = 84.6 ± 2.1 J/g (Figure 5.8, g). The percentage of 
crystalline content of DCP attached onto MMT may be calculated by the ratio of 
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enthalpy of fusion of the samples and that of a 100 % crystalline reference if no 
recrystallisation of the amorphous phase takes place during heating, and the onset of 
melting and the enthalpy of fusion of the crystalline DCP is not altered in the 
presence of MMT [21]. The absence of melting endotherm of a reheated 100 % DCP 
sample after fast cooling of the melt verifies that the amorphous form does not 
recrystallise at the applied heating rate (Figure 5.8, h). The melting onset temperature 
of DCP physically mixed with MMT (Figure 5.8, d-f) and DCP – MMT 
nanocomposite microparticles (Figure 5.8, a-c) only decreased marginally, by a 
maximum of 1.5 °C. However, the enthalpy of fusion of the physical mixtures, 
normalised to the mass of drug present, reduced to 54.1 % - 68.1 % compared to the 
pure drug, originating from an interaction between the melted DCP molecules and 
MMT [22]. Thus, crystalline content in DCP – MMT nanocomposite microparticles 
were estimated using the heat of fusion of the corresponding physical mixtures. 
Important to note, that this method may overestimate crystalline content if, due to 
spatial arrangement of the crystalline and amorphous DCP particles around MMT, 
the percentage of molecules interacting with MMT during melting is less than those 
in the corresponding physical mixtures. With the above mentioned assumption, the 
crystalline DCP content of the samples at 20.9 %, 23.9 % and 28.4 % drug loadings 
were estimated to be 9.2 ± 7.2 %, 17.9 ± 3.9% and 38.9 ± 11.3 %, respectively 
(Table 5.3). These values correlate with the amount of undissolved DCP at 15 min, 
suggesting that the decrease of the dissolution rate above 20.9 % DCP loading is 
governed by an increase of DCP crystallinity.  
Table 5.3. Heat of fusion (ΔHf) of DCP, determined from DSC curves, on MMT at 
different loadings (“Sample”) and that of physical mixtures of Form A DCP and 
MMT. ΔHf of pure Form A DCP is also included. 100 % loading refers to the 
absence of MMT. 
DCP 
loading 
ΔHf, Sample  
(J/g) 





after 15 min (%) 
20.9 % 4.0 ± 2.9 43.5 ± 2.6 9.2 ± 7.2 9.3 ± 2.2 
23.9 % 9.5 ± 1.4 53.2 ± 3.7 17.9 ± 3.9 13.2 ± 1.6 
28.4 % 22.4 ± 5.1 57.6 ± 3.6 38.9  ± 11.3 32.8 ± 8.5 




Figure 5.8. DSC curves showing melting peak of DCP from (a-c) DCP – MMT 
nanocomposite microparticles having a DCP content of (a) 20.9 %, (b) 23.9 %, (c) 
28.4 %; (d-f) physical mixtures of a DCP and MMT at a DCP content of (d) 20.9 %, 
(e) 23.9 %, (f) 28.4 %; (g) pure DCP; (h) pure DCP at second heating; and (i) DSC 
curve of MMT.  
5.4. DISCUSSION 
DCP is a highly hydrophobic drug due to its large hydrocarbon content (Figure 5.1). 
Due to the high hydrophobicity and the only moderate negative zeta potential of the 
particles in suspension, -14.0 ± 2.5 mV, a nanosuspension is highly unstable. Within 
a few minutes in the absence of MMT carrier particles or soluble additives, particle 
growth commences (Figure A5.1, Appendix A). By addition of MMT carrier 
























maintained, even after isolation and drying. Thus this simple process combines the 
advantages of nanoparticle stabilisation with a filtration based isolation technique.  
The aluminosilicate MMT has an expandable layered structure where an octahedral 
sheet is sandwiched between two tetrahedral sheets [12][23], Figure 5.9. 
Isomorphous substitution of Si4+ with Al3+ or Fe3+ in the outer siloxane sheet 
introduces negative charge and hydrophilic patches onto the originally hydrophobic 
surface [24]. MMT, when present initially in the antisolvent or added 15 s after the 
injection of drug solution (Table 5.2 and Figure 5.3), provides a surface for DCP 
nanoparticle attachment through hydrophobic interaction between the large 
hydrocarbon groups of DCP and the hydrophobic siloxane patches [24][25][26]. In 
addition, interaction of DCP with the MMT surface through hydrogen bonding is 
also possible. A favorable interaction between DCP molecules and MMT was also 
verified by a reduced heat of fusion in the physical mixtures (Table 5.3). Although 
the surface of MMT particles bears a significant negative charge (-26.9 ± 1.2. mV, 
[7]), surface functionalisation with the positively charged protamine was not required 
to achieve high drug loadings at a maintained fast dissolution rate (Figure 5.5 and 
Figure A5.2 in Appendix A). This can be explained by the less negative charge of 
DCP nanoparticles compared to that of fenofibrate (-25.3 ± 0.9 mV,[7]) or 
mefenamic acid (-35.3 ± 1.3 mV, [27]) nanoparticles isolated by Tierney et al. [7].  
 
Figure 5.9. Structural unit of montmorillonite [12] 
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While the presence of most of the studied soluble additives (Tween 20, PVP, PF127, 
PA) did not interfere with the high isolation efficiency using MMT, determined both 
by filtration and centrifugation, attachment to MMT was greatly reduced in the 
presence of an anionic surfactant DOSS alone or in combination with HPMC or PVP 
(Figure 5.3). Adsorption of DOSS ions onto the surface of DCP not only decreases 
surface hydrophobicity like the adsorption of other uncharged surface active 
stabilisers [28] but also expected to increase the negative surface charge of DCP 
nanoparticles. This in turn increases electrostatic repulsion between DCP 
nanoparticles and the negative patches of the MMT surface or already attached DCP 
nanoparticles. Adsorption of DOSS onto the bare MMT surface might also contribute 
to an increased electrostatic repulsion. Attachment was also reduced when MMT was 
added 15 s after nanoparticle precipitation in the presence of Tween 20, PVP or 
PF127, showing that DCP nanoparticles already coated with stabilisers have a lower 
affinity for interaction with MMT probably due to a lower hydrophobicity of the 
nanoparticle surface or steric stabilisation [29]. These results highlight that the 
carrier, added to the system prior to or just after the nucleation of the nanoparticles, 
could attract drug nanoparticles more efficiently when other soluble stabiliser 
additives are omitted. Thus, the integration of carrier mediated nanoparticle isolation 
at an early stage of the formulation development process can eliminate the need for 
selection of soluble additives for stabilisation.  
Even directly from the fresh suspension and at low drug loading, DCP loaded 
nanocomposites have a slightly lower dissolution rate compared to that of the free 
nanoparticles (Figure 5.4). The initial dissolution rate over the first 40 seconds has 
decreased by 30 % at 4.2 % drug loading (Table 5.4), and further decrease occur up 
to 20.9 % drug loading. In these experiments the loading is increased by decreasing 
the amount of MMT, while the amount of DCP remains constant. A rough 
calculation over the possible surface coverage of DCP nanoparticles evenly 
distributed over the surface of the MMT microparticles reveals that, at the loading of 
4.2 %, (i.e. at the highest amount of MMT), the entire MMT surface area is covered 
by nanoparticles. Accordingly, the reduced dissolution rate is related to the fact that 
the full surface area of the nanoparticles is not exposed to dissolution, because part of 
the area is attaching to the MMT surface, and possibly part of the nanoparticles are 
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covered by a second layer. As the amount of MMT and accordingly the total surface 
area of MMT particles decreases, the loading increases, and additional layers of 
nanoparticles are added. Since the exposed surface area of the nanoparticle coated 
MMT particles decreases with higher loadings, it is expected that the dissolution rate 
would decrease, in agreement with the decrease up to 20.9 % drug loading. At 
28.4 % loading, the relative amount of DCP nanoparticles to MMT microparticles 
amounts to 14 layers, and the exposed nanoparticle covered MMT surface area is 
about 10 times smaller. Notably, the decrease in initial disolution rate is clearly less 
than that, suggesting e.g. a looser attachment of DCP nanoparticles in the outer 
layers and/or an actual release of nano particles from the surface during the 
dissolution. 
Table 5.4. Number of layers of DCP nanoparticles per an MMT particle and initial 
dissolution rates in fresh suspensions at a given drug loading of the DCP – MMT 
nanocomposite microparticles.  
DCP loading (%) DCP layers / MMT Initial dissolution rate (%/min) 
 
- 104 
4.2 1.5 70 
11.7 4.6 45 
20.9 9.2 32 
23.9 10.9 30 
28.4 13.8 31 
The relatively moderate decrease of the dissolution rate with increasing loading of 
the nanocomposite microparticles contrasts with previous work [7][30], where 
heavily agglomerated patches of nanoparticles on the carrier surface or a thick local 
layer leads to a more dramatic decrease in dissolution rate at higher loadings.  
The isolation and drying of the composite particles do not alter the initial dissolution 
rate, but certainly increase the time needed for complete dissolution (Figure 5.4 and 
Figure 5.6, compared on Figure A5.5 in Appendix A). The effect is moderate at low 
loading but clearly increases at drug loading above 20.9 %. This behaviour was 
found to correlate with increasing crystallinity of the dried DCP particles (Table 5.3). 
Accordingly, it is assumed that amorphous nanoparticles form initially in the 
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suspension at all drug loadings, and may completely dissolve from the fresh 
suspensions (sampled at 1 min) within 15 min. However, after the crystalline form 
has nucleated the crystals grow at the expense of the amorphous material via a 
solvent mediated transformation in the suspension or in the wet filter cake [31]. In 
the system here, this occurs predominantly during the isolation and drying processes 
(started at 1 min aging time) and leads to a gradually increasing crystalline content. 
Remaining amorphous material will provide the initial rapid dissolution while the 
crystalline content having lower solubility and potentially increased size, will have a 
lower dissolution rate. More crystalline particles are formed at higher loadings in the 
range of 20.9-28.4 % drug loading, possibly due to a higher local density of 
amorphous particles.  
 
Figure 5.10. Factors affecting the dissolution of DCP from solid-state drug – carrier 
nanocomposite microparticles. 
Fast dissolving DCP nanoparticles, free from soluble additives, have been prepared 
with an antisolvent precipitation method and recovered by simple filtration process 
using an insoluble carrier microparticle, MMT. Drug dissolution from DCP – MMT 
nanocomposite microparticles was not compromised even at a drug loading of 20.9 
%, and was far superior than that of the larger as received drug crystals (Figure 5.6). 
The isolated particles retained their stability in the dry solid state for a minimum of 
10 weeks, demonstrated by an unchanged dissolution profile (Figure A5.4 in 
Fast dissolution of carrier 
isolated nanoparticles at 
high particle loading 
Drug loading on 













Appendix A). Accordingly, this method, summarised in Figure 5.10, appears to 
deliver on several of the critical attributes of a nanoparticle formulation produced by 
a wet method. The high dissolution rate must be retained into the formulated drug, 
the drug particles must be efficiently isolated and dried, the drug content in the 
isolated materials needs to be high to avoid high excipient costs, and of course the 
product must have sufficient shelf life stability. The maximum achievable drug 
loading while maintaining fast dissolution rates from the solid formulation is 
regulated by the interplay of nanoparticle attachment efficiency, drug loading, 
dissolution of carrier attached nanoparticles in suspension and stability during 
isolation and drying.  
5.5. CONCLUSIONS 
Fast dissolving drug (dalcetrapib) – carrier (montmorillonite) nanocomposite 
microparticles were prepared with an antisolvent precipitation method and isolated 
by a simple, fast, industrially relevant filtration process. In the absence of MMT, 
under optimum process conditions, nanoparticles (429 nm) formed in suspension but 
were highly unstable and difficult to isolate. MMT, when present during or shortly 
after nanoparticle formation, provided a surface for attachment of the nanoparticles, 
retaining more than 99 % of them up to a corresponding DCP loading of 28.4 % in 
the nanocomposite microparticles. Fast dissolution of isolated DCP nanoparticles 
could be maintained even at a drug loading of 20.9 % of the composite, with the 
formulation being stable up to 10 weeks of storage. The use of soluble stabilisers was 
not required or even decreased nanoparticle attachment, especially when MMT was 
introduced later to a suspension of stabiliser coated nanoparticles. The MMT surface 
did not require a surface functionalisation, due to a fairly low negative charge of 
DCP nanoparticles and thus, lack of strong electrostatic repulsion with the negative 
MMT surface. Thus, this montmorillonite based carrier mediated system has proven 
to enable solution crystallisation methods for the development of solid dose 
nanoparticle formulations of high drug content of dalcetrapib, having high 
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The objective of this thesis was to advance the state of the art nanoparticle 
preparation using an antisolvent precipitation method, with the ultimate aim to 
facilitate the industrial scale production of drug nanoparticles with improved 
bioavailability. Based on a thorough literature review, two challenging areas were 
identified: (i) rationale selection and use of molecular additives to control the 
formation and stabilisation of nanoparticles and (ii) isolation of nanoparticles using a 
filtration-based process. Using mefenamic acid and dalcetrapib as model active 
pharmaceutical ingredients, the above challenges have been targeted: the mechanism 
by which soluble additives could stabilise a nanosuspension of MEF was elucidated; 
a novel stepwise additive addition process for particle stabilisation during antisolvent 
precipitation was developed; influence of a surfactant additive on the nucleation of 
MEF was studied and the carrier mediated stabilisation and isolation method via 
simple filtration was further developed for DCP nanoparticles at high drug loadings 
(~20 %). While each experimental chapter included specific conclusions of the work 
done, below more general conclusions are drawn that could be applied for future 
systems.  
Antisolvent precipitation is relatively straightforward and simple method for the 
production of low micron sized (MEF) or nanoparticles (DCP) even in the absence of 
additives. While being system dependant, a low (5-25 °C) temperature, fast mixing 
of the solvent with the antisolvent, medium concentration of the solute in the solvent 
(< 100 mg/mL) and a moderately high antisolvent to solvent ratio (10-20) may be a 
good starting condition for further optimisation. However, care must be taken to 
select a suitable size characterisation method for the particles. While characterisation 
in suspension is a fast method for screening the conditions, immediate agglomeration 
of highly hydrophobic drugs may conceal the size of the primary particles. In 
contrast, microscopic techniques can shed light on the size of primary particles, 
broadening the understanding of the system.  
Low micron sized MEF particles could be prepared by optimising the process 
parameters; however, the presence of an anionic additive, docusate sodium, was 
required to reduce the size into the nanometre range (300 nm). This verifies that 
additives are not just needed for stabilising the nanosuspension but can play a crucial 
role in the formation of the nanoparticles. In contrast, polymeric additives interfered 
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with the particle formation process, leading to increased particle size. Thus, while 
attempts have been made in the literature to rationalise the effectiveness of an 
additive for a particular drug by studying the strengths of the drug-additive 
interaction, a simple correlation does not exist. Strong interactions do not necessarily 
lead to smaller particles. More importantly, as additives can influence the different 
stages of the nanoparticle formation and stabilisation processes, i.e. nucleation, 
growth and particle stabilisation, in different manners, timing of additive addition 
should be considered as an additional parameter of the antisolvent precipitation 
process. Additives that fail in reducing the particle size when present initially in the 
system can be very useful when added later. Thus, stepwise use of additives, 
presented in this study, can separately target the different stages of the process: early 
presence of an additive for stimulating nucleation, and later addition for inhibiting 
particle growth. This widens the applicability of an additive and serves as an 
additional tool for process control. 
Considering the above findings, a recommended additive screening protocol for the 
preparation of nanosuspensions is summarised on Figure 6.1. (i) A selection of 
pharmaceutically acceptable additives should be classified as ionic or non-ionic 
surfactants, amphiphilic block-copolymers, polymers with donating, accepting or 
both hydrogen bonding capability, etc.. (ii) Primary particle size in the presence of 
single additives should be tested, the additive providing the smallest size should be 
selected as “additive 1”. If this initial size is smaller or equal to the size in the 
absence of any additives, then nucleation retardation is not a concern, while a larger 
size in the presence of the additive suggests a negative influence on nucleation. In 
such a case, when even the smallest particle size is bigger than in the absence of any 
additives, screening should be repeated by adding single additives shortly after 
nucleation of the particles. (iii) The stability of the particles prepared with “additive 
1” should be tested. If instability is an issue, combinations of additives should be 
tested as a next step. From the initial screening results, a strategy to screen one or 
several additives from each classes of additives as “additive 2” can be decided: if the 
particle sizes obtained with additives within a class of additives (e.g. non-ionic 
surfactants) are similar but distinctly different from the particle size with other 
classes of additives, one additive could be selected for further screening from that 
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class as “additive 2”. (iv) A second additive should be tested in the presence of the 
first one, comparing the results with initial or later addition. A difference in the size 
with the two addition methods reflects a strong interaction during the early stages of 
particle formation which may positively affect stability. 
 
Figure 6.1. Additive screening protocol proposed for the production of drug 
nanosuspensions. 
ii. Screen single additives, present initially 
(additive 1)  
v. Optimise concentration 
and molecular weight/tail 
length of additive(s) 
yes 
iii. Stability testing. Stabile? 
Are the sizes within specific 
classes of additives similar?  
no 
yes: use use one 
additive per a class 
as additive 2 
no: use more 
additives per a 
class as additive 2 
iv. Screen additive 2 in the presence of 
additive 1, being present initially or added 
later 
i. Define classes of additives 
Surfactants: non-ionic, ionic  
Polymers: H-bond donating, H-bond 
accepting, both H-bond properties, block-
copolymers 
Is the primary particle size 
smaller/equal than in the 
absence of additive 1?  
yes 
no 
Is the stability acceptable?  yes 
no 
Redefine starting additive concentrations, 
screen additional additives 
Screen single additives, adding 
shortly after nucleation (additive 1) 
Is the primary particle size 
smaller/equal than in the 





If the screening method fails to provide nanosuspensions with acceptable stability, 
redefining additive concentrations, or screening of additional types of additives 
might be necessary. (v) Concentration and molecular weight/length of the 
hydrophobic tail of the additives may be further tuned with the help of an 
experimental design.  
During the course of the work, the influence of docusate sodium on the nucleation of 
mefenamic acid has been studied under different crystallisation conditions than those 
used during the antisolvent process to probe the fundamental influence of the 
additive on nucleation. Evaluating the results using classical nucleation theory 
revealed an influence on the pre-exponential factor while the interfacial energy was 
essentially unchanged. Thus, this work provided an example that additives may 
facilitate a nucleation process by an effect other than reducing the interfacial energy, 
adding to the limited number of studies in the area. Using an antisolvent – solvent 
system in which the solution composition is tuneable could provide a more detailed 
influence of solvent composition and supersaturation on the effect of an additive. In 
addition, studying the effect of a series of structurally related additives could shed 
light on the molecular mechanisms involved. 
Solid state DCP – MMT nanocomposite microparticles with improved dissolution 
properties have been prepared combining the enhanced dissolution rate of 
nanoparticles with the good filtration properties of carrier microparticles. Concerning 
the necessity of surface functionalisation, it can be concluded that balancing the 
negative surface charge of MMT with a positively charged polymer is only necessary 
when the nanoparticles themselves have a high negative surface charge. In contrast, 
moderately charged nanoparticles such as DCP attach uniformly even to the bare 
MMT surface, that results in high dissolution rates even at high drug loadings. 
Results using soluble additives revealed that the presence of additives is not needed 
or even hinders the nanoparticle attachment process, limiting the achievable drug 
loadings. Thus, while additives are vital for the formulation of nanosuspensions, their 
role may be limited if a solid state nanocomposite formulation, prepared by an 
antisolvent and carrier particle mediated isolation approach, is the aim. Future 
research is recommended on generalising the approach of the carrier-mediated 
filtration process for the production of solid nanocomposite microparticles. 
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Additional drugs with positive surface charges could be tested to elaborate the 
usability of bare or surface functionalised MMT, while carrier particles with 
modifiable surface functional groups could be studied to understand the role and 




























SUPPORTING INFORMATION FOR CHAPTER III  
Table A3.1. Solubility of MEF Form I in DMA – water mixtures from T = 25 °C to 
45 °C.  
T 
(°C) 
Solubility (standard deviation) (mg/g) solvent mixture 
0 v/v % w 10 v/v % w 20 v/v % w 30 v/v % w 40 v/v % w 
25 553.1 (1.4) 185.6 (2.2) 35.36 (1.62) 5.675 (0.189) 1.041 (0.035) 
30 579.1 (2.4) 213.7 (2.2) 44.16 (0.54) 7.209 (0.018) 1.263 (0.013) 
35 614.5 (3.5) 242.7 (7.0) 53.20 (0.45) 9.372 (0.139) 1.812 (0.044) 
40 647.8 (3.6) 267.6 (3.2) 64.42 (0.26) 11.794 (0.041) 2.366 (0.048) 
45 682.7 (4.4) 303.8 (5.0) 78.48 (0.32) 14.951 (0.076) 3.040 (0.113) 
 
Figure A3.1. SEM micrographs of MEF crystals prepared with different process 
conditions, showing the presence of spherical agglomerates using the combination of 
10 µm 10 µm 2 µm 
10 µm 10 µm 2 µm 
10 µm 10 µm 2 µm 
D AD AD 
10 µm 10 µm 2 µm 
BD ABD ABD 
CD ACD ACD 
BCD ABCD ABCD 
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high concentration and high antisolvent to solvent ratio during antisolvent 
precipitation in the absence of additives. Process conditions: X = final concentration 
of 2 mg/ml, stirring rate of 200 rpm, antisolvent temperature of 25 °C, antisolvent to 
solvent ratio of 4; A = higher final concentration (cf = 5 mg/ml); B = higher stirring 
rate (s = 1600 rpm); C = lower antisolvent temperature (TAS = 5 °C); D = higher 
antisolvent to solvent ratio (AS/S = 19). Particles were isolated at 30 seconds aging 
time. 
Table A3.2. Concentration of MEF in the filtrate after separating off the particles 
prepared in the presence of various additives, using the optimum process conditions. 
Additive Concentrationa (µg/ml) 
No additive 0.28 ± 0.06b 
HPMC 5.14 ± 0.16c 
PVA 2.92 ± 0.91b 
PF127 1.79 ± 0.29b 
PF68 0.44 ± 0.08b 
Tween 80 6.04 ± 0.64b 
Tween 20 3.76 ± 0.88b 
DOSS 1.67 ± 0.15b 
SDS 2.41 ± 1.60b 
 aMean ± standard deviation 






Figure A3.2. SEM images of MEF crystals prepared in the presence of different 
additives and isolated after 30 minutes aging time, indicating the average particle 
length and the deviation of the average among different samples. Crystals were 
prepared using the optimum process conditions.  
 
Figure A3.3. DSC thermograms of pure MEF polymorphs, up to the melting point of 
MEF. 
3 µm 3 µm 
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1.00 ± 0.03 µm 1.14 ± 0.02 µm 2.09 ± 0.21 µm 
2.63 ± 0.06 µm 1.92 ± 0.01 µm 1.03 ± 0.04 µm 
1.14 ± 0.05 µm 0.48 ± 0.02 µm 0.87 ± 0.01 µm 
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Wavenumber (1/cm)  
Figure A3.4. IR spectra of MEF polymorphs: (a) pure Form I, (b) pure Form II; (c) 
spectra of particles prepared with the combination of initial use of DOSS and 
subsequent addition of HPMC at 5 s; and spectra of additives: (d) pure HPMC, (e) 
pure DOSS.  
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SUPPORTING INFORMATION FOR CHAPTER IV  
 
Figure A4.1. Solubility of MEF Form I in 70 % DMA – 30 % water at 15 °C, 20 °C, 





















































Figure A4.2. IR spectra of MEF polymorphs: (a) pure Form I, (b) pure Form II; 
spectra of particles prepared at S II = 4.40 in 40 % DMA – 60 % water (c-d) without 






























Figure A4.3. IR spectra of MEF polymorphs: (a) pure Form I, (b) pure Form II; 
spectra of particles prepared at S II = 2.20 in 40 % DMA – 60 % water (c-d) without 
DOSS, (e-f) with 0.1 mg/mL DOSS, (g-h) with 0.2 mg/mL DOSS. All samples 
















Figure A4.4. PXRD diffractogram of pure MEF polymorphs and MEF crystals 
nucleated in 70 % DMA – 30 % water at S I = 1.99 in the absence of DOSS. Crystals 
were isolated at 8 min aging time.  
 
Figure A4.5. SEM images of MEF crystals prepared in the absence or presence of 
DOSS in 40 % DMA – 60 % water, at the highest (S II = 4.40, isolated at 8 min) and 
lowest (S II = 2.20, isolated at 15 min) employed supersaturation. Based on IR, 
samples are a mixture of Form I and Form II crystals, with the images showing 
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examples of Form I crystals (circled). No Form I crystals were detected in SEM 
samples at S II = 4.40 and 0.1 mg/mL DOSS and thus, not presented herein. 
 
Figure A4.6. Plot of ln (J/S) versus T-3ln-2S for the determination of the pre-
exponential factor A and interfacial energy γ of the nucleation from fitting to 














pure MEF, 40 % DMA -
60 % water
MEF + 0.1 mg/ml DOSS,
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40 % DMA - 60 % water
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Critical micelle concentration (CMC) 
Conductometry was used for determination of CMC of DOSS in deionized water and 
in 40 % DMA – 60 % water at 25 °C. The conductivity of DOSS solutions at 
different concentrations were measured using a Malvern Zetasizer Nano ZSP and a 
folded capillary cell (cell type: DTS1070). Prior to the measurement, the temperature 
of the solutions was equilibrated for 10 min at 25 °C. The conductivity was measured 
using three sub-runs and the average was reported as the result. Shown on Figure 
A4.7, in pure water, the critical micelle concentration (CMC) of DOSS was 
7.8 mM = 3.5 mg/mL. In 40 % DMA – 60 % water, micelles were not detected up to 
25 mM = 11.1 mg/mL DOSS, above which the standard deviation of the conductivity 
values increased significantly, restricting further collection of reliable data points. 
This means that micelle formation is not expected at 0.2 mg/mL DOSS in 
40 % DMA – 60 % water, and on the basis that the CMC of a surfactant generally 
increases with increasing fraction of organic solvent in a water – organic solvent 
mixture [1][2][3], it is also not expected in 70 % DMA – 30 % water even at 
5 mg/mL DOSS. 
 
Figure A4.7. Conductivity of DOSS solutions at 25 °C. The critical micelle 





















40 % DMA - 60 % water
CMC = 7.8 mM
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Figure A5.1. Particle size of DCP suspensions at different times after the 
preparation of the particles. After 3 min, visually detectable agglomerates are also 
present in the suspension. Suspensions were prepared using the optimised process 























Figure A5.2. Dissolution profiles of fresh DCP suspension and fresh suspensions of 
DCP – MMT nanocomposite microparticles prepared in the presence of different 
amount of surface modifier PA, at a DCP loading of (a) 4.2 % and (b) 20.9 %. 
Dissolution experiments at 4.2 % DCP loadings in the presence of PA was done only 
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Figure A5.3.  Distributions of (a) length and (b) width of the as received elongated 
DCP crystals. 
 
Figure A5.4. Dissolution of DCP from dried DCP – MMT composites at 20.9 % 
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Figure A5.5. Comparison of DCP – MMT composite dissolution profiles from 
suspensions and dried samples at different DCP loadings. 
 
Figure A5.6. Area ratio of PXRD peaks characteristic of DCP and MMT versus 
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